



Cancer In Louisiana 2017 - 2021

Volume 39

October 2024

LSU Health
NEW ORLEANS
Louisiana Tumor Registry

Editors

Ingrid Wagner, MPH
Lauren Maniscalco, MPH
Meichin Hsieh, PhD, MSPH, ODS-C
Christina Lefante, MPH, ODS-C
Yong Yi, MS, PhD
Lisa Pareti, BS, RHIT, ODS-C
Brent Mumphrey, BS
Mary Anne Lynch, MPH
Xiao-Cheng Wu, MD, MPH, ODS-C

The contents of the monograph are the responsibility solely of the editors.

§

Student Researchers

Tommy Nguyen

The above student researchers contributed to the preparation of this monograph.

§

The work on this monograph was supported in part by:

SEER Contract HHSN261201800007I/HHSN26100002 from the National Cancer Institute,
Cooperative Agreement NU58DP006332
from the Centers for Disease Control and Prevention, and
the State of Louisiana.

§

Cover design by Tommy Nguyen.

This volume will be published solely as an online document.

Previous volumes of *Cancer in Louisiana* are available at
<http://sph.lsuhsu.edu/monographs-publications>

All information in this report is in the public domain and may be reproduced or copied without permission. Citation of source, however, is appreciated.

Suggested Citation:

Wagner I, Maniscalco L, Hsieh M, Lefante C, Yi Y, Pareti L, Mumphrey B, Lynch MA, and Wu XC (eds). Cancer in Louisiana, 2017-2021. New Orleans: Louisiana Tumor Registry, 2024. (Cancer in Louisiana; Vol. 39.)

§

For more information about the Louisiana Tumor Registry, please visit our website:

<http://louisianatumorregistry.lsuhs.edu>

Or email us:

LTR-info@lsuhsc.edu

Table of Contents

Acknowledgments	7
Introduction	8
Presentation of the Data.....	13
Cautions in Interpretation	18
Summary	20
Incidence, 2017-2021.....	20
Cancer Deaths, 2017-2021.....	22
Figures.....	23
Figure 1. All Cancers Combined	23
Figure 2. Time Trends: All Cancers Combined	25
Figure 3. Lung Cancer.....	26
Figure 4. Colorectal Cancer	28
Figure 5. Female Breast Cancer	30
Figure 6. Prostate Cancer.....	32
Figure 7. Cervical Cancer.....	34
Figure 8. Tobacco-Related Cancers.....	36
Figure 9. Obesity-Related Cancers	37
Figure 10. Human Papillomavirus (HPV)-Related Cancers.....	38
Figure 11. Pediatric Cancer	39
Incidence Tables	41
Table A1. Average Annual Number of Cancer Cases by Site, Race, and Sex, 2017-2021, Louisiana	41
Table A2. Percent Distribution of Cancer Cases by Site, Race, and Sex, 2017-2021, Louisiana	44
Table B. Average Annual Cancer Incidence Rates by Site, Race, and Sex, ¹ 2017-2021, Louisiana	47
Table C1. Average Annual Cancer Incidence Rates by Race and Sex, ¹ 2017-2021: U.S., Louisiana, and 7- Parish Industrial Corridor ² (Please review: Cautions in Interpretation)	50
Table C2. Average Annual Cancer Incidence Rates by Race and Sex, ¹ 2017-2021: U.S., Louisiana, and 11- Parish Industrial Corridor ² (Please review: Cautions in Interpretation)	51
Table D1. Cancer Incidence Rates ¹ among the Hispanic Population, 2017-2021: U.S. and Louisiana	52
Table D2. Cancer Incidence Rates ¹ among the NH American Indian/Alaska Native and Asian and Pacific Islander Population, 2017-2021: U.S. and Louisiana	53

Table E1. Incidence Rates ¹ by Louisiana Parish ² for the Ten Most Commonly Diagnosed Cancers, 2017-2021: NH White Males	54
Table E2. Incidence Rates ¹ by Louisiana Parish ² for the Ten Most Commonly Diagnosed Cancers, 2017-2021: NH White Females	57
Table E3. Incidence Rates ¹ by Louisiana Parish ² for the Ten Most Commonly Diagnosed Cancers, 2017-2021: NH Black Males	60
Table E4. Incidence Rates ¹ by Louisiana Parish ² for the Ten Most Commonly Diagnosed Cancers, 2017-2021: NH Black Females.....	63
Table F1. Incidence Rates ¹ by LTR Region ² for the Ten Most Commonly Diagnosed Cancers, 2017-2021: NH White Males.....	66
Table F2. Incidence Rates ¹ by LTR Region ² for the Ten Most Commonly Diagnosed Cancers, 2017-2021: NH White Females	67
Table F3. Incidence Rates ¹ by LTR Region ² for the Ten Most Commonly Diagnosed Cancers, 2017-2021: NH Black Males	68
Table F4. Incidence Rates ¹ by LTR Region ² for the Ten Most Commonly Diagnosed Cancers, 2017-2021: NH Black Females.....	69
Table G1. Incidence Rates ¹ by LA OPH Region ² for the Ten Most Commonly Diagnosed Cancers, 2017-2021: NH White Males.....	70
Table G2. Incidence Rates ¹ by LA OPH Region ² for the Ten Most Commonly Diagnosed Cancers, 2017-2021: NH White Females	71
Table G3. Incidence Rates ¹ by LA OPH Region ² for the Ten Most Commonly Diagnosed Cancers, 2017-2021: NH Black Males	72
Table G4. Incidence Rates ¹ by LA OPH Region ² for the Ten Most Commonly Diagnosed Cancers, 2017-2021: NH Black Females.....	73
Table H1. Number of Children and Adolescent Cancer Diagnoses, ¹ 2017-2021 Combined, Louisiana.....	74
Table H2. Percent Distribution of Children and Adolescent Cancers, ¹ 2017-2021, Louisiana.....	75
Table H3. Average Annual Cancer Incidence Rates ¹ of Children and Adolescent Cancers, ² 2017-2021, Louisiana	76
Table I1. Age-specific Number of Cancer Cases ¹ , 2017-2021, Louisiana	77
Table I2. Age-Specific Average Annual Cancer Incidence Rates, ¹ 2017-2021, Louisiana.....	81
Mortality Tables.....	85
Table J1. Average Annual Number of Cancer Deaths by Site, Race, and Sex, 2017-2021, Louisiana	85
Table J2. Percent Distribution of Cancer Deaths by Site, Race, and Sex, 2017-2021, Louisiana	87
Table K. Average Annual Death Rate ¹ by Site, Race, and Sex, 2017-2021, Louisiana.....	89

Table L1. Average Annual Death Rates ¹ for Selected Cancers by Race and Sex, 2017-2021: U.S., Louisiana, and 7-Parish Industrial Corridor ² (Please review: Cautions in Interpretation)	91
Table L2. Average Annual Death Rates ¹ for Selected Cancers by Race and Sex, 2017-2021: U.S., Louisiana, and 11-Parish Industrial Corridor ² (Please review: Cautions in Interpretation)	92
Table M1. Death Rates ¹ by Louisiana Parish ² for the Ten Most Common Cancer Deaths, 2017-2021: NH White Males	93
Table M2. Death Rates ¹ by Louisiana Parish ² for the Ten Most Common Cancer Deaths, 2017-2021: NH White Females	96
Table M3. Death Rates ¹ by Louisiana Parish ² for the Ten Most Common Cancer Deaths, 2017-2021: NH Black Males	99
Table M4. Death Rates ¹ by Louisiana Parish ² for the Ten Most Common Cancer Deaths, 2017-2021: NH Black Females.....	102
Table N1. Death Rates ¹ by LTR Region ² for the Ten Most Common Cancer Deaths, 2017-2021: NH White Males	105
Table N2. Death Rates ¹ by LTR Region ² for the Ten Most Common Cancer Deaths, 2017-2021: NH White Females	106
Table N3. Death Rates ¹ by LTR Region ² for the Ten Most Common Cancer Deaths, 2017-2021: NH Black Males	107
Table N4. Death Rates ¹ by LTR Region ² for the Ten Most Common Cancer Deaths, 2017-2021: NH Black Females.....	108
Table O1. Death Rates ¹ by LA OPH Region ² for the Ten Most Common Cancer Deaths, 2017-2021: NH White Males.....	109
Table O2. Death Rates ¹ by LA OPH Region ² for the Ten Most Common Cancer Deaths, 2017-2021: NH White Females	110
Table O3. Death Rates ¹ by LA OPH Region ² for the Ten Most Common Cancer Deaths, 2017-2021: NH Black Males	111
Table O4. Death Rates ¹ by LA OPH Region ² for the Ten Most Common Cancer Deaths, 2017-2021: NH Black Females.....	112
Survival and Prevalence Tables.....	113
Table P. 5-Year Relative Survival, 2010-2020, Louisiana	113
Table Q. Louisiana Prevalence Counts by Region, Invasive Cancers Only, January 1, 2021 ^{1,2}	116
Table R. Louisiana Prevalence Counts by Age Group, Invasive Cancers Only, January 1, 2021 ^{1,2}	117
Other Tables.....	118
Table S. Percent of Cases ^{1,2} with Microscopic Confirmation by Primary Site, All Races and Both Sexes Combined, 2017-2021, Louisiana	118

References	119
Appendices	120
Appendix A. Abbreviations and Symbols	120
Appendix B. Regions of Louisiana	121
Regions of the Louisiana Tumor Registry.....	122
Regions of the Office of Public Health	123
Appendix C. Host Institutions of the LTR Regional Registries.....	124
Appendix D. Cancer-Related Organizations	125
Appendix E. Data Use.....	126

Acknowledgments

As with all reports produced by the Louisiana Tumor Registry, much appreciation goes to those whose dedication and hard work contribute to the timely collection of high-quality data for this monograph. The LTR sincerely thanks:

Louisiana Tumor Registry Regional Directors/Managers

Angela Crossgrow, ODS-C, Manager, Regions 1 & 3
Danielle Ritchie, ODS-C, Director, Regions 2 & 5
Lea G. Guidry, RHIA, ODS-C, Director, Regions 4 & 6
Candace B. Crowe, ODS-C, Director: Regions 7 & 8, Coordinator: Region 7
Paula Franklin, RHIA, ODS-C, Coordinator, Region 8

Host Institutions

Regions 1 & 3: LSU Board of Supervisors and LSU Health Sciences Center-New Orleans (since 1995)
Region 2: Mary Bird Perkins Cancer Center (since 1983)
Region 4: Acadiana Medical Research Foundation (since 1983)
Region 5: Mary Bird Perkins Cancer Center (since 2013)
Region 6: Acadiana Medical Research Foundation (since 2023)
Regions 7 & 8: University of Louisiana at Monroe (since 1988)

Regional registrars and staff members of the Louisiana Tumor Registry

Central office staff members

Lili Bao, MD, MS, ODS-C	Reem Muhsen, BA
Anna Brewer, BS, RHIA, ODS-C	Nektarios Pappas, MD, ODS-C
Mary Davidson, MN, RN, ODS-C	Lisa Peterson, BA, RHIT, ODS-C
Natalie Gomez, BSN, RN	Gregory Esteven, BA
Betty Gonzales, MBA	Tracie Shroeder, BS
Lisa Moses, MS, MPH, LCSW	

Hospital cancer registries in Louisiana

Louisiana Cancer Registrars' Association

Physicians and staff members in:

Medical records offices, Pathology laboratories, Physician offices and clinics,
Free-standing treatment facilities, Hospice programs

School of Public Health, LSU Health Sciences Center–New Orleans

Louisiana Cancer Advisory Board *(formerly the Louisiana Cancer and Lung Trust Fund Board)*

Coroners' offices

Louisiana Department of Health: Office of Public Health (STD/HIV Program, Immunization Program), Office of the State Registrar and Vital Records, Bureau of Health Informatics (Louisiana Hospital Inpatient Discharge Database)

Introduction

The Louisiana Tumor Registry (LTR) is pleased to present Volume 39 of its annual ***Cancer in Louisiana*** monograph series, documenting cancer incidence and mortality from 2017 to 2021 in Louisiana as well as incidence and mortality trends from 1988 to 2021. Survival statistics are for cases diagnosed from 2010 to 2020 and followed into 2021. Prevalence is also presented for cancer cases diagnosed from January 1, 2000, to January 1, 2021. New to this volume is Table D1 in which we present data for Louisiana's Hispanic population separately for the first time. Data for Hispanics is also included in Tables A1 and A2. More details on this change are provided in the [Presentation of the Data](#) section.

The COVID-19 pandemic disrupted access to medical care leading to delays in cancer diagnoses in 2020, as reflected in the decline in incidence rates for that year. Thus, caution is advised when interpreting data from the diagnosis year 2020. While the number of new cases diagnosed in 2021 remained slightly lower for some cancer types, others have returned to pre-pandemic levels.

Purpose of the Registry

The state legislature authorized the establishment of the LTR in 1978. In the early 1980s, the state began providing funding support to the LTR for the collection, analysis, and dissemination of information on cancer in Louisiana.

Cancer is a reportable disease in all states of the United States (U.S.). Data collected by statewide population-based registries are used to calculate cancer incidence counts and rates by age, race, sex, and geographic region, as well as trends over time. With these statistics, data-driven cancer prevention and control programs have been implemented to reduce cancer morbidity and mortality. Registry data are not only used for cancer surveillance but also as the foundation for cancer control programs in studies evaluating screening and early detection programs, health care planning, clinical therapies, cancer research (including etiology and disparity studies), and other cancer prevention and control initiatives. Registry information directs efforts to lessen the burden of cancer in our state.

Historical Background of the LTR

Achieving Statewide Cancer Surveillance Coverage

Cancer registration in Louisiana began in 1947 in the Charity Hospital Tumor Registry in New Orleans and was limited to patients in that facility. In 1974, as part of its Surveillance, Epidemiology and End Results (SEER) Program, the National Cancer Institute (NCI) provided funds for a population-based cancer incidence and survival registry, which then encompassed only Jefferson, Orleans, and St. Bernard parishes; the data were included in the 1974–1977 SEER national incidence rates.

In 1979, the LTR was transferred from Charity Hospital to Louisiana's Office of Public Health (OPH). The catchment area for the LTR was expanded in 1983 to include 35 parishes of South

Louisiana (LTR Regions 1–5). In 1988, when the 29 parishes of North Louisiana (LTR Regions 6–8) were added, statewide coverage was achieved. In 1995, the LTR was transferred from the OPH to the LSU Board of Supervisors. Since then, the LSU Health Sciences Center in New Orleans has been responsible for the cancer registry program and has provided state funds for its work. State funding provided to the LTR supports the collection of cancer data for the in-house regions (Regions 1 and 3), as well as the LTR’s subcontractors located at non-profit organizations around the state (Mary Bird Perkins Cancer Center, Acadiana Medical Research Foundation, Christus St. Patrick Hospital (contract ended 06/30/2014), and the University of Louisiana at Monroe). Oversight of the registry has been exercised by the Louisiana Cancer Advisory Board (previously known as the Louisiana Cancer and Lung Trust Fund Board), whose members represent various health institutions throughout the state and are appointed by the governor (see [Acknowledgements](#), above). Vivien W. Chen, Ph.D., served as the director of the registry from 1991 until 2012. On July 1, 2012, Xiao-Cheng Wu, MD, MPH, ODS-C, assumed the directorship.

Joining the CDC’s National Program of Cancer Registries (NPCR)

Since 1994, the Centers for Disease Control and Prevention (CDC) has provided funds for most states, including Louisiana, to participate in the National Program of Cancer Registries (NPCR). When CDC-NPCR was established, many states had already established a cancer registry program, including Louisiana. For those states that already had an established program, limited funding was received for enhancements to advanced activities, such as quality control audits, registry education and training programs, and data use to support cancer control programs.

Joining the NCI’s Surveillance, Epidemiology, and End Results (SEER) Program

In 2001, after a competitive application process, the LTR was selected to join the NCI’s SEER Program as an expansion registry on a provisional basis. Four years later, it became a full member of SEER. In 2017, the LTR again participated in a competitive application process and was awarded funding for 10 years (2018-2028). The funds from NCI-SEER are used for specific tasks, including the collection of patient follow-up data, more advanced case editing and consolidation, quality improvement and evaluation activities, and more complete data collection from non-hospital settings. In addition, these funds are used to enhance LTR infrastructure to support research, such as increasing electronic pathology reporting, conducting linkages with external datasets, and improving processing efficiency and quality through natural language processing initiatives.

Operations of the Registry

The operations of the registry are mandated by public law, R.S. 40:1105.1 et seq., which requires all medical facilities and health care providers to provide information on all reportable cancer cases defined by national standards to the registry or provide access to medical records so that LTR staff members can collect the required information according to the national standards. The legislative rules require strict confidentiality of all data.

Central Office and Regional Registries

The LTR comprises a central office and eight regional registries, based on Louisiana’s historic Office of Public Health districts ([Appendix B](#)), at four locations (New Orleans, Baton Rouge,

Lafayette, and Monroe) that collect and process cancer incidence data from corresponding catchment areas.

Collection of Cancer Incidence Data

Each regional registry is responsible for the complete ascertainment of cancer cases diagnosed and treated in its region. About one-fourth of all hospitals in Louisiana maintain their own cancer registries which covers about two-thirds of incident cases, and the regional registries are responsible for abstracting cases from the remaining hospitals and other facilities such as treatment centers, outpatient surgical facilities, physician offices, and freestanding pathology laboratories.

Regional registries monitor the facilities in their area for completeness of case ascertainment, as well as consolidate multiple reports from multiple sources to obtain accurate cancer information on the same case. The central office oversees and monitors operations of regional registries, conducts quality assurance and case completeness audits, and coordinates regional offices to ensure the quality, completeness, and timeliness of reporting. The central office leads the direction of the Louisiana cancer surveillance system by promulgating new legislative rules to meet the needs of cancer registry operations, building infrastructure to electronically capture and report cancer cases, establishing new procedures to improving the efficiency of data processing, and training new hospital registry employees on state requirements. The central office also assists the regional offices by resolving issues with non-compliant reporting facilities. Additionally, the central office plays an essential role in enhancing the use of cancer registry data by conducting research and participating in or supporting cancer research with partners and stakeholders. Furthermore, its research staff respond to data requests, prepare publications, and participate in research activities.

Exchange of data with other state cancer registries began in 1997 to ensure a higher level of case ascertainment and data completeness. This permits the LTR to obtain cancer data on residents of Louisiana who have traveled out of state for cancer diagnosis and/or treatment. In October of 2014, Louisiana signed the National Interstate Data Exchange Agreement. Louisiana now has established agreements with 50 population-based cancer registries, including 45 states (all neighboring states), Washington D.C., three United States territories (Guam, Puerto Rico, and the Virgin Islands), and Bermuda. Strict protocols on patient confidentiality are followed.

Reportable Diagnoses

The LTR complies with national standards in requiring that all in situ and invasive neoplasms (cancers with behavior codes 2 or 3 in the *ICD-O-3* [1]) are reported. Carcinoma in situ of the cervix and cervical intraepithelial neoplasia III (CIN III) were reportable for cases diagnosed before 1996. CIN III was again deemed reportable for cases diagnosed after 2008 in Louisiana and 3 other state cancer registries with funding support from the CDC-NPCR. While funding from CDC-NPCR for the CIN III project was discontinued, the LTR has continued collecting this data through the support of the LSU-LCMC Cancer Center since July 2022. Non-reportable cancers include intraepithelial carcinoma of the prostate diagnosed in 2011 and after and basal and squamous cell carcinomas of the skin regardless of diagnosis year.

Benign and borderline tumors of the brain and central nervous system are also reportable in accordance with national standards if diagnosed in 2004 and after, but rates and counts are only presented for children and adolescents (ages 0-19) in this monograph in compliance with nationwide cancer surveillance monographs. Rates and counts for these tumors are not reported for adults, because the completeness of these benign tumors is uncertain. In addition, pilocytic astrocytoma is classified as benign by the World Health Organization but as malignant in North America.

Data Quality

Quality assurance procedures in the LTR regional registries and central office minimize abstracting and coding errors and ensure and evaluate the completeness of case ascertainment.

Activities to Ensure Complete Case Ascertainment:

To ensure complete case ascertainment, several activities are conducted routinely. One of these activities utilizes electronic pathology reports in the registry database. Reportable pathology reports that are not attached to a submitted case are investigated to identify if the case is indeed reportable and why that case was not submitted. The LTR also conducts casefinding audits on a routine basis for selected facilities each year to ensure that cases have not been missed. The LTR requests a disease index from each facility being audited, links that list with existing cases, and identifies potentially reportable cases that were not submitted. Then, the facility investigates those cases to see if any reportable cases need to be abstracted.

Furthermore, unrecorded cancer diagnoses identified among Louisiana residents through an annual linkage with death certificates are traced back to hospitals, other facilities, or physician offices to be abstracted. If the original diagnostic information cannot be located, the case is considered a “death-certificate-only” case, and the date of death is recorded as the diagnosis date in compliance with standard practices of cancer surveillance. Since some Louisiana cancer patients may die outside of the state, their deaths may not be recorded within Louisiana’s death certificates. Thus, the LTR links its data with the National Death Index annually to capture death information for those who died in other states.

The LTR also conducts annual casefinding audits using disease indices to identify any missed cases, as well as the Louisiana Hospital Inpatient Discharge Database (HIDD) file to primarily capture missed cases of the brain, kidney, pancreas, liver, lung, and myeloma, which are more likely to be clinically diagnosed, to ensure complete case ascertainment.

Activities to Ensure High Quality Data:

In addition to collecting all reportable cases, the LTR works tirelessly to ensure high quality data. Electronic and manual review and consolidation of all reportable cases is conducted by the LTR’s editing team, which allows us to identify and correct inconsistencies in the data. Furthermore, the LTR conducts recoding audits, consolidation audits, and re-abstraction audits to further validate its data.

Data Standards:

To enhance the quality of incidence data across the U.S., the North American Association of Central Cancer Registries (NAACCR) sets standards for quality, timeliness, and completeness. Data from U.S. central cancer registries that meet those standards are used in calculating the “U.S. Combined Cancer Incidence Rates,” which are reported in NAACCR’s annual publication, *Cancer in North America*. LTR data have qualified for inclusion every year since the inception of the certification process in 1997 and have been certified at the gold level for high quality and timely data every year since 1997. The LTR has also received the first-place award every year since 2009 from the SEER program for meeting all data quality benchmarks on completeness, timeliness, and follow-up rates. In addition, the LTR has achieved the NPCR Standards for Data completeness, Timeliness, and Quality since 2002 and received a Registry of Excellence or Distinction award from the CDC’s NPCR since 2015.

Data Use

LTR data are included in many cancer surveillance publications that accept only high-quality data: *Cancer Incidence in Five Continents*, published by the World Health Organization’s International Association for Research on Cancer; *United States Cancer Statistics*, published by the CDC and the NCI; *SEER Cancer Statistics Review*, published by the SEER Program; CINA Deluxe, published by NAACCR; State Cancer Profiles, published by the CDC; and the SEER Public Use data file. Links to several of these publications can be found in [Appendix E](#).

To enhance cancer registry data dissemination and access to LTR data, in 2019, the LTR launched an interactive, user-friendly [data visualization tool](#) on its website presenting cancer incidence, mortality, and survival rates, as well as region and parish-specific statistics and prevalence counts. In 2021, LTR released a dashboard presenting cancers associated with tobacco, obesity, alcohol, and HPV. Additionally, LTR data are presented in several external data visualization websites: State Cancer Profiles, United States Cancer Statistics: Data Visualizations, American Cancer Society: Cancer Statistics Center, NAACCR: CiNA Explorer, and SEER*Explorer. Links to these data visualization websites can be found in [Appendix E](#).

Confidentiality of Data

Confidentiality is of the highest priority in LTR operations. Louisiana law mandates strict confidentiality of data about cancers and health care providers and protects participating facilities and physicians from any liability that may arise from reporting to the cancer registry program. LTR Data Release Policies are in accordance with HIPAA rules and state law. Any request for case-level cancer data will be reviewed and approved by the LTR Research Committee as required by law.

LTR personnel sign an “Agreement to Maintain Confidentiality of Data” and are subject to penalty if they disclose confidential information. LTR data are published in aggregate form only. Data released in public presentations or publications are not intended to correspond to individual cases.

Presentation of the Data

Volume 39 of *Cancer in Louisiana* presents cancer incidence and mortality information about residents of Louisiana diagnosed with cancer between January 1, 2017 and December 31, 2021. Statistics on incidence are found in Tables A–I, and Tables J–O contain data on mortality. Survival statistics can be found in Figure 1, Figures 3–7, Figure 11, and Table P. Statistics on prevalence in Louisiana are included in this volume in Tables Q and R.

Incidence and mortality rates are provided for the state, the regions of the LTR, the regions of the OPH and the Louisiana Cancer Prevention and Control Programs, the Industrial Corridor (7-Parish and 11-Parish), and individual parishes. While parish is the smallest geographic region presented in this monograph, cancer data at the census tract level can be found in our annual report [Cancer Incidence in Louisiana by Census Tract, 2011–2020](#). Visit <http://new.dhh.louisiana.gov/index.cfm/page/394> for descriptions of the OPH and Cancer Control Program regions.

To ensure statistical stability, rates are not presented when based on fewer than 16 cases or deaths, which is in compliance with the rule used by the United States Cancer Statistics (<https://www.cdc.gov/united-states-cancer-statistics/technical-notes/suppression.html>).

Incidence counts are not presented when there are fewer than 6 cases to preserve confidentiality of the data; mortality counts are not presented by the NCI when there are fewer than 10 cases.

Data Use Standards

Incidence

Cancer incidence, the best indicator of cancer risk in a population, is the number of new cancers of a specific site/type diagnosed by medical professionals in a specified population during a specific diagnosis year. The LTR follows standard protocols in computing and publishing cancer incidence data so that Louisiana data can be compared with those from other cancer surveillance publications. These conventions include:

- Only primary cancers are included in the LTR database used for calculating incidence counts or rates.
- SEER Multiple Primary and Histology Coding Rules for cases diagnosed in 2007–2017 (<https://seer.cancer.gov/tools/mphrules/>) and SEER Solid Tumor Rules for 2018 onward (<https://seer.cancer.gov/tools/solidtumor/>) are used to determine whether multiple primary cancers for a given patient are considered one case or more than one.
- For preparing statistics, anatomic subsites are combined according to code groupings compiled by the SEER Program of the NCI (https://seer.cancer.gov/siterecode/icdo3_dwhoheme/index.html).
- Except for bladder cancer, only invasive neoplasms are included in the tables for incidence rates (ICD-O-3 behavior code of 3 (Malignant)) to be consistent with other cancer surveillance monographs published by NCI, CDC, NAACCR, and the American Cancer Society (ACS). For cancers of the bladder, both in situ and invasive cases are included. In situ carcinomas of the breast are listed separately from the invasive cancers and are

excluded from the “all sites” totals.

- Neoplasms of the lymphatic, hematopoietic, and reticuloendothelial systems (e.g., lymphomas and leukemias), as well as mesothelioma and Kaposi sarcoma, are grouped by their histologies and not by the anatomical sites where they occur.

Cancer Deaths (Mortality)

Information on residents of Louisiana who died with cancer as the underlying cause of death was compiled by the National Center for Health Statistics, using mortality data from the Louisiana OPH and its counterparts in other states. Louisiana residents who died out of state are included in Louisiana statistics.

The SEER Program’s detailed anatomical site codes from the *International Classification of Diseases, 10th Revision* for calculating mortality statistics can be found at its website: https://seer.cancer.gov/codrecode/1969_d03012018/index.html.

Survival

The SEER program requires follow-up data collection for all cancer patients from the time of diagnosis to death. Survival statistics in this volume were based on cases diagnosed from 2010 through 2020 followed into 2021. The cases diagnosed in 2021 are excluded from the survival analyses since these patients may have less than 1 year of follow-up. For patients with more than one cancer, only the first cancer was included in the analysis. Also excluded are those with unknown age, who are lost to follow-up, and cases diagnosed at death and/or autopsy.

To conduct the survival analysis, cancer stage was coded using Combined Summary Stage, a staging method established by the NCI’s SEER program, at diagnosis, and survival rates were grouped by cancer stage at the time of diagnosis. Combined Summary Stage is created from SEER Combined Summary Stage 2000 (2004-2017) and Derived Summary Stage 2018 (2018+). It consists of five categories, which combine the clinical and pathological documentation of disease. Although our analysis focuses on Local, Regional, and Distant Stage, the five main categories and a brief description of each are below.

1. In Situ – The presence of malignant cells within the cell group from which they arose, and the abnormal cells have not penetrated the protective basement membrane of the tissue. This diagnosis can only be made microscopically and excludes organs and tissues without an epithelial layer.
2. Localized – A malignancy limited to the organ of origin, but the cancer has invaded the protective epithelial (basement) membrane.
3. Regional – The broadest category, can include malignant cancer that 1) has extended beyond the organ of origin directly into surrounding organs or tissue; 2) involves the regional lymph nodes; or 3) has both regional extension and involvement of regional lymph nodes.
4. Distant – A malignancy that has broken away from the primary tumor and has travelled to other parts of the body and begun growth. This stage is often referred to as metastasis.
5. Unknown – A malignancy with an unknown primary site or for which crucial staging data were not recorded will be assigned an unknown summary stage.

Prevalence

Cancer prevalence is defined as the number or percent of people alive on a certain date in a population who previously had a diagnosis of cancer, regardless of how long ago the diagnosis occurred (complete prevalence), which includes new (incidence) and pre-existing cases. Prevalence estimates are generally limited-duration prevalence due to the length of time cancer registries have been in existence. Prevalence provides little information on the risk of cancer in a population. [See Overview of Prevalence at <https://surveillance.cancer.gov/prevalence/>]

For prevalence statistics, 21-Year limited duration prevalence is presented in this monograph. For all cancer sites, the first invasive tumor for each person diagnosed during the previous 21 years (2000-2020) is counted. For each specific cancer site, the first invasive tumor for each site diagnosed during the previous 21 years (2000-2020) is included. Breast tumors include both sexes, and the urinary bladder category includes in situ cases.

Race

Race for cancer cases is based primarily on information contained in a patient's medical record, supplemented by information on death certificates, the HIDD file, and voter registration files.

Louisiana cancer incidence and mortality data in this volume utilizes a new race variable that is recommended by the SEER Program: "Race and origin (recommended by SEER)" (https://seer.cancer.gov/seerstat/variables/seer/race_ethnicity/). This is a system-supplied merged variable and includes five mutually exclusive race and ethnicity categories that SEER uses for reporting cancer statistics: non-Hispanic (NH) White, NH Black, NH American Indian/Alaska Native, NH Asian or Pacific Islander, and Hispanic. While this change will not affect the overall cancer incidence, mortality, and survival statistics, statistics presented by race/ethnicity will reflect these mutually exclusive race and ethnicity categories.

Counts and rates for Hispanics, NH American Indians/Alaska Natives, and NH Asian or Pacific Islanders are included in Tables A1, A2, D1, and D2. Other groups were not analyzed separately because of small case numbers. Less than one percent of 2017-2021 cases were of unknown race. Cases with unknown race were included in the calculations of rates for "all races and ethnicities" but not in the race-specific computations.

Population Estimates

Five-year population estimates by race, sex and age for Louisiana and the U.S. were obtained from the NCI and are based on the U.S. Census Bureau's estimates of the populations for 2017-2021 or specified years. More details regarding the population estimates utilized can be found here: <https://seer.cancer.gov/popdata/methods.html>.

Age Adjustment

Age adjustment allows meaningful comparisons of cancer risk across different populations by controlling for differences in the age distributions of those populations. This is important because cancer is diagnosed more frequently among the elderly. Age-adjusted rates are the weighted average of the age-specific rates, where the weights represent the age distribution of a standard

population.

Rates in this monograph are age adjusted to the 2000 U.S. standard population. Rates in earlier publications (with data predating 1999), however, were age adjusted to the 1970 U.S. standard population. Because the U.S. populace was older in 2000 than in 1970, the new standard will cause most rates to appear to rise markedly. Thus, incidence and mortality rates in Volumes 1-16 of this series should not be compared with those in subsequent volumes.

Comparison Groups

Incidence

Estimates of the average annual age-adjusted incidence rates for the U.S. were calculated using data from the SEER Program of the NCI. Data from the SEER Program are recognized for their high quality, and SEER estimates have been traditionally cited as national rates.

The SEER Program estimates in this volume are based on data representing up to 26.5% of the U.S. population¹. The SEER 8 (previously 9) includes five states (Connecticut, Hawaii, Iowa, New Mexico, and Utah) and three metropolitan areas (Atlanta, San Francisco – Oakland, and Seattle/Puget Sound). The SEER 17 (previously 18) includes nine states (California, Connecticut, Georgia, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico and Utah), one metropolitan area (Seattle-Puget Sound), and the Alaska Native Tumor Registry. For more information on registry groupings in SEER data and statistics, please visit: <https://seer.cancer.gov/registries/terms.html>.

Mortality

Mortality statistics for the U.S. are based on data from the National Center for Health Statistics, to which all states submit death certificate information.

Calculations

The following databases in SEER*Stat, developed by the NCI, were used for all calculations:

Incidence

Frequency Sessions:

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 17 Registries, Nov 2023 Sub (2000-2021) - Linked To County Attributes - Total U.S., 1969-2022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2024, based on the November 2023 submission.

Rate Sessions:

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 17 Registries, Nov 2023 Sub (2000-2021) - Linked To County Attributes - Total U.S., 1969-2022 Counties, National Cancer Institute, DCCPS,

¹ <https://seer.cancer.gov/registries/data.html>

Surveillance Research Program, released April 2024, based on the November 2023 submission.

Rate Session, Time Trends:

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 17 Registries, Nov 2023 Sub (2000-2021) - Linked To County Attributes - Total U.S., 1969-2022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2024, based on the November 2023 submission.

Mortality

Frequency Sessions:

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With County, Total U.S. (1969-2021) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released May 2024. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Rate Sessions:

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With County, Total U.S. (1990-2021) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released May 2024. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Rate Session, Time Trends:

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2022) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2024. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Survival

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 17 Registries, Nov 2023 Sub (2000-2021) - Linked To County Attributes - Total U.S., 1969-2022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2024, based on the November 2023 submission.

Prevalence

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 17 Registries, Nov 2023 Sub (2000-2021), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2024, based on the November 2023 submission.

Cautions in Interpretation

Misperceptions, Misinterpretation, and Misapplication of Cancer Registry Data

Population-based cancer registry data is intended to support cancer prevention, control, and research. Cancer registry data allows us to monitor cancer incidence over time, guide cancer control programs, identify priorities for allocation of healthcare resources, and advance clinical, epidemiologic, and health services research. In comparing rates among geographic areas, it is important to keep in mind that various factors, in addition to true differences in the risk of developing or dying from cancer, can contribute to variations in cancer rates. Therefore, geographic differences should be interpreted with caution and used to generate, not test, hypotheses.

Summary cancer incidence rates for geographies within the state (i.e., Regions, Industrial Corridor, Parishes, etc.) do not represent cancer incidence in subset populations within that geography, such as fenceline communities. Fenceline communities (those communities bordering or near industrial facilities) are a much smaller geographic area. To study the impact of industrial facilities on the risk of cancer, in-depth research that considers facility-specific exposures, confounding variables, disease latency, sampling error, and systematic and random error would need to be conducted. Such research is beyond the scope of population-based cancer registry data and LTR's essential responsibilities.

The lack of significantly higher cancer rates in census tracts, parishes, regions, etc., does not mean problems associated with environmental exposures in smaller geographic areas do not exist. This is a common misperception that we feel very strongly is important to correct.

The following facts explain why such assertions are fundamentally scientifically unsound:

- **Ecological Fallacy:** One cannot conclude that data for a wider geographic area apply to a smaller population within that area that is differentially exposed to other sources. Not everyone in a parish or even a census tract will be exposed to the same pollution levels emitted from specific facilities. Therefore, measures of diseases among an exposed community could be diluted when using a summary statistic from a larger unexposed population.
- **Causal Associations:** The various chemical emissions and releases and the variety of industry sources in some areas make it extremely difficult, if not impossible, to establish a specific link between one disease and a particular chemical emission or release when using population-based data. For example, gaps in our understanding of long-term health impacts of early-life low-dose chronic exposures to one chemical and chemical mixtures present a problem for establishing links, as frequently we do not know which diseases to look for in relation to those compounds and mixtures. Another complicating factor is when there are multiple possible health outcomes from the same exposures or a mix of exposures.

- **Non-Cancer Health Effects:** There are many chemical compounds to which exposures can manifest as different diseases - besides cancer. For example, particulate matter can produce respiratory or cardiovascular disease. Other disease outcomes include asthma, chronic obstructive pulmonary disease, adverse reproductive and developmental outcomes, irritation of the nose, eyes, throat, and lungs, and immune system diseases.
- **Cancer Risk Factors:** Health statistics are impacted not just by the outside environment but also by other risk factors, including confounders. For example, the age of the population, their diet, their smoking status, their access to and use of health care services, differences in genetic predispositions, different behaviors like outdoor activities, and a variety of other factors can influence the exposures or health outcomes of interest that one would expect in a population, as these factors will be unevenly distributed within a population. Moreover, it is always possible that the majority of a fenceline community can consist of workers in those nearby factories. Workers are usually subject to what is called the “healthy worker effect,” in that they are often healthier than the general population, which also consists of children, the elderly, the sick, pregnant women, etc.
- **Cancer Latency:** The long latency of some cancers, that is, the years to decades it takes to manifest between the time it is triggered and the time a diagnosis is made, makes it impossible to assert that a lack of significantly higher cancer rates in one area suggests there is no problem with the current environmental conditions. This factor is further complicated when the population is susceptible to mobility due to either natural disasters, the search for job opportunities, or the need for specialized health care not available in their area. Latent periods for some cancers can be as long as 40 years.
- **Sample Size:** Small population sizes often lack statistical power. Any summary statistic for a small population can be an artifact of the small number of people in the area. It is less likely that an effect will be detected in a smaller (vs. larger) population because smaller datasets yield less precise estimates due to more significant impacts from sampling error and random error.

Summary

Incidence, 2017-2021

1. Number of new cancer cases: New diagnoses of invasive cancer averaged 26,851 cases per year among Louisiana residents ([Table A1](#)).
2. Most frequently diagnosed cancers: For all Louisianans combined, the most frequently diagnosed cancers were prostate (14.8% of all new cases), breast (13.9%), lung (13.1%), colorectal (9.0%), and kidney (4.8%) ([Table A2](#)).
3. Highest annual incidence rates per 100,000 people: The 5 most frequently diagnosed cancers in Louisiana are: (1) prostate (141.6), (2) female breast (130.4), (3) lung (61.1), (4) colorectal (44.5), and (5) kidney/renal pelvis (23.4). In the U.S., however, the following is the order of highest rates: female breast, prostate, lung, colorectal, and melanoma of the skin. The five most common invasive cancers by race/sex group in Louisiana were ([Table B](#)):
 - a. NH White men: prostate (124.6 cases per 100,000 people), lung (72.5), colorectal (49.2), bladder (37.0), and kidney/renal pelvis (33.3).
 - b. NH Black men: prostate (197.8), lung (89.5), colorectal (60.8), kidney (29.8), and liver/bile duct (22.1).
 - c. NH White women: breast (130.2), lung (54.9), colorectal (37.6), thyroid (22.6), and melanoma of the skin (20.6).
 - d. NH Black women: breast (137.3), lung (44.4), colorectal (43.6), uterus (24.6), and pancreas (15.6).
4. Louisiana vs. nationwide rates: The incidence rates for cancers of all sites combined among NH White and NH Black men as well as NH Black women in Louisiana were significantly higher than those for their national counterparts ($p < 0.05$). However, the rate for NH White women in the state did not differ significantly from the nationwide rate ([Table C1](#)).
5. 7-Parish Industrial Corridor: The 7-Parish Industrial Corridor includes Ascension, East Baton Rouge, Iberville, St. Charles, St. James, St. John the Baptist, and West Baton Rouge parishes. The incidence rates for all cancers combined in NH Black men were significantly higher than the statewide rate. Rates for all cancers combined for NH White men, NH White women, and NH Black women did not differ significantly from the Louisiana rates ([Table C1](#)).
6. 11-Parish Industrial Corridor: The 11-Parish Industrial Corridor includes Ascension, East Baton Rouge, Iberville, Jefferson, Orleans, Plaquemines, St. Bernard, St. Charles, St. James, St. John the Baptist, and West Baton Rouge parishes. The incidence rates for all cancers combined for the 4 race/sex groups were significantly lower than the statewide rate. ([Table C2](#)).
7. Hispanic Population: The incidence rates for cancers of all sites combined among Hispanic people in Louisiana are significantly lower than those of their national counterparts for men and women. Louisiana Hispanic people also have significantly lower incidence rates of colorectal, breast, uterine, and ovarian cancer among women, and significantly lower

incidence rates of colorectal, liver/bile duct, lung, prostate, and brain/other nervous system cancer among men ([Table D1](#)).

8. NH American Indians/Alaska Natives, Asians and Pacific Islanders (AI/AN and APIs): The incidence rates for cancers of all sites combined among NH AI/AN and APIs in Louisiana are significantly lower than those of their national counterparts for women and did not differ significantly for men. Louisiana NH AI/AN and APIs also have significantly lower incidence rates of breast, uterine, and ovarian cancer among women, a significantly higher incidence rate of kidney cancer among women, and a significantly higher incidence rate of liver/bile duct cancer among men ([Table D2](#)).
9. Cancer among children and adolescents: Louisiana's incidence rates for all sites combined among children and adolescents (aged 0–19) were lower than U.S. rates for both boys and girls, but only the rate for girls was significantly lower ([Figure 11](#)). The most common cancers among children and adolescents in Louisiana are central nervous system tumors ([Tables H1-H3](#)); this is also true for the U.S. However, if you exclude benign and borderline brain tumors, the most common cancer in Louisiana and the U.S. among children is leukemia.
10. Tobacco-Related Cancers: The incidence rates of tobacco-related cancers are significantly higher in Louisiana than in the U.S. for all race and sex groups ([Figure 8](#)).
11. Obesity-Related Cancers: Incidence rates for obesity-related cancers are significantly higher in Louisiana than in the U.S. for the four major race-sex groups, with the exception of incidence for white women, which is not significantly different from the national rate ([Figure 9](#)).
12. HPV-Related Cancers: Incidence rates for HPV-related cancers are significantly higher in Louisiana than in the U.S. for NH White men, NH White women, and NH Black women. The incidence rate for NH Black men is not significantly different from the national rate ([Figure 10](#)).


Cancer Deaths, 2017-2021

1. Total cancer deaths: An average of 9,364 deaths were attributed to cancer each year, 2017-2021 ([Table J1](#)). Only heart disease caused more deaths (an average of 11,744 per year in Louisiana) than cancer.
2. Leading causes of cancer death: For all Louisiana residents combined, cancer mortality was highest for cancer of the lung (25.8% of all cancer deaths), colorectum (9.2%), pancreas (7.4%), breast (7.2%), and liver/bile duct (5.6%) ([Table J2](#)).
3. Highest annual mortality rates: The highest rates for cancer death in Louisiana were ([Table K](#)):
 - a. NH White men: lung (52.8 per 100,000 person-years), colorectum (17.5), prostate (16.4), pancreas (13.6), and liver/bile duct (11.5).
 - b. NH Black men: lung (67.9), prostate (35.0), colorectal (26.1), liver/bile duct (18.3), and pancreas (16.8).
 - c. NH White women: lung (35.4), breast (20.4), colorectal (11.8), pancreas (10.4), and ovary (6.2).
 - d. NH Black women: lung (30.1), breast (28.7), colorectal (16.1), pancreas (12.9), and uterus (7.9).
4. Louisiana vs. nationwide rates: Statewide, each of the four major race/sex groups had a significantly higher death rate for all sites combined than its national counterpart. Lung, colorectal, liver, and kidney mortality rates were significantly higher in Louisiana than in the U.S. for all four race-sex groups ([Table L1](#)).
5. 7-Parish Industrial Corridor: Death rates for all cancers combined were significantly lower than those for Louisiana among NH White men, NH White women, and NH Black women; NH Black men in the Industrial Corridor experienced about the same mortality rates as their counterparts statewide ([Table L1](#)).
6. 11-Parish Industrial Corridor: Death rates for all cancers combined were significantly lower than those for Louisiana among all race/sex groups ([Table L2](#)).
7. Cancer death among those aged 0-19: In Louisiana's 0–19 age-group, the mortality rates were about the same in Louisiana and the U.S. for both boys and girls. ([Figure 11](#)).
8. Tobacco-Related Cancers: The mortality rates of tobacco-related cancers are significantly higher in Louisiana than in the U.S. for all race and sex groups ([Figure 8](#)).
9. Obesity-Related Cancers: The mortality rates for obesity-related cancers are significantly higher in Louisiana than in the U.S. for the four major race-sex groups ([Figure 9](#)).
10. HPV-Related Cancers: The mortality rate for HPV-related cancers is significantly higher for NH black men and women in Louisiana when compared to their national counterparts. The rates for NH White men and women did not differ significantly from the nationwide rates ([Figure 10](#)).

Note: All incidence and death rates in this volume are average annual rates per 100,000 population for the five-year period, except for incidence rates for those 0-19 years of age, which are presented as average annual rates per 1,000,000 population for the five-year period. They are age adjusted to the U.S. 2000 standard and should **not** be compared with rates that are adjusted to the 1970 population.

Figures

Figure 1. All Cancers Combined



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate is significantly higher than the U.S. rate (p < 0.05).

U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute. Underlying mortality data provided by NCHS (National Center for Health Statistics).

Incidence

- An average of **26,851 new cases of invasive cancer** were diagnosed each year, 2017-2021, in Louisiana ([Table A1](#)).
- Invasive cancer incidence rates are significantly higher in Louisiana for NH White men, NH Black men, and NH Black women when compared to their national counterparts (Figure 1a, above).

Mortality

- An average of 9,364 deaths had an underlying cause of death of cancer in Louisiana each year, 2017-2021 ([Table J1](#)).
- Cancer mortality rates in Louisiana are significantly higher for all four race-sex groups when compared to their national counterparts (Figure 1b, above).
- Nearly half (49.6%) of the cancer deaths in Louisiana from 2017-2021 were attributed to lung, colorectal, breast, and pancreatic cancers ([Table J2](#)).

Figure 1c. 5-Year Survival, LA Male, All Cancers, 2010-2020*





Figure 1d. 5-Year Survival, LA Female, All Cancers, 2010-2020*




*Cases diagnosed from 2010 through 2020 and followed into 2021

Survival rates calculated using the Actuarial method with the Ederer II method used for cumulative expected.

5-Year Relative Survival

- Five-year relative survival for all cancers combined diagnosed in Louisiana between 2010 and 2020 showed a steady decline by summary stage at diagnosis for males (90.0%, 61.0%, and 27.0% for localized, regional, and distant stage, respectively) and females (89.1%, 66.2%, and 29.8%, respectively) of both races.
- NH White males diagnosed at regional and distant stages had a significantly higher survival rate compared to NH Black males in the same category; no significant difference was identified at the localized stage.
- NH White females had significantly higher 5-year relative survival rates than NH Black females at all stages of diagnosis.

Figure 2. Time Trends: All Cancers Combined



¹U.S. incidence rates are based on 8 regions from the SEER Program of the National Cancer Institute.


²Underlying mortality data provided by NCHS (National Center for Health Statistics).

*Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups - Census P25-1130) standard.

Incidence & Mortality

- Cancer incidence and mortality are higher for men in Louisiana than in the U.S.
- Over time, however, both trends have been declining for men in Louisiana and in the U.S.
- For women, mortality is declining in Louisiana and the U.S., but this trend is not seen in the overall cancer incidence rates.
- The sharp decline in incidence rates from 2019 to 2020 is attributed to delayed cancer screenings and diagnoses caused by the COVID-19 pandemic.

Figure 3. Lung Cancer



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate is significantly higher than the U.S. rate ($p < 0.05$).

U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.

Underlying mortality data provided by NCHS (National Center for Health Statistics).



Risk factors for lung cancer include [2]:		
Cigarette use	Certain metals (chromium, cadmium, arsenic)	<u>Other occupational risks:</u>
Cigar and pipe smoking	Some organic chemicals	Rubber manufacturing, paving,
Secondhand smoke	Radiation	roofing, painting, chimney
Radon gas	Air pollution	sweeping, aluminum
Asbestos	Diesel exhaust	production, and steel founding.

Incidence

- Lung cancer incidence rates are significantly higher in Louisiana than in the U.S. for NH White men, NH Black men, and NH White women (Figure 3a, above).
- Lung cancer accounted for 13.1% of all new cancer diagnoses from 2017 to 2021 in Louisiana ([Table A2](#)).
- For NH White men, NH White women, and NH Black women, lung cancer incidence rates in the 7-Parish Industrial Corridor are significantly lower than the statewide rates ([Table C1](#)). For the 11-Parish Industrial Corridor, lung cancer incidence rates are significantly lower than the statewide rates for all race-sex groups except NH Black women ([Table C2](#)).

Mortality

- Louisiana mortality is significantly higher than the national levels for all four race-sex groups (Figure 3b, above).
- Lung cancer accounted for 25.8% of all cancer deaths from 2017-2021 in Louisiana ([Table J2](#)).




*Cases diagnosed from 2009 through 2019 and followed into 2020

Survival rates calculated using the Actuarial method with the Ederer II method used for cumulative expected.

5-Year Relative Survival

- For lung cancer diagnosed in Louisiana (2010-2020), the 5-year relative survival consistently dropped based on the summary stage at diagnosis for both males (48.3%, 26.0%, and 5.6% for localized, regional, and distant stage respectively) and females (55.8%, 32.4%, and 7.5%, respectively).
- Females had a 5-year relative survival significantly higher than males at all stages of diagnosis. There was no statistically significant difference among NH Black and NH White sex-specific survival at the localized, regional, or distant stage at diagnosis for females.
- Though not detectable above, five-year relative survival at a distant stage at diagnosis was significantly higher for NH Black males when compared to their NH White counterparts.

Figure 4. Colorectal Cancer



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate is significantly higher than the U.S. rate ($p < 0.05$).

U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.

Underlying mortality data provided by NCHS (National Center for Health Statistics).

Risk factors for colorectal cancer include [2]:

Excess body weight ²	Heavy alcohol consumption	Type 2 Diabetes
Physical inactivity	Very low intake of fruits, veggies, and whole-grain fiber	Low calcium intake
Long-term smoking	Personal or family history of colorectal cancer and/or polyps	Certain inherited genetic conditions
Diet high in red or processed meat		Personal history of chronic inflammatory bowel disease



Incidence & Mortality

- Colorectal cancer incidence and mortality rates are significantly higher in Louisiana than in the U.S. for all race-sex groups (Figure 4a-4b, above).
- Colorectal cancer accounted for 9.0% of all new cancer diagnoses and 9.2% of all cancer deaths from 2017 through 2021 in Louisiana ([Table A2](#), [Table J2](#)).
- Incidence and mortality rates of colorectal cancer have decreased in the U.S. and in Louisiana for several decades, which has been attributed to colorectal cancer screening tests, changes in risk factors, and improvements in treatment [2].

Screening

- People at average risk for colorectal cancer should begin screening by the age of 45 and continue up to age 75 depending on health status and prior screening history. Screening provides an opportunity to detect and remove precancerous and cancerous growths; it can identify cancer at an early stage when it is easier to treat. Following screening guidelines can reduce the number of premature deaths related to colorectal cancer [2]. Everyone should discuss the timing and type of screening procedure with his or her physician.

² Defined as those with a body mass index falling in the overweight or obesity categories ($\text{BMI} \geq 25.0 \text{ kg/m}^2$).




* Cases diagnosed from 2010 through 2020 and followed into 2021

Survival calculated using the Actuarial method with the Ederer II method used for cumulative expected.

5-Year Relative Survival

- For cancers of the colon and rectum diagnosed in Louisiana between 2010 and 2020, the 5-year relative survival fell dramatically between regional and distant stage at diagnosis for both males (87.6%, 72.2%, and 12.6% for localized, regional, and distant stage, respectively) and females (90.2%, 72.7%, 14.4%, respectively).
- There was no statistically significant difference in 5-year relative survival between sexes at all stages of diagnosis.
- NH White males and NH White females diagnosed at distant stages had significantly higher ($p < 0.05$) 5-year relative survival than NH Black males and NH Black females in the same categories (Fig. 4c). There was no statistically significant difference among NH Black and NH White sex-specific survival for males and females with localized or regional stages at diagnosis.

Figure 5. Female Breast Cancer



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate differs significantly from the U.S. rate ($p < 0.05$).

U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.


Underlying mortality data provided by NCHS (National Center for Health Statistics).

Incidence & Mortality

- Breast cancer is the most frequently diagnosed cancer among women, both in Louisiana and the U.S. (Table C).
- NH Black women in Louisiana have significantly higher incidence rates than their national counterparts (Figures 5a, and Tables C1 & C2).
 - Continued efforts to expand early detection programs can narrow these gaps. Information about no-cost or reduced-cost mammograms is available through the Louisiana Breast and Cervical Health Program at www.lbchp.org or by calling (888) 599-1073.
- In recent years, breast cancer incidence rates have increased slightly over time. However, since 1989, declines in breast cancer mortality in the U.S. among women have been observed and attributed to both early detection and advances in treatment. Between 1989 and 2021, the mortality rate decreased by 42% in the U.S. [2].

Risk Factors

- Increasing age, family history of breast or ovarian cancer, a long menstrual history, never having had children, having a first child after age 30, recent use of hormonal contraceptives, certain inherited mutations in BRCA1 or BRCA2, certain benign breast conditions, and high breast tissue density are risk factors associated with breast cancer [2].
- Weight gain after the age of 18, being overweight or obese, use of menopausal hormone therapy (combined estrogen and progestin), physical inactivity, and alcohol consumption are potentially modifiable risk factors associated with increased risk of breast cancer [2].




* Cases diagnosed from 2010 through 2020 and followed into 2021

Survival calculated using the Actuarial method with the Ederer II method used for cumulative expected.

5-Year Relative Survival

- For Louisiana women, breast cancer 5-year relative survival rates for those diagnosed between 2010 and 2020 differed significantly by race for each stage at diagnosis.
- The 5-year relative survival for NH White females (99.2%, 87.0%, and 30.7% for localized, regional, and distant stage, respectively) was significantly higher than that for black females (96.1%, 79.0%, and 23.6% for localized, regional, and distant stage, respectively) diagnosed at the same stage.

Figure 6. Prostate Cancer



Incidence & Mortality

- Prostate cancer incidence rates are significantly higher in Louisiana than in the U.S. for both NH White and NH Black men (Figure 6a, above).
- Prostate cancer incidence and mortality are notably higher among NH Black men than NH White men (Figure 6a and 6b, above). This discrepancy is not fully understood.
- Prostate cancer accounted for 27.5% of all new cancer diagnoses and 8.8% of all cancer deaths from 2017-2021 for Louisiana men ([Table A2](#), [Table J2](#)).


Risk Factors

- Well-established risk factors include increasing age, African ancestry, family history of the disease, and certain inherited genetic conditions [2].
- Inherited conditions associated with increased risk include Lynch syndrome and BRCA1 and BRCA2 mutations. Smoking and excess body weight³ may increase the risk of fatal prostate cancer [2].

Screening

- The prostate-specific antigen (PSA) test permits the early detection of prostate cancer. The American Cancer Society recommends that men 50 or older discuss the benefits and limitations of a PSA test with their physicians. Those men at higher risk (i.e. Black men and those with a family history of prostate cancer) are encouraged to speak with their care providers at an earlier age of 45 [2].

³ Defined as those with a body mass index falling in the overweight or obesity categories ($\text{BMI} \geq 25.0 \text{ kg/m}^2$).




*Cases diagnosed from 2010 through 2020 and followed into 2021

Survival calculated using the Actuarial method with the Ederer II method used for cumulative expected.

5-Year Relative Survival

- The 5-year relative survivals for prostate cancer diagnosed at localized and regional stages are 100% for both NH White and NH Black males in Louisiana.
- There was no statistically significant difference in 5-year relative survival among NH Black and NH White males (100.0% vs. 100.0%) when diagnosed at any stage in Louisiana between 2010 and 2020.
- Although 5-year relative survival for NH White men with distant disease (34.6% for NH White; 31.1% for NH Black) appears to be better than black men diagnosed at the same stage, the observed difference was not statistically significant ($p = 0.49$).

Figure 7. Cervical Cancer



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate is significantly higher than the U.S. rate ($p < 0.05$).

U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.

Underlying mortality data provided by NCHS (National Center for Health Statistics).

Incidence & Mortality


- Cervical cancer incidence and mortality rates are significantly higher in Louisiana than in the U.S. for NH Black and NH White women (Figure 7a-7b, above).
- Among women, cervical cancer accounted for 1.8% of all new cancer diagnoses and 1.8% of all cancer deaths from 2017 through 2021 in Louisiana ([Table A2](#), [Table J2](#)).
- Both incidence and mortality have declined over the past several decades, though declines in mortality have begun to taper off in recent years [2].

Risk Factors

- Risk factors for cervical cancer include persistent infection with certain types of human papillomavirus (HPV), having sex at an early age or with multiple partners, immunosuppression, a high number of childbirths, cigarette smoking, and long-term use of oral contraceptives [2].

Prevention & Screening

- Cervical cancer attributed to the most common types of HPV can be prevented through vaccination. These vaccines are available for use in those that are 9 to 12 years of age, with catch-up vaccination through age 26 [2].
- Screening with the Pap test is still recommended and allows for early detection and removal of precancerous lesions. A newer HPV test can detect cervical cancer and precancer by identifying the infection that precedes the cancer [2].



* Cases diagnosed from 2010 through 2020 and followed into 2021

Survival calculated using the Actuarial method with the Ederer II method used for cumulative expected.

5-Year Relative Survival

- For Louisiana women, 5-year relative survival for cervical cancer for those diagnosed between 2010 and 2020 did not differ significantly by race for regional and distant stages at diagnosis.
- NH White females diagnosed at a localized stage had significantly higher ($P < 0.05$) 5-year relative survival (91.9%) than NH Black females in the same category (84.3%) (Fig. 7c).

Pre-Invasive Cervical Lesions by Age and Race


To assess the impact of the HPV vaccine, the LTR collects data on pre-invasive cervical lesions (CIN3). The frequency of these lesions by diagnosis year and age and race can be found in the tables below:

Diagnosis Year	Count	%
2017	1,210	14.26
2018	1,242	14.63
2019	2,137	25.18
2020	1,797	21.17
2021	2,102	24.76
Total	8,488	100.0

Age Group	White	Black	Other	Total
20-29	1,478 (29.7)	927 (31.7)	107 (30.2)	2,512 (30.4)
30-39	2,144 (43.1)	1,209 (41.3)	140 (39.6)	3,493 (42.3)
40-49	806 (16.2)	445 (15.2)	70 (19.8)	1,321 (16.0)
50-59	334 (6.7)	193 (6.6)	21 (5.9)	548 (6.6)
60+	213 (4.3)	151 (5.2)	16 (4.5)	380 (4.6)
Total	4,975 (60.3)	2,925 (35.4)	354 (4.3)	8,254 (100.0)

Exclusion Criteria: Cases aged <20 and unknown race.

Figure 8. Tobacco-Related Cancers



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate is significantly higher from the U.S. rate ($p < 0.05$).

¹Incidence rates include all cancers listed in the table below. U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.

²Mortality rates include all cancers listed in the table below. Underlying mortality data provided by NCHS (National Center for Health Statistics).


Tobacco Use (cigarettes, smokeless tobacco products, and cigars) increases your risk for cancers listed below [2]:

oral cavity	esophagus	bladder	acute myeloid leukemia
pharynx	pancreas	stomach	trachea
larynx	uterine cervix	colorectum	
lung and bronchus	kidney	liver	

Incidence & Mortality

- Incidence and mortality rates for tobacco-related cancers are significantly higher in Louisiana than in the U.S. for the four major race-sex groups (Figures 8a-8b).
 - Despite this, Louisiana is ranked 38th in the nation for its cigarette tax of \$1.08 [3].
- While the risk of these cancers increases with tobacco use, not all the cases utilized to calculate these rates are tobacco related. In other words, it is not known how many of these cases can be attributed to tobacco use.

Figure 9. Obesity-Related Cancers



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate is significantly higher than the U.S. rate ($p < 0.05$).

¹Incidence rates include all cancers listed in the table below. U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.

²Mortality rates include the following sites due to limitations of the cause of death recode: postmenopausal female breast, colorectum, liver, gallbladder, pancreas, corpus uterus, ovary, kidney, thyroid, myeloma, stomach, and esophagus. Underlying mortality data provided by NCHS (National Center for Health Statistics).


Obesity increases your risk for the cancers listed below [4]:

Colorectum	Liver	Gallbladder	Pancreas
Corpus Uterus	Ovary	Kidney	Thyroid
Multiple Myeloma	Postmenopausal Female Breast	Gastric Cardia	Meningioma
Esophageal adenocarcinoma			

Incidence & Mortality

- Incidence and mortality rates for obesity-related cancers are significantly higher in Louisiana than in the U.S. for the four major race-sex groups, except for incidence for NH White women (Figures 9a-9b).
 - Rates of cancers associated with overweight and obesity, except for colorectal cancer, increased by 7% from 2005 to 2014 [4].
 - While all states had more than 20% of adults with obesity, only 3 states had a prevalence of obesity 40% or greater. Louisiana ranks 2nd highest for self-reported obesity at 40.1% [5].
- While the risk of these cancers increases with adult obesity, not all the cases utilized to calculate these rates are obesity related. In other words, it is not known how many of these cases can be attributed to adult obesity.

Figure 10. Human Papillomavirus (HPV)-Related Cancers



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 100,000.

* The Louisiana rate is significantly higher than the U.S. rate ($p < 0.05$).

¹Incidence rates include all cancers listed in the table below. U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.

²Mortality data includes all cervical, anal, vulvar, vaginal, penile, rectal, and oropharyngeal cancers. Underlying mortality data provided by NCHS (National Center for Health Statistics).

HPV increases your risk for cancers listed below as defined by the CDC [6]:

Cervical

Squamous cell carcinomas of:

Oropharynx

Penis

Anus

Vulva

Vagina

Rectum


Incidence & Mortality

- Incidence rates for HPV-related cancers are significantly higher in Louisiana than in the U.S. for the all major race-sex groups with the exception of NH Black men (Figure 9a).
- The mortality rate for HPV-related cancers is significantly higher for NH Black men and women in Louisiana when compared to their national counterparts (Figure 9b).
- While the risk of these cancers increases with HPV, not all the cases utilized to calculate these rates are HPV-related. In other words, it is not known how many of these cases can be attributed to HPV.

Prevention

- CDC recommends that all children who are 11 or 12 years of age should receive the HPV vaccine.
- If not vaccinated previously, HPV vaccination is also recommended for everyone through age 26 [7].

Figure 11. Pediatric Cancer



Average Annual Age-Adjusted (2000 U.S. Standard Population) Rates per 1,000,000.

* The Louisiana rate differs significantly from the U.S. rate ($p < 0.05$).


U.S. incidence rates are from the SEER Program (17 regions) of the National Cancer Institute.

Underlying mortality data provided by NCHS (National Center for Health Statistics).

Incidence rates include all cancers diagnosed among individuals aged 0-19, including myelodysplastic syndromes, benign/borderline brain/CNS tumors, and in situ bladder tumors.

Incidence & Mortality

- Pediatric cancer incidence rates for boys and girls are lower in Louisiana when compared to their national counterparts; however, only the incidence rate for girls in Louisiana and the U.S. are significantly different (Figure 11a, above).
- The most commonly diagnosed cancers in Louisiana among the 0-19 age group continue to be brain and central nervous system tumors, leukemia, and lymphoma ([Table H3](#)).
- The mortality rate for boys and girls aged 0-19 was lower for Louisiana than the U.S., but this difference was not significant (19.1 vs. 21.1 per 1,000,000, respectively).
- Advances in treatment have led to a steady decline in cancer deaths for children and adolescents. In 1975, the mortality rate was 50.7 per 1,000,000 youth, age 0-19, in the U.S., but this has dropped to 21.1 per 1,000,000 youth (2017-2021).



*Cases diagnosed from 2010 through 2020 and followed into 2021

Survival calculated using the Actuarial method with the Ederer II method used for cumulative expected.

Survival rates exclude benign/borderline brain/CNS tumors.

5-Year Relative Survival

- The 5-year relative survival for all pediatric cancers combined diagnosed in Louisiana between 2010 and 2020 falls between 88.4% for NH White females and 79.1% for NH Black males.
- NH White female 5-year relative survival is higher than NH Black female survival (White: 88.4%, Black: 80.7%), but this difference is not statistically significant.
- Similarly, although NH White male survival is higher than NH Black male survival (White: 85.8%, Black: 79.1%), this difference was also not statistically significant.
- No statistically significant difference was found by gender when all races were combined (Male: 84.4% and Female: 86.7%).

Incidence Tables

Table A1. Average Annual Number of Cancer Cases by Site, Race, and Sex, 2017-2021, Louisiana

Primary Site	All Races & Ethnicities			NH White			NH Black			Hispanic			NH AI/AN ¹ & APis ²		
<i>Invasive Cancers³</i>	Total ⁴	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Sites	26,851	14,420	12,430	18,202	9,821	8,382	7,654	4,089	3,566	564	276	287	343	179	164
Oral Cavity and Pharynx	742	545	197	562	417	145	156	111	44	13	9	4	9	6	3
Lip	29	23	6	27	21	6	1	1	^	^	^	^	^	^	^
Tongue	234	170	64	191	140	51	35	25	10	5	4	^	3	^	2
Salivary Gland	66	42	24	46	32	14	16	9	7	2	^	2	^	^	^
Floor of Mouth	35	25	10	23	17	7	11	8	3	^	^	^	^	^	^
Gum and Other Mouth	105	64	40	75	47	28	26	15	11	1	^	^	2	1	^
Nasopharynx	30	22	8	17	12	5	10	8	3	^	^	^	2	1	^
Tonsil	142	120	22	114	96	18	26	22	4	2	2	^	^	^	^
Oropharynx	47	36	11	36	27	9	10	9	2	^	^	^	^	^	^
Hypopharynx	42	33	9	25	19	5	15	12	3	^	^	^	1	1	^
Other Oral Cavity and Pharynx	13	9	3	8	6	2	5	3	2	^	^	^	^	^	^
Digestive System	5,039	2,858	2,181	3,166	1,807	1,359	1,663	926	737	115	63	52	84	55	29
Esophagus	253	201	52	188	154	34	60	42	18	4	3	^	2	2	^
Stomach	384	232	152	195	122	73	166	96	70	14	8	6	7	5	2
Small Intestine	184	95	89	104	57	47	75	36	39	3	^	2	1	^	^
Colon and Rectum	2,419	1,297	1,122	1,553	837	716	770	404	366	50	29	21	41	24	17
Colon excluding Rectum	1,682	864	818	1,076	556	520	547	274	273	31	18	14	24	14	10
Cecum	334	155	179	221	103	118	104	48	56	5	2	2	4	1	3
Appendix	98	42	55	71	30	42	22	11	12	2	1	^	1	^	^
Ascending Colon	329	152	177	212	98	114	110	50	60	4	3	1	3	^	2
Hepatic Flexure	76	43	34	46	25	21	26	15	11	2	1	^	1	1	^
Transverse Colon	158	84	75	99	54	45	54	27	28	3	2	1	2	2	^
Splenic Flexure	54	29	24	28	17	11	23	11	13	1	^	^	^	^	^
Descending Colon	118	67	51	69	43	26	44	22	22	3	^	2	2	1	^
Sigmoid Colon	418	241	177	270	156	114	129	73	56	10	6	3	8	5	3
Large Intestine, NOS	97	51	46	59	30	29	35	19	16	2	^	1	1	^	^
Rectum and Rectosigmoid Junction	737	433	304	477	281	196	223	130	94	19	11	8	17	10	7
Rectosigmoid Junction	127	72	54	86	49	37	35	19	16	3	2	^	3	2	1
Rectum	611	360	250	392	232	159	188	110	78	16	9	7	13	8	5
Anus, Anal Canal and Anorectum	109	40	69	81	28	53	25	12	13	3	^	2	^	^	^
Liver and Intrahepatic Bile Duct	641	474	168	377	275	103	226	172	54	18	11	8	18	15	3
Liver	553	426	127	315	241	74	204	160	45	16	10	6	17	14	3
Intrahepatic Bile Duct	89	48	41	63	34	29	22	12	10	3	^	2	1	^	^
Gallbladder	72	25	47	39	12	26	29	11	18	2	^	2	2	^	^

Other Biliary	87	48	40	58	32	26	24	13	11	3	1	2	2	^	^
Pancreas	813	417	396	523	272	251	262	130	132	16	9	8	10	6	4
Retroperitoneum	16	6	10	9	4	5	6	1	4	^	^	^	^	^	^
Peritoneum, Omentum and Mesentery	21	2	19	14	^	13	7	1	5	^	^	^	^	^	^
Other Digestive Organs	39	21	18	25	13	12	13	7	5	^	^	^	^	^	^
Respiratory System	3,853	2,190	1,663	2,674	1,469	1,205	1,084	668	416	43	23	19	48	27	21
Nose, Nasal Cavity and Middle Ear	42	27	16	29	18	11	10	7	4	2	1	^	^	^	^
Larynx	281	220	62	182	143	40	93	72	21	3	3	^	2	2	^
Lung and Bronchus	3,522	1,939	1,583	2,458	1,305	1,152	978	587	391	37	19	18	45	25	20
Pleura	1	1	^	1	1	^	^	^	^	^	^	^	^	^	^
Trachea, Mediastinum and Other	6	4	2	3	2	2	2	2	^	^	^	^	^	^	^
Bones and Joints	48	25	23	33	17	17	12	6	5	1	^	^	^	^	^
Soft Tissue including Heart	200	115	85	139	85	54	54	26	28	4	2	1	1	^	^
Skin excluding Basal and Squamous	1,074	668	407	1,021	641	381	27	13	14	10	5	5	4	3	^
Melanoma of the Skin	958	597	361	925	580	345	12	6	6	8	4	4	3	2	^
Other Non-Epithelial Skin	116	70	46	96	61	35	15	7	8	2	^	1	1	^	^
Breast	3,743	35	3,708	2,448	24	2,424	1,153	10	1,143	86	^	85	50	^	50
Female Genital System	1,269	--	1,269	791	--	791	413	--	413	41	--	41	20	--	20
Cervix Uteri	221	--	221	119	--	119	84	--	84	12	--	12	5	--	5
Corpus and Uterus, NOS	643	--	643	391	--	391	222	--	222	18	--	18	10	--	10
Corpus Uteri	621	--	621	380	--	380	211	--	211	18	--	18	10	--	10
Uterus, NOS	22	--	22	11	--	11	11	--	11	^	--	^	^	--	^
Ovary	246	--	246	169	--	169	67	--	67	7	--	7	4	--	4
Vagina	27	--	27	16	--	16	10	--	10	^	--	^	^	--	^
Vulva	87	--	87	63	--	63	21	--	21	2	--	2	^	--	^
Other Female Genital Organs	44	--	44	32	--	32	10	--	10	^	--	^	^	--	^
Male Genital System	4,101	4,101	--	2,501	2,501	--	1,460	1,460	--	75	75	--	41	41	--
Prostate	3,966	3,966	--	2,398	2,398	--	1,439	1,439	--	67	67	--	39	39	--
Testis	106	106	--	85	85	--	11	11	--	7	7	--	2	2	--
Penis	22	22	--	13	13	--	8	8	--	^	^	--	^	^	--
Other Male Genital Organs	7	7	--	4	4	--	2	2	--	^	^	--	^	^	--
Urinary System	2,336	1,618	718	1,754	1,246	508	503	319	184	48	33	15	23	15	8
Urinary Bladder	1,000	779	222	816	642	174	159	115	44	14	12	2	8	6	1
Kidney and Renal Pelvis	1,285	810	475	898	579	319	336	201	135	33	20	12	15	8	7
Ureter	27	16	11	23	14	9	3	^	2	^	^	^	^	^	^
Other Urinary Organs	24	14	10	17	12	6	6	2	4	^	^	^	^	^	^
Eye and Orbit	40	24	17	35	20	15	4	2	1	^	^	^	^	^	^
Brain and Other Nervous System	294	166	128	223	127	96	58	32	25	9	4	5	4	2	2
Brain	277	156	121	211	120	92	54	31	23	8	4	5	3	2	1
Cranial Nerves Other Nervous System	17	10	7	12	7	4	3	1	2	^	^	^	^	^	^
Endocrine System	698	198	500	498	149	348	155	37	118	27	7	20	14	3	11
Thyroid	649	171	478	474	136	337	133	25	108	26	7	20	13	2	11

Other Endocrine including Thymus	48	26	22	24	13	11	22	12	10	^	^	^	1	^	^
Lymphoma	1,150	624	527	844	461	383	253	131	123	33	20	14	16	10	7
Hodgkin Lymphoma	131	73	58	82	46	37	42	23	19	5	4	2	2	^	^
Hodgkin - Nodal	130	72	58	81	45	36	41	22	19	5	4	2	2	^	^
Hodgkin - Extranodal	1	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Non-Hodgkin Lymphoma	1,019	550	469	762	416	346	212	108	104	28	16	12	15	9	6
NHL - Nodal	690	377	314	526	289	237	136	71	64	17	9	8	10	6	4
NHL - Extranodal	329	174	155	235	126	109	76	37	39	11	7	4	5	3	2
Myeloma	464	254	210	236	140	96	213	103	110	9	7	2	5	4	2
Leukemia	747	433	314	548	320	228	164	93	72	22	12	9	10	6	4
Lymphocytic Leukemia	370	226	144	283	175	109	70	41	29	12	7	5	3	1	1
Acute Lymphocytic Leukemia	67	39	28	41	23	18	17	10	7	7	5	2	^	^	^
Chronic Lymphocytic Leukemia	283	174	109	226	141	86	49	29	20	4	2	2	2	^	^
Other Lymphocytic Leukemia	20	13	7	16	11	5	3	2	2	^	^	^	^	^	^
Myeloid and Monocytic Leukemia	347	191	156	244	135	109	87	47	40	9	4	4	6	4	2
Acute Myeloid Leukemia	225	124	101	157	86	70	57	31	26	6	3	3	5	3	2
Acute Monocytic Leukemia	6	4	2	4	3	2	1	^	^	^	^	^	^	^	^
Chronic Myeloid Leukemia	113	62	51	80	44	36	28	15	13	3	1	1	1	^	^
Other Myeloid/Monocytic Leukemia	4	3	2	4	2	2	^	^	^	^	^	^	^	^	^
Other Leukemia	29	16	14	20	10	10	7	4	3	^	^	^	^	^	^
Other Acute Leukemia	9	4	4	6	3	3	2	^	^	^	^	^	^	^	^
Aleukemic, Subleukemic and NOS	21	12	9	14	7	7	6	4	2	^	^	^	^	^	^
Mesothelioma	58	41	17	43	31	12	12	8	4	1	^	^	^	^	^
Kaposi Sarcoma	23	21	2	8	7	^	13	12	1	2	2	^	^	^	^
Miscellaneous	971	505	466	677	358	319	257	131	127	24	11	13	10	4	6
<i>In Situ Cancers (not included above)</i>															
Breast In Situ	733	4	730	455	2	454	247	2	245	19	^	19	10	^	10

¹American Indians/Alaska Natives

²Asians and Pacific Islanders

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴The total case count for each cancer site may not have the same number as the sum of male and female due to rounding.

^ Count is not displayed due to fewer than 6 cases during the five-year period.

--Not applicable

Table A2. Percent Distribution of Cancer Cases by Site, Race, and Sex, 2017-2021, Louisiana

Primary Site <i>Invasive Cancers</i> ³	All Races & Ethnicities			White			Black			Hispanic			AI/AN ¹ & APIs ²		
	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Sites	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Oral Cavity and Pharynx	2.8	3.8	1.6	3.1	4.3	1.7	2.0	2.7	1.2	2.3	3.1	1.5	2.6	3.5	1.7
Lip	0.1	0.2	0.0	0.1	0.2	0.1	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0
Tongue	0.9	1.2	0.5	1.0	1.4	0.6	0.5	0.6	0.3	0.9	1.4	0.3	0.8	0.6	1.0
Salivary Gland	0.2	0.3	0.2	0.3	0.3	0.2	0.2	0.2	0.2	0.4	0.2	0.6	0.2	0.2	0.2
Floor of Mouth	0.1	0.2	0.1	0.1	0.2	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.2	0.2	0.1
Gum and Other Mouth	0.4	0.4	0.3	0.4	0.5	0.3	0.3	0.4	0.3	0.2	0.3	0.2	0.5	0.8	0.2
Nasopharynx	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.2	0.2	0.1	0.5	0.8	0.1
Tonsil	0.5	0.8	0.2	0.6	1.0	0.2	0.3	0.5	0.1	0.3	0.6	0.1	0.0	0.0	0.0
Oropharynx	0.2	0.2	0.1	0.2	0.3	0.1	0.1	0.2	0.0	0.1	0.1	0.1	0.1	0.1	0.0
Hypopharynx	0.2	0.2	0.1	0.1	0.2	0.1	0.2	0.3	0.1	0.1	0.2	0.0	0.4	0.7	0.0
Other Oral Cavity and Pharynx	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Digestive System	18.8	19.8	17.5	17.4	18.4	16.2	21.7	22.7	20.7	20.4	22.7	18.2	24.5	30.6	17.7
Esophagus	0.9	1.4	0.4	1.0	1.6	0.4	0.8	1.0	0.5	0.7	1.1	0.3	0.5	0.9	0.0
Stomach	1.4	1.6	1.2	1.1	1.2	0.9	2.2	2.4	2.0	2.5	2.9	2.1	2.0	2.8	1.2
Small Intestine	0.7	0.7	0.7	0.6	0.6	0.6	1.0	0.9	1.1	0.6	0.3	0.8	0.4	0.3	0.4
Colon and Rectum	9.0	9.0	9.0	8.5	8.5	8.5	10.1	9.9	10.3	8.9	10.3	7.4	11.9	13.3	10.4
Colon excluding Rectum	6.3	6.0	6.6	5.9	5.7	6.2	7.1	6.7	7.7	5.6	6.4	4.8	7.0	7.7	6.2
Cecum	1.2	1.1	1.4	1.2	1.1	1.4	1.4	1.2	1.6	0.8	0.8	0.8	1.3	0.8	1.8
Appendix	0.4	0.3	0.4	0.4	0.3	0.5	0.3	0.3	0.3	0.4	0.4	0.3	0.4	0.3	0.5
Ascending Colon	1.2	1.1	1.4	1.2	1.0	1.4	1.4	1.2	1.7	0.7	1.0	0.4	0.8	0.6	1.0
Hepatic Flexure	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.3	0.4	0.4	0.3	0.4	0.7	0.1
Transverse Colon	0.6	0.6	0.6	0.5	0.5	0.5	0.7	0.7	0.8	0.5	0.6	0.4	0.7	0.9	0.5
Splenic Flexure	0.2	0.2	0.2	0.2	0.2	0.1	0.3	0.3	0.4	0.2	0.2	0.2	0.3	0.6	0.0
Descending Colon	0.4	0.5	0.4	0.4	0.4	0.3	0.6	0.5	0.6	0.5	0.3	0.6	0.6	0.8	0.4
Sigmoid Colon	1.6	1.7	1.4	1.5	1.6	1.4	1.7	1.8	1.6	1.7	2.3	1.2	2.2	2.7	1.7
Large Intestine, NOS	0.4	0.4	0.4	0.3	0.3	0.3	0.5	0.5	0.4	0.4	0.3	0.5	0.4	0.4	0.2
Rectum and Rectosigmoid Junction	2.7	3.0	2.4	2.6	2.9	2.3	2.9	3.2	2.6	3.3	4.0	2.6	4.9	5.6	4.2
Rectosigmoid Junction	0.5	0.5	0.4	0.5	0.5	0.4	0.5	0.5	0.4	0.5	0.7	0.2	1.0	1.1	0.9
Rectum	2.3	2.5	2.0	2.2	2.4	1.9	2.5	2.7	2.2	2.8	3.3	2.4	3.9	4.5	3.3
Anus, Anal Canal and Anorectum	0.4	0.3	0.6	0.4	0.3	0.6	0.3	0.3	0.4	0.5	0.1	0.8	0.1	0.0	0.2
Liver and Intrahepatic Bile Duct	2.4	3.3	1.3	2.1	2.8	1.2	3.0	4.2	1.5	3.3	3.9	2.6	5.4	8.6	1.8
Liver	2.1	3.0	1.0	1.7	2.5	0.9	2.7	3.9	1.3	2.8	3.6	1.9	5.0	8.0	1.6
Intrahepatic Bile Duct	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.5	0.3	0.7	0.4	0.6	0.2
Gallbladder	0.3	0.2	0.4	0.2	0.1	0.3	0.4	0.3	0.5	0.4	0.2	0.6	0.5	0.6	0.5
Other Biliary	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.6	0.5	0.6	0.6	0.6	0.6
Pancreas	3.0	2.9	3.2	2.9	2.8	3.0	3.4	3.2	3.7	2.9	3.2	2.6	2.8	3.2	2.3
Retroperitoneum	0.1	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.2	0.3	0.1

Peritoneum, Omentum and Mesentery	0.1	0.0	0.1	0.1	0.0	0.2	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0
Other Digestive Organs	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.1	0.1	0.0	0.1	0.0	0.1
Respiratory System	14.4	15.2	13.4	14.7	15.0	14.4	14.2	16.3	11.7	7.6	8.5	6.7	14.1	15.3	12.8
Nose, Nasal Cavity and Middle Ear	0.2	0.2	0.1	0.2	0.2	0.1	0.1	0.2	0.1	0.3	0.4	0.1	0.2	0.3	0.1
Larynx	1.0	1.5	0.5	1.0	1.5	0.5	1.2	1.8	0.6	0.6	1.1	0.1	0.6	0.9	0.4
Lung and Bronchus	13.1	13.4	12.7	13.5	13.3	13.7	12.8	14.4	11.0	6.6	6.8	6.4	13.2	14.0	12.3
Pleura	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Trachea, Mediastinum and Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.0
Bones and Joints	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.3	0.2	0.3	0.4	0.1
Soft Tissue including Heart	0.7	0.8	0.7	0.8	0.9	0.6	0.7	0.6	0.8	0.7	0.9	0.5	0.4	0.6	0.2
Skin excluding Basal and Squamous	4.0	4.6	3.3	5.6	6.5	4.5	0.4	0.3	0.4	1.8	1.8	1.7	1.1	1.7	0.5
Melanoma of the Skin	3.6	4.1	2.9	5.1	5.9	4.1	0.2	0.1	0.2	1.4	1.4	1.3	0.8	1.2	0.2
Other Non-Epithelial Skin	0.4	0.5	0.4	0.5	0.6	0.4	0.2	0.2	0.2	0.4	0.4	0.4	0.4	0.4	0.2
Breast	13.9	0.2	29.8	13.4	0.2	28.9	15.1	0.2	32.1	15.3	0.2	29.7	14.7	0.3	30.4
Female Genital System	4.7	--	10.2	4.3	--	9.4	5.4	--	11.6	7.2	--	14.1	5.8	--	12.2
Cervix Uteri	0.8	--	1.8	0.7	--	1.4	1.1	--	2.4	2.1	--	4.2	1.3	--	2.8
Corpus and Uterus, NOS	2.4	--	5.2	2.1	--	4.7	2.9	--	6.2	3.3	--	6.4	2.9	--	6.1
Corpus Uteri	2.3	--	5.0	2.1	--	4.5	2.8	--	5.9	3.2	--	6.3	2.9	--	6.1
Uterus, NOS	0.1	--	0.2	0.1	--	0.1	0.1	--	0.3	0.1	--	0.1	0.0	--	0.0
Ovary	0.9	--	2.0	0.9	--	2.0	0.9	--	1.9	1.2	--	2.3	1.1	--	2.3
Vagina	0.1	--	0.2	0.1	--	0.2	0.1	--	0.3	0.2	--	0.3	0.0	--	0.0
Vulva	0.3	--	0.7	0.3	--	0.8	0.3	--	0.6	0.4	--	0.7	0.3	--	0.6
Other Female Genital Organs	0.2	--	0.4	0.2	--	0.4	0.1	--	0.3	0.1	--	0.2	0.2	--	0.4
Male Genital System	15.3	28.4	--	13.7	25.5	--	19.1	35.7	--	13.4	27.3	--	11.9	22.8	--
Prostate	14.8	27.5	--	13.2	24.4	--	18.8	35.2	--	11.9	24.3	--	11.3	21.6	--
Testis	0.4	0.7	--	0.5	0.9	--	0.1	0.3	--	1.3	2.7	--	0.5	1.0	--
Penis	0.1	0.2	--	0.1	0.1	--	0.1	0.2	--	0.1	0.2	--	0.1	0.2	--
Other Male Genital Organs	0.0	0.0	--	0.0	0.0	--	0.0	0.1	--	0.0	0.1	--	0.0	0.0	--
Urinary System	8.7	11.2	5.8	9.6	12.7	6.1	6.6	7.8	5.2	8.5	11.9	5.3	6.7	8.4	4.9
Urinary Bladder	3.7	5.4	1.8	4.5	6.5	2.1	2.1	2.8	1.2	2.5	4.5	0.6	2.2	3.5	0.9
Kidney and Renal Pelvis	4.8	5.6	3.8	4.9	5.9	3.8	4.4	4.9	3.8	5.8	7.4	4.3	4.4	4.7	4.0
Ureter	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.1	0.1	0.0	0.2	0.1	0.2	0.0
Other Urinary Organs	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.0	0.0	0.0
Eye and Orbit	0.2	0.2	0.1	0.2	0.2	0.2	0.0	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1
Brain and Other Nervous System	1.1	1.1	1.0	1.2	1.3	1.1	0.8	0.8	0.7	1.6	1.5	1.7	1.1	1.1	1.1
Brain	1.0	1.1	1.0	1.2	1.2	1.1	0.7	0.8	0.7	1.5	1.3	1.6	0.9	1.0	0.9
Cranial Nerves Other Nervous System	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.1	0.1	0.2	0.1	0.2	0.1	0.2
Endocrine System	2.6	1.4	4.0	2.7	1.5	4.2	2.0	0.9	3.3	4.9	2.7	7.0	4.1	1.7	6.8
Thyroid	2.4	1.2	3.8	2.6	1.4	4.0	1.7	0.6	3.0	4.7	2.5	6.8	3.8	1.3	6.5
Other Endocrine including Thymus	0.2	0.2	0.2	0.1	0.1	0.1	0.3	0.3	0.3	0.2	0.2	0.1	0.4	0.3	0.4
Lymphoma	4.3	4.3	4.2	4.6	4.7	4.6	3.3	3.2	3.4	5.9	7.1	4.8	4.8	5.5	4.0
Hodgkin Lymphoma	0.5	0.5	0.5	0.5	0.5	0.4	0.5	0.6	0.5	1.0	1.3	0.6	0.5	0.4	0.5

Hodgkin - Nodal	0.5	0.5	0.5	0.4	0.5	0.4	0.5	0.5	0.5	1.0	1.3	0.6	0.5	0.4	0.5
Hodgkin - Extranodal	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Non-Hodgkin Lymphoma	3.8	3.8	3.8	4.2	4.2	4.1	2.8	2.6	2.9	5.0	5.8	4.2	4.3	5.0	3.5
NHL - Nodal	2.6	2.6	2.5	2.9	2.9	2.8	1.8	1.7	1.8	3.1	3.3	2.8	3.0	3.5	2.4
NHL - Extranodal	1.2	1.2	1.2	1.3	1.3	1.3	1.0	0.9	1.1	1.9	2.5	1.4	1.3	1.6	1.1
Myeloma	1.7	1.8	1.7	1.3	1.4	1.1	2.8	2.5	3.1	1.5	2.4	0.7	1.6	2.0	1.1
Leukemia	2.8	3.0	2.5	3.0	3.3	2.7	2.1	2.3	2.0	3.8	4.5	3.2	2.9	3.2	2.4
Lymphocytic Leukemia	1.4	1.6	1.2	1.6	1.8	1.3	0.9	1.0	0.8	2.1	2.6	1.6	0.8	0.7	0.9
Acute Lymphocytic Leukemia	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	1.2	1.7	0.8	0.3	0.2	0.4
Chronic Lymphocytic Leukemia	1.1	1.2	0.9	1.2	1.4	1.0	0.6	0.7	0.6	0.8	0.8	0.8	0.5	0.4	0.5
Other Lymphocytic Leukemia	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0
Myeloid and Monocytic Leukemia	1.3	1.3	1.3	1.3	1.4	1.3	1.1	1.2	1.1	1.6	1.6	1.5	1.8	2.1	1.5
Acute Myeloid Leukemia	0.8	0.9	0.8	0.9	0.9	0.8	0.7	0.8	0.7	1.1	1.2	1.0	1.4	1.7	1.1
Acute Monocytic Leukemia	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0
Chronic Myeloid Leukemia	0.4	0.4	0.4	0.4	0.5	0.4	0.4	0.4	0.4	0.5	0.4	0.5	0.4	0.3	0.4
Other Myeloid/Monocytic Leukemia	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Leukemia	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.3	0.1	0.3	0.4	0.1
Other Acute Leukemia	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.1	0.1	0.1
Aleukemic, Subleukemic and NOS	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.0	0.2	0.3	0.0
Mesothelioma	0.2	0.3	0.1	0.2	0.3	0.1	0.2	0.2	0.1	0.2	0.4	0.1	0.2	0.3	0.0
Kaposi Sarcoma	0.1	0.1	0.0	0.0	0.1	0.0	0.2	0.3	0.0	0.3	0.6	0.0	0.0	0.0	0.0
Miscellaneous	3.6	3.5	3.8	3.7	3.6	3.8	3.4	3.2	3.6	4.3	4.1	4.4	3.0	2.5	3.7

¹American Indians/Alaska Natives

²Asians and Pacific Islanders

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

--Not applicable

Table B. Average Annual Cancer Incidence Rates by Site, Race, and Sex,¹ 2017-2021, Louisiana

Primary Site <i>Invasive Cancers</i> ²	All Races			NH White			NH Black		
	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Sites	483.6	555.0	430.2	491.6	554.9	444.1	496.4	599.5	423.1
Oral Cavity and Pharynx	13.2	20.5	6.7	15.0	23.1	7.5	9.9	15.9	5.3
Lip	0.5	0.9	0.2	0.7	1.2	0.3	^	^	^
Tongue	4.1	6.3	2.2	5.1	7.7	2.7	2.2	3.6	1.2
Salivary Gland	1.2	1.7	0.9	1.3	1.9	0.8	1.1	1.3	0.9
Floor of Mouth	0.6	0.9	0.3	0.6	0.9	0.4	0.6	1.1	^
Gum and Other Mouth	1.9	2.5	1.4	2.0	2.7	1.4	1.7	2.2	1.3
Nasopharynx	0.6	0.9	0.3	0.5	0.7	0.2	0.7	1.2	^
Tonsil	2.5	4.3	0.7	3.0	5.2	0.9	1.6	3.0	0.4
Oropharynx	0.8	1.3	0.3	0.9	1.4	0.5	0.6	1.2	^
Hypopharynx	0.7	1.2	0.3	0.6	1.0	0.3	0.9	1.7	^
Other Oral Cavity and Pharynx	0.2	0.4	0.1	0.2	0.3	^	0.3	0.5	^
Digestive System	90.4	110.3	73.5	84.8	102.8	69.0	108.3	137.0	86.8
Esophagus	4.4	7.7	1.7	4.9	8.6	1.6	3.7	6.0	1.9
Stomach	6.9	9.2	5.1	5.2	7.0	3.6	11.2	15.1	8.4
Small Intestine	3.3	3.7	3.1	2.8	3.3	2.5	5.0	5.5	4.7
Colon and Rectum	44.5	51.4	38.7	43.0	49.2	37.6	51.0	60.8	43.6
Colon excluding Rectum	30.8	34.3	27.8	29.3	32.5	26.7	36.5	41.8	32.5
Cecum	6.1	6.3	6.0	5.8	6.1	5.6	7.1	7.5	6.8
Appendix	1.9	1.7	2.2	2.4	1.9	2.8	1.4	1.5	1.3
Ascending Colon	6.0	6.1	5.8	5.6	5.7	5.5	7.4	7.9	7.1
Hepatic Flexure	1.4	1.7	1.1	1.2	1.4	1.0	1.8	2.5	1.3
Transverse Colon	2.9	3.3	2.5	2.6	3.1	2.2	3.7	4.0	3.4
Splenic Flexure	1.0	1.2	0.8	0.7	1.0	0.5	1.5	1.6	1.5
Descending Colon	2.1	2.6	1.7	1.9	2.6	1.3	2.7	3.0	2.6
Sigmoid Colon	7.6	9.4	6.2	7.5	9.0	6.2	8.4	10.7	6.6
Large Intestine, NOS	1.8	2.0	1.5	1.6	1.8	1.4	2.4	3.1	1.9
Rectum and Rectosigmoid Junction	13.7	17.1	10.9	13.7	16.8	10.9	14.5	19.0	11.1
Rectosigmoid Junction	2.3	2.8	1.9	2.4	2.9	2.0	2.3	2.9	1.8
Rectum	11.4	14.2	9.0	11.3	13.9	8.9	12.2	16.2	9.3
Anus, Anal Canal and Anorectum	2.0	1.6	2.4	2.2	1.6	2.7	1.8	1.9	1.6
Liver and Intrahepatic Bile Duct	10.6	16.6	5.3	9.4	14.3	5.0	13.0	22.1	5.8
Liver	9.0	14.8	4.0	7.8	12.5	3.6	11.6	20.2	4.7
Intrahepatic Bile Duct	1.5	1.8	1.3	1.6	1.9	1.4	1.4	1.9	1.1
Gallbladder	1.3	1.0	1.5	1.0	0.7	1.2	1.9	1.7	2.1
Other Biliary	1.5	1.9	1.3	1.5	1.8	1.2	1.6	2.1	1.3
Pancreas	14.5	16.3	13.0	13.6	15.3	12.1	17.6	20.2	15.6
Retroperitoneum	0.3	0.2	0.4	0.3	0.2	0.3	0.4	^	0.5
Peritoneum, Omentum and Mesentery	0.4	^	0.6	0.4	^	0.7	0.4	^	0.6
Other Digestive Organs	0.7	0.8	0.6	0.7	0.8	0.6	0.8	1.0	0.6
Respiratory System	66.8	84.1	53.1	68.1	81.4	57.5	69.8	101.2	47.2

Nose, Nasal Cavity and Middle Ear	0.8	1.1	0.5	0.8	1.0	0.6	0.7	1.1	0.5
Larynx	4.8	8.1	2.0	4.6	7.7	1.9	5.7	10.3	2.3
Lung and Bronchus	61.1	74.7	50.5	62.5	72.5	54.9	63.2	89.5	44.4
Pleura	^	^	^	^	^	^	^	^	^
Trachea, Mediastinum and Other	0.1	0.2	^	0.1	^	^	^	^	^
Bones and Joints	1.0	1.1	0.9	1.1	1.2	1.0	0.8	0.9	0.6
Soft Tissue including Heart	3.9	5.0	3.1	4.1	5.4	3.1	3.6	4.0	3.4
Skin excluding Basal and Squamous	20.4	27.6	15.0	29.3	38.4	22.4	2.0	2.2	1.8
Melanoma of the Skin	18.2	24.5	13.4	26.7	34.6	20.6	0.9	1.1	0.8
Other Non-Epithelial Skin	2.2	3.1	1.6	2.6	3.8	1.8	1.1	1.2	1.0
Breast	69.9	1.4	130.4	68.5	1.4	130.2	77.7	1.7	137.3
Female Genital System	23.7	--	44.9	22.7	--	43.9	27.1	--	48.5
Cervix Uteri	4.7	--	9.2	4.1	--	8.2	6.0	--	10.9
Corpus and Uterus, NOS	11.4	--	21.5	10.6	--	20.6	13.9	--	24.6
Corpus Uteri	11.0	--	20.8	10.3	--	20.1	13.2	--	23.4
Uterus, NOS	0.4	--	0.7	0.3	--	0.5	0.6	--	1.2
Ovary	4.6	--	8.7	4.8	--	9.2	4.5	--	8.0
Vagina	0.5	--	0.9	0.4	--	0.8	0.7	--	1.2
Vulva	1.7	--	3.1	1.8	--	3.4	1.4	--	2.6
Other Female Genital Organs	0.8	--	1.5	0.9	--	1.7	0.7	--	1.2
Male Genital System	68.2	147.6	--	62.3	132.3	--	87.0	201.1	--
Prostate	65.3	141.6	--	58.5	124.6	--	85.5	197.8	--
Testis	2.4	4.8	--	3.3	6.6	--	0.8	1.7	--
Penis	0.4	0.9	--	0.4	0.8	--	0.5	1.3	--
Other Male Genital Organs	0.1	0.3	--	0.1	0.3	--	^	^	--
Urinary System	42.2	64.7	24.2	46.8	71.7	26.0	33.3	49.5	21.5
Urinary Bladder	17.9	31.7	7.2	21.1	37.0	8.4	10.9	19.0	5.2
Kidney and Renal Pelvis	23.4	31.7	16.3	24.6	33.3	16.9	21.8	29.8	15.5
Ureter	0.5	0.7	0.4	0.6	0.8	0.4	^	^	^
Other Urinary Organs	0.5	0.6	0.4	0.5	0.7	0.3	0.4	^	0.5
Eye and Orbit	0.8	0.9	0.6	1.0	1.2	0.9	0.2	^	^
Brain and Other Nervous System	5.7	6.7	4.8	6.8	8.0	5.7	3.8	4.8	3.1
Brain	5.4	6.3	4.5	6.4	7.5	5.4	3.6	4.6	2.9
Cranial Nerves Other Nervous System	0.3	0.4	0.3	0.4	0.5	0.3	0.2	^	^
Endocrine System	14.2	8.0	20.2	16.3	9.3	23.3	10.4	5.4	14.7
Thyroid	13.2	6.9	19.4	15.5	8.5	22.6	8.9	3.5	13.5
Other Endocrine including Thymus	0.9	1.0	0.8	0.7	0.8	0.6	1.4	1.8	1.2
Lymphoma	21.7	25.7	18.5	23.6	27.8	20.1	17.3	20.1	15.2
Hodgkin Lymphoma	2.8	3.1	2.4	2.9	3.2	2.6	2.8	3.3	2.4
Hodgkin - Nodal	2.7	3.1	2.4	2.9	3.1	2.6	2.8	3.2	2.4
Hodgkin - Extranodal	^	^	^	^	^	^	^	^	^
Non-Hodgkin Lymphoma	18.9	22.5	16.0	20.8	24.6	17.5	14.5	16.8	12.8
NHL - Nodal	12.8	15.5	10.6	14.3	17.2	11.8	9.3	11.2	7.9
NHL - Extranodal	6.1	7.1	5.4	6.4	7.4	5.6	5.2	5.7	4.8
Myeloma	8.3	10.1	6.9	6.2	8.0	4.6	14.3	16.3	12.9
Leukemia	14.1	17.9	11.0	15.4	19.4	12.2	11.3	14.6	8.8
Lymphocytic Leukemia	6.9	9.2	5.0	7.9	10.5	5.8	4.7	6.1	3.6

Acute Lymphocytic Leukemia	1.4	1.7	1.2	1.6	1.8	1.3	1.1	1.3	0.9
Chronic Lymphocytic Leukemia	5.1	6.9	3.6	5.9	8.0	4.1	3.3	4.6	2.4
Other Lymphocytic Leukemia	0.4	0.5	0.3	0.5	0.7	0.3	0.3	^	^
Myeloid and Monocytic Leukemia	6.6	8.1	5.6	6.9	8.3	5.9	6.1	7.8	4.9
Acute Myeloid Leukemia	4.3	5.2	3.6	4.4	5.3	3.8	3.9	5.0	3.2
Acute Monocytic Leukemia	0.1	0.2	^	0.1	^	^	^	^	^
Chronic Myeloid Leukemia	2.2	2.6	1.8	2.3	2.8	2.0	2.0	2.4	1.6
Other Myeloid/Monocytic Leukemia	0.1	^	^	0.1	^	^	^	^	^
Other Leukemia	0.6	0.7	0.5	0.6	0.6	0.5	0.5	0.7	^
Other Acute Leukemia	0.2	0.2	0.2	0.2	^	^	^	^	^
Aleukemic, Subleukemic and NOS	0.4	0.5	0.3	0.4	0.4	0.4	0.4	0.6	^
Mesothelioma	1.1	1.7	0.6	1.2	1.8	0.6	0.9	1.5	0.5
Kaposi Sarcoma	0.5	1.0	^	0.3	0.5	^	0.9	1.8	^
Miscellaneous	17.8	20.7	15.6	18.2	21.2	15.9	17.7	21.1	15.3
<i>In Situ Cancers (not included above)</i>									
Breast In Situ	13.5	0.2	25.5	12.8	^	24.8	16	^	28.4

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups - Census P25-1130) standard.

²Except for urinary bladder (in situ and invasive), only invasive cases are included.

³Statistic not displayed due to fewer than 16 cases in the five-year period.

--Not applicable

Table C1. Average Annual Cancer Incidence Rates by Race and Sex,¹ 2017-2021: U.S., Louisiana, and 7-Parish Industrial Corridor² (Please review: [Cautions in Interpretation](#))

Primary Site <i>Invasive Cancers</i> ³	NH White Men				NH Black Men				NH White Women				NH Black Women			
	US	LA	Ind. Corr.		US	LA	Ind. Corr.		US	LA	Ind. Corr.		US	LA	Ind. Corr.	
All Sites	509.0	554.8	↑	561.3	530.3	599.5	↑	623.7 #	445.7	444.1		435.6	405.2	423.1	↑	417.6
Oral Cavity and Pharynx	20.1	23.1	↑	27.5 #	13.4	15.9	↑	16.4	7.4	7.5		8.0	4.8	5.3		4.0
Esophagus	8.1	8.6		9.0	5.5	6.0		6.8	1.8	1.6		1.4	1.9	1.9		^
Stomach	7.3	7.0		7.8	12.7	15.1	↑	15.7	3.6	3.6		2.6	8.0	8.4		8.4
Colon excluding Rectum	27.9	32.5	↑	26.7 *	35.5	41.8	↑	36.8	23.9	26.7	↑	21.3 *	28.4	32.5	↑	29.2
Rectum and Rectosigmoid Junction	13.9	16.8	↑	15.9	14.1	19.0	↑	20.9	9.0	10.9	↑	9.9	9.3	11.1	↑	11.5
Liver and Intrahepatic Bile Duct	10.9	14.3	↑	14.0	16.0	22.1	↑	27.0 #	4.2	5.0	↑	5.2	5.1	5.8		6.2
Pancreas	15.5	15.3		13.5	17.8	20.2	↑	19.4	11.8	12.1		11.3	15.1	15.6		14.9
Larynx	4.6	7.7	↑	6.8	6.7	10.3	↑	8.7	1.1	1.9	↑	1.9	1.3	2.3	↑	2.4
Lung and Bronchus	57.6	72.5	↑	57.3 *	66.5	89.5	↑	83.2	49.5	54.9	↑	50.4 *	43.0	44.4		37.8 *
Melanoma of the Skin	43.1	34.6	↓	42.4 #	1.1	1.1		^	28.9	20.6	↓	23.8 #	0.9	0.8		^
Breast	1.3	1.4		^	1.8	1.7		^	138.7	130.2	↓	136.7	131.3	137.3	↑	141.1
Cervix Uteri	--	--		--	--	--		--	6.9	8.2	↑	6.4	8.4	10.9	↑	8.9
Corpus and Uterus, NOS	--	--		--	--	--		--	27.4	20.6	↓	18.8	29.0	24.6	↓	24.4
Ovary	--	--		--	--	--		--	10.2	9.2	↓	12.0 #	8.7	8.0		9.2
Prostate	113.7	124.6	↑	141.9 #	190.6	197.8	↑	216.1 #	--	--		--	--	--		--
Testis	7.2	6.6		7.0	1.5	1.7		^	--	--		--	--	--		--
Urinary Bladder	37.3	36.9		36.2	19.4	19.0		21.9	9.0	8.4		8.2	5.9	5.2		4.9
Kidney and Renal Pelvis	23.4	33.3	↑	33.4	25.3	29.8	↑	34.0	11.4	16.9	↑	14.6	13.2	15.5	↑	14.9
Brain and Other Nervous System	8.7	8.0	↓	6.9	4.7	4.8		5.4	6.2	5.7		5.8	3.5	3.1		2.7
Thyroid	8.1	8.5		10.1	3.5	3.5		3.9	20.5	22.6	↑	25.1	11.9	13.5	↑	15.7
Hodgkin Lymphoma	3.1	3.2		3.1	2.8	3.3		3.0	2.5	2.6		1.7	2.3	2.4		2.9
Non-Hodgkin Lymphoma	24.1	24.6		24.3	17.1	16.8		17.4	16.3	17.5	↑	16.5	11.9	12.8		15.3
Myeloma	8.1	8.0		8.5	17.2	16.3		20.4	4.9	4.6		3.9	13.1	12.9		15.9 #
Leukemia	19.4	19.4		18.8	14.0	14.6		16.3	11.8	12.2		11.5	9.4	8.8		9.1

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Ascension, East Baton Rouge, Iberville, St. Charles, St. James, St. John the Baptist, and West Baton Rouge Parishes comprise the Industrial Corridor.

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The Industrial Corridor rate is significantly lower (P <0.05) than the Louisiana rate.

#The Industrial Corridor rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

--Not applicable

Table C2. Average Annual Cancer Incidence Rates by Race and Sex,¹ 2017-2021: U.S., Louisiana, and 11-Parish Industrial Corridor² (Please review: [Cautions in Interpretation](#))

Primary Site <i>Invasive Cancers</i> ³	NH White Men				NH Black Men				NH White Women				NH Black Women			
	US	LA	Ind. Corr.		US	LA	Ind. Corr.		US	LA	Ind. Corr.		US	LA	Ind. Corr.	
All Sites	509.0	554.8	↑	537.1 *	530.3	599.5	↑	577.2 *	445.7	444.1	427.8 *		405.2	423.1	↑	406.8 *
Oral Cavity and Pharynx	20.1	23.1	↑	24.5	13.4	15.9	↑	14.7	7.4	7.5	7.2		4.8	5.3		3.9 *
Esophagus	8.1	8.6		8.5	5.5	6.0		5.6	1.8	1.6	1.6		1.9	1.9		1.7
Stomach	7.3	7.0		6.6	12.7	15.1	↑	15.5	3.6	3.6	2.8 *		8.0	8.4		8.1
Colon excluding Rectum	27.9	32.5	↑	27.7 *	35.5	41.8	↑	36.5 *	23.9	26.7	↑	22.9 *	28.4	32.5	↑	28.4 *
Rectum and Rectosigmoid Junction	13.9	16.8	↑	15.4	14.1	19.0	↑	18.5	9.0	10.9	↑	9.2 *	9.3	11.1	↑	10.9
Liver and Intrahepatic Bile Duct	10.9	14.3	↑	15.5	16.0	22.1	↑	24.2	4.2	5.0	↑	5.3	5.1	5.8		6.1
Pancreas	15.5	15.3		14.3	17.8	20.2	↑	17.5	11.8	12.1		10.8	15.1	15.6		14.4
Larynx	4.6	7.7	↑	7.1	6.7	10.3	↑	8.4	1.1	1.9	↑	1.6	1.3	2.3	↑	2.3
Lung and Bronchus	57.6	72.5	↑	60.6 *	66.5	89.5	↑	82.9 *	49.5	54.9	↑	49.3 *	43.0	44.4		41.3
Melanoma of the Skin	43.1	34.6	↓	37.8 #	1.1	1.1		^	28.9	20.6	↓	22.5	0.9	0.8		^
Breast	1.3	1.4		1.8	1.8	1.7		1.4	138.7	130.2	↓	138.0 #	131.3	137.3	↑	135.9
Cervix Uteri	--	--		--	--	--		--	6.9	8.2	↑	6.2 *	8.4	10.9	↑	9.8
Corpus and Uterus, NOS	--	--		--	--	--		--	27.4	20.6	↓	19.0	29.0	24.6	↓	21.8 *
Ovary	--	--		--	--	--		--	10.2	9.2	↓	11.0 #	8.7	8.0		9.0
Prostate	113.7	124.6	↑	128.5	190.6	197.8	↑	194.7	--	--		--	--	--		--
Testis	7.2	6.6		6.6	1.5	1.7		1.6	--	--		--	--	--		--
Urinary Bladder	37.3	36.9		37.8	19.4	19.0		19.9	9.0	8.4		8.8	5.9	5.2		5.3
Kidney and Renal Pelvis	23.4	33.3	↑	30.7	25.3	29.8	↑	30.1	11.4	16.9	↑	13.8 *	13.2	15.5	↑	15.2
Brain and Other Nervous System	8.7	8.0	↑	6.9	4.7	4.8		5.3	6.2	5.7		5.0	3.5	3.1		3.3
Thyroid	8.1	8.5		7.9	3.5	3.5		3.7	20.5	22.6	↑	22.1	11.9	13.5	↑	13.8
Hodgkin Lymphoma	3.1	3.2		3.5	2.8	3.3		3.4	2.5	2.6		1.9	2.3	2.4		2.5
Non-Hodgkin Lymphoma	24.1	24.6		23.9	17.1	16.8		18.2	16.3	17.5	↑	16.9	11.9	12.8		13.9
Myeloma	8.1	8.0		7.9	17.2	16.3		16.2	4.9	4.6		4.2	13.1	12.9		13.1
Leukemia	19.4	19.4		18.1	14.0	14.6		13.0	11.8	12.2		10.5 *	9.4	8.8		8.0

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Ascension, East Baton Rouge, Iberville, Jefferson, Orleans, Plaquemines, St. Bernard, St. Charles, St. James, St. John the Baptist, and West Baton Rouge Parishes comprise the Industrial Corridor.

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The Industrial Corridor rate is significantly lower (P <0.05) than the Louisiana rate.

#The Industrial Corridor rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

--Not applicable

Table D1. Cancer Incidence Rates¹ among the Hispanic Population, 2017-2021: U.S. and Louisiana

Primary Site	Male			Female		
<i>Invasive Cancers</i> ²	U.S.	LA		U.S.	LA	
All Sites	351.7	298.4	↓	343.5	304.8	↓
Oral Cavity and Pharynx	9.6	8.9		4.4	4.7	
Esophagus	4.5	^		1.1	^	
Stomach	11.8	9.4		8.5	6.6	
Colon and rectum	37.0	30.6	↓	28.4	22.8	↓
Liver and Intrahepatic Bile Duct	19.1	10.6	↓	8.6	8.3	
Pancreas	12.6	9.6		11.1	8.3	
Larynx	3.3	^		0.5	^	
Lung and Bronchus	28.4	21.8	↓	22.0	20.3	
Melanoma of the Skin	4.8	4.9		5.2	4.1	
Breast	0.6	^		100.9	90.9	↓
Cervix Uteri	--	--		9.1	11.9	
Corpus and Uterus, NOS	--	--		26.6	19.5	↓
Ovary	--	--		10.0	6.8	↓
Prostate	86.4	74.0	↓	--	--	
Testis	6.4	5.5		--	--	
Urinary Bladder	16.9	16.7		4.8	^	
Kidney and Renal Pelvis	22.2	22.6		13.0	13.4	
Brain and Other Nervous System	5.7	3.4	↓	4.6	4.5	
Thyroid	5.7	5.9		20.5	19.6	
Hodgkin Lymphoma	2.4	3.4		1.8	^	
Non-Hodgkin Lymphoma	20.0	16.5		15.3	13.3	
Myeloma	7.5	7.3		5.4	^	
Leukemia	12.7	11.2		9.1	8.9	

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases in the five-year period.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

--Not applicable

Table D2. Cancer Incidence Rates¹ among the NH American Indian/Alaska Native and Asian and Pacific Islander Population, 2017-2021: U.S. and Louisiana

Primary Site <i>Invasive Cancers</i> ²	Male		Female		
	U.S.	LA	U.S.	LA	
All Sites	303.7	307.6	321.4	256.3	↓
Oral Cavity and Pharynx	11.8	10.0	5.5	^	
Esophagus	3.9	^	1.0	^	
Stomach	11.4	7.7	6.8	^	
Colon and rectum	35.7	40.6	26.7	26.5	
Liver and Intrahepatic Bile Duct	17.4	24.2	6.6	^	↑
Pancreas	11.4	10.9	9.7	6.4	
Larynx	1.9	^	0.2	^	
Lung and Bronchus	40.5	44.6	28.2	32.6	
Melanoma of the Skin	1.9	^	1.6	^	
Breast	0.6	^	113.2	77.2	↓
Cervix Uteri	--	--	6.3	7.1	
Corpus and Uterus, NOS	--	--	25.0	14.8	↓
Ovary	--	--	9.4	5.5	↓
Prostate	62.7	65.3	--	--	
Testis	2.8	^	--	--	
Urinary Bladder	14.8	12.4	3.6	^	
Kidney and Renal Pelvis	13.6	14.4	6.7	9.9	↑
Brain and Other Nervous System	4.5	^	3.2	^	
Thyroid	6.5	^	20.2	17.1	
Hodgkin Lymphoma	1.5	^	1.2	^	
Non-Hodgkin Lymphoma	16.1	15.0	11.5	8.9	
Myeloma	5.0	6.9	3.5	^	
Leukemia	10.2	11.2	6.7	6.7	

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases in the five-year period.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

--Not applicable

Table E1. Incidence Rates¹ by Louisiana Parish² for the Ten Most Commonly Diagnosed Cancers, 2017-2021:
NH White Males

	All Sites ³	Prostate	Lung and Bronchus	Colon and Rectum	Urinary Bladder	Melanoma of the Skin	Kidney and Renal Pelvis	Non- Hodgkin Lymphoma	Oral Cavity and Pharynx	Leukemia	Pancreas
Louisiana	554.9	124.6	72.5	49.2	37.0	34.6	33.3	24.6	23.1	19.4	15.3
Acadia	627.4	134.2	90.4	59.5	36.0	24.1	46.6	22.5	29.2	20.1	15.0
Allen	625.0	122.9	95.7	68.9	33.3	34.0	40.7	34.4	^	^	^
Ascension	563.0	148.2	57.1	40.4	31.4	40.8	34.2	24.9	28.1	18.8	14.0
Assumption	590.1	146.7	70.2	31.6	49.5	^	40.6	^	^	^	^
Avoyelles	595.2	127.6	85.5	65.7	53.6	28.2	40.5	23.8	19.2	^	17.8
Beauregard	591.4	125.5	69.2	64.8	32.9	29.6	33.9	32.7	18.2	25.0	^
Bienville	592.0	122.3	88.9	78.3	^	^	^	^	^	^	^
Bossier	549.7	109.6	73.9	47.7	42.9	37.5	34.5	23.9	20.9	18.7	16.5
Caddo	517.5	119.1	67.5	43.0	38.0	28.5	27.6	22.3	22.8	20.0	15.5
Calcasieu	542.0	124.5	75.8	51.2	31.5	34.1	30.0	24.1	19.8	20.4	13.2
Caldwell	462.1	110.4	108.1	^	^	^	^	^	^	^	^
Cameron	546.4	113.1	^	^	^	^	^	^	^	^	^
Catahoula	600.4	143.3	59.9	118.2	^	^	^	^	^	^	^
Claiborne	605.8	121.0	60.1	68.1	^	^	^	^	^	^	^
Concordia	498.8	112.1	61.4	48.0	^	^	^	^	^	^	^
De Soto	527.7	104.6	74.2	38.4	32.2	^	35.4	^	^	^	^
East Baton Rouge	552.7	149.0	49.8	37.2	36.6	48.8	32.5	24.0	26.1	16.8	13.7
East Carroll	446.1	^	^	^	^	^	^	^	^	^	^
East Feliciana	527.0	123.1	71.1	48.7	32.5	^	^	^	^	^	^
Evangeline	577.4	80.3	93.4	63.8	51.7	41.1	31.1	40.6	26.0	^	^
Franklin	574.9	93.8	109.8	65.6	51.0	41.5	^	^	^	^	^
Grant	557.9	104.6	73.7	71.7	34.1	^	^	^	30.5	^	^
Iberia	641.8	152.5	82.1	73.1	40.1	29.2	32.7	22.0	23.4	30.4	17.9
Iberville	710.7	141.9	99.4	58.0	50.1	44.8	55.0	^	34.8	^	^
Jackson	573.7	142.4	85.4	48.4	^	^	^	^	^	^	^
Jefferson	522.9	113.7	67.0	43.6	42.5	28.9	32.2	23.0	21.9	18.4	15.3
Jefferson Davis	590.9	151.2	84.1	32.7	35.9	32.7	42.5	20.7	20.5	^	^

Lafayette	554.9	147.4	62.7	44.1	31.7	30.8	39.6	26.7	21.3	19.4	14.9
Lafourche	532.7	112.0	73.7	51.2	35.3	20.5	38.2	29.9	17.1	18.9	16.1
La Salle	551.4	100.1	98.8	74.7	49.9	^	^	^	^	^	^
Lincoln	492.1	118.2	52.3	46.3	23.5	35.1	28.8	21.9	22.2	28.3	^
Livingston	548.1	110.5	85.8	49.9	33.5	41.1	31.2	27.6	27.5	21.7	10.5
Madison	559.8	149.9	106.4	^	^	^	^	^	^	^	^
Morehouse	529.2	120.9	75.5	71.4	^	^	^	^	^	^	^
Natchitoches	580.7	120.8	78.1	67.7	31.1	^	31.8	27.8	29.1	30.3	^
Orleans	496.1	127.0	51.0	41.8	29.9	46.9	18.2	23.2	24.0	17.9	15.1
Ouachita	561.7	127.8	69.4	46.5	32.2	46.2	34.1	23.8	23.8	17.5	16.5
Plaquemines	543.3	138.9	65.8	57.6	43.3	^	36.2	^	^	^	^
Pointe Coupee	581.9	112.8	58.5	62.5	51.8	25.6	40.3	33.0	^	^	^
Rapides	542.3	110.1	70.7	50.2	36.7	29.9	31.0	23.1	23.7	21.8	17.6
Red River	592.7	115.1	91.7	^	^	^	^	^	^	^	^
Richland	521.8	93.6	92.7	59.4	34.1	^	^	^	^	^	^
Sabine	619.6	125.4	98.7	48.8	34.4	30.7	41.0	33.2	^	^	^
St. Bernard	529.3	92.3	75.6	49.4	41.3	^	37.2	28.3	^	^	^
St. Charles	541.8	115.8	55.0	58.2	45.1	24.9	26.4	19.4	34.1	18.9	15.5
St. Helena	494.1	120.6	^	^	^	^	^	^	^	^	^
St. James	594.4	141.1	67.4	92.5	^	^	^	^	^	^	^
St. John the Baptist	573.6	85.8	82.1	44.9	39.9	^	37.7	42.9	^	^	^
St. Landry	584.6	130.6	79.3	62.7	27.8	28.1	34.8	22.0	27.8	25.1	13.5
St. Martin	641.7	143.8	92.5	70.1	42.0	28.0	48.1	29.5	21.2	18.8	22.2
St. Mary	581.6	113.2	105.1	55.7	37.3	22.3	29.1	29.6	21.5	20.4	20.1
St. Tammany	571.9	125.9	69.6	46.4	41.4	49.6	31.9	26.6	21.6	16.3	19.2
Tangipahoa	567.9	141.2	76.1	47.1	31.5	34.9	34.5	25.1	23.8	14.4	16.1
Tensas	398.5	^	^	^	^	^	^	^	^	^	^
Terrebonne	588.9	111.1	98.0	53.2	48.7	24.0	41.5	28.6	24.0	19.7	16.3
Union	490.2	89.1	100.5	33.2	35.4	^	34.9	^	^	^	^
Vermilion	619.1	152.1	67.2	63.1	42.4	32.5	44.9	25.0	17.9	25.4	13.3
Vernon	541.7	98.3	107.9	61.3	41.2	^	22.0	^	^	^	^
Washington	606.7	96.8	98.3	53.2	35.4	46.3	33.6	23.2	20.2	22.3	19.6
Webster	566.8	124.8	88.2	46.8	38.0	21.9	38.8	^	32.4	27.5	^
West Baton Rouge	512.4	139.6	79.1	^	^	36.1	^	^	^	^	^

West Carroll	528.6	129.6	106.4	70.9	^	^	^	^	^	^	^
West Feliciana	500.3	131.0	53.7	^	^	^	^	^	^	^	^
Winn	576.8	87.6	98.8	59.9	^	^	^	^	54.0	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Table E2. Incidence Rates¹ by Louisiana Parish² for the Ten Most Commonly Diagnosed Cancers, 2017-2021:
NH White Females

	All Sites ³	Breast	Lung and Bronchus	Colon and Rectum	Thyroid	Melanoma of the Skin	Corpus and Uterus, NOS	Non- Hodgkin Lymphoma	Kidney and Renal Pelvis	Leukemia	Pancreas
Louisiana	444.1	130.2	54.9	37.6	22.6	20.6	20.6	17.5	16.9	12.2	12.1
Acadia	474.9	129.9	58.4	38.6	27.9	14.3	25.7	15.8	18.5	18.4	14.3
Allen	468.5	96.8	64.5	71.4	^	^	^	^	^	^	^
Ascension	469.7	142.0	66.6	28.9	34.0	24.1	17.2	13.3	17.4	11.0	9.6
Assumption	407.6	95.1	67.6	32.9	^	^	^	^	^	^	^
Avoyelles	369.5	84.2	51.1	38.3	^	^	25.3	19.3	21.4	^	^
Beauregard	497.3	107.5	71.2	48.3	26.0	19.6	30.9	21.6	24.6	16.7	^
Bienville	470.0	83.3	68.1	^	^	^	^	^	^	^	^
Bossier	442.1	121.3	60.5	40.4	25.4	26.6	17.7	15.9	12.8	15.4	12.3
Caddo	468.3	128.8	57.4	38.9	23.7	19.8	26.1	18.6	14.3	15.3	12.7
Calcasieu	408.7	115.3	51.3	32.5	14.4	17.7	18.8	17.3	18.4	14.8	11.2
Caldwell	531.2	82.5	92.6	83.8	^	^	^	^	^	^	^
Cameron	626.6	200.6	88.2	^	^	^	^	^	^	^	^
Catahoula	441.6	127.4	^	^	^	^	^	^	^	^	^
Claiborne	467.0	143.7	^	54.3	^	^	^	^	^	^	^
Concordia	428.0	79.8	55.0	55.8	^	^	^	^	^	^	^
De Soto	464.0	116.5	50.6	42.5	^	^	^	27.4	^	^	^
East Baton Rouge	414.2	134.0	43.0	30.5	21.6	27.4	18.6	15.4	13.1	11.2	11.4
East Carroll	430.1	^	^	^	^	^	^	^	^	^	^
East Feliciana	433.8	128.2	83.7	^	^	^	^	^	^	^	^
Evangeline	474.1	110.9	69.4	45.3	29.0	^	^	20.3	38.0	^	^
Franklin	469.3	107.6	54.5	78.9	^	^	^	^	^	^	^
Grant	451.4	119.2	52.4	53.5	^	^	^	^	^	^	^
Iberia	446.9	135.1	61.4	41.3	15.1	16.3	20.6	15.3	17.2	15.5	15.6
Iberville	476.4	141.9	72.0	36.4	^	^	^	^	^	^	^
Jackson	475.5	119.4	55.0	61.9	^	^	^	^	^	^	^
Jefferson	429.3	140.7	50.0	34.2	23.0	18.3	18.9	19.0	14.7	9.3	12.1
Jefferson Davis	410.7	109.6	55.0	48.7	^	^	22.4	^	23.2	^	^

Lafayette	445.2	148.8	49.1	33.5	23.9	14.1	20.6	18.8	16.8	12.2	12.8
Lafourche	418.8	132.5	52.3	33.3	20.9	15.0	21.3	19.5	20.5	11.6	8.9
La Salle	474.2	125.3	66.8	62.9	^	^	^	^	^	^	^
Lincoln	367.5	114.0	50.4	33.0	^	^	27.0	^	^	^	^
Livingston	454.6	112.1	67.1	35.4	23.8	20.9	20.1	17.5	19.5	12.0	10.9
Madison	488.3	^	^	^	^	^	^	^	^	^	^
Morehouse	469.8	122.0	71.8	43.8	^	^	^	^	^	^	^
Natchitoches	492.1	152.2	42.7	51.8	^	^	29.9	^	^	^	^
Orleans	388.0	140.1	33.9	30.2	13.7	29.7	18.6	13.0	7.5	9.7	6.1
Ouachita	452.2	120.9	53.9	41.6	22.6	31.6	16.7	14.0	16.9	12.2	12.3
Plaquemines	443.3	117.6	86.8	^	^	^	^	^	^	^	^
Pointe Coupee	464.2	132.6	39.6	31.2	^	^	^	^	^	^	^
Rapides	427.0	111.7	53.9	32.4	30.5	20.7	18.7	19.0	14.0	13.4	11.4
Red River	367.0	129.8	^	^	^	^	^	^	^	^	^
Richland	441.6	108.4	68.4	44.8	^	^	^	^	^	^	^
Sabine	486.2	125.3	59.7	54.8	^	^	^	^	^	^	^
St. Bernard	463.9	130.7	67.3	28.3	^	^	30.1	^	20.7	^	^
St. Charles	442.0	126.8	50.5	27.3	26.1	^	20.1	17.2	18.9	^	^
St. Helena	499.4	122.1	83.6	^	^	^	^	^	^	^	^
St. James	518.0	166.5	42.1	58.8	^	^	^	^	^	^	^
St. John the Baptist	469.2	147.6	41.2	44.7	^	^	^	^	^	^	^
St. Landry	496.5	136.5	62.5	42.4	25.9	17.6	25.0	18.6	27.3	^	16.5
St. Martin	455.6	148.1	60.3	45.9	24.0	^	22.4	14.5	^	^	^
St. Mary	411.3	107.8	56.5	32.8	^	^	23.6	24.6	21.0	^	^
St. Tammany	465.8	150.5	54.7	36.5	24.0	24.6	16.9	18.9	16.6	11.8	11.3
Tangipahoa	451.4	131.3	53.3	38.0	20.2	20.4	22.8	16.5	16.4	11.1	15.5
Tensas	583.3	^	^	^	^	^	^	^	^	^	^
Terrebonne	462.7	140.9	58.3	44.4	18.6	17.5	19.1	19.3	16.0	13.7	14.4
Union	520.4	120.2	63.9	50.9	^	32.9	^	^	^	^	^
Vermilion	475.8	135.8	69.6	42.1	19.0	15.9	27.4	19.6	24.6	11.2	14.8
Vernon	487.3	87.4	78.6	52.9	28.9	23.4	40.8	^	17.7	^	^
Washington	457.6	125.8	75.5	33.9	21.2	^	15.7	19.6	22.8	^	^
Webster	460.8	126.8	41.2	48.9	35.9	^	24.9	27.3	^	^	21.3
West Baton Rouge	433.9	132.1	79.6	^	^	^	^	^	^	^	^

West Carroll	524.8	135.3	58.4	61.1	^	^	^	^	^	^	^
West Feliciana	386.7	139.7	^	^	^	^	^	^	^	^	^
Winn	498.2	107.7	66.2	63.0	^	^	^	^	^	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases during the five-year period

Table E3. Incidence Rates¹ by Louisiana Parish² for the Ten Most Commonly Diagnosed Cancers, 2017-2021:
NH Black Males

	All Sites ³	Prostate	Lung and Bronchus	Colon and Rectum	Kidney and Renal Pelvis	Liver and Intrahepatic Bile Duct	Pancreas	Urinary Bladder	Non-Hodgkin Lymphoma	Myeloma	Oral Cavity and Pharynx
Louisiana	599.5	197.8	89.5	60.8	29.8	22.1	20.2	19.0	16.8	16.3	15.9
Acadia	608.0	173.7	123.6	82.4	^	^	^	^	^	^	^
Allen	505.0	170.8	^	^	^	^	^	^	^	^	^
Ascension	656.1	226.3	76.6	78.1	41.4	30.6	^	^	^	^	^
Assumption	641.8	177.2	136.3	114.0	^	^	^	^	^	^	^
Avoyelles	771.1	180.6	151.0	80.9	^	^	^	^	^	^	^
Beauregard	580.0	181.6	^	^	^	^	^	^	^	^	^
Bienville	660.4	251.0	100.4	^	^	^	^	^	^	^	^
Bossier	541.9	175.8	79.4	57.9	31.9	^	^	^	^	29.3	^
Caddo	585.6	179.1	98.1	62.9	29.7	25.0	21.9	19.8	17.2	16.7	15.5
Calcasieu	620.2	184.9	92.6	62.9	31.2	21.2	19.8	18.1	16.8	16.7	13.5
Caldwell	^	^	^	^	^	^	^	^	^	^	^
Cameron	^	^	^	^	^	^	^	^	^	^	^
Catahoula	557.6	^	^	^	^	^	^	^	^	^	^
Claiborne	620.5	153.3	119.0	79.9	^	^	^	^	^	^	^
Concordia	534.0	228.4	^	^	^	^	^	^	^	^	^
De Soto	744.5	209.6	110.9	85.1	^	^	^	^	^	^	^
East Baton Rouge	613.8	211.2	82.6	55.1	33.0	28.5	20.3	20.8	18.4	20.3	16.0
East Carroll	629.5	237.3	^	^	^	^	^	^	^	^	^
East Feliciana	655.3	246.3	114.2	^	^	^	^	^	^	^	^
Evangeline	622.6	177.0	133.0	^	^	^	^	^	^	^	^
Franklin	588.3	169.3	^	^	^	^	^	^	^	^	^
Grant	645.3	258.7	^	^	^	^	^	^	^	^	^
Iberia	688.2	207.0	109.3	60.6	41.5	^	43.5	^	^	^	^
Iberville	815.2	256.7	127.8	79.5	^	^	^	^	^	^	^
Jackson	632.3	198.6	138.8	^	^	^	^	^	^	^	^
Jefferson	582.6	197.2	84.9	55.8	30.3	18.7	16.6	21.4	21.3	17.6	12.4

Jefferson Davis	598.8	255.8	^	^	^	^	^	^	^	^	^
Lafayette	609.2	171.0	106.9	61.1	36.8	25.8	28.6	16.8	13.5	20.6	16.0
Lafourche	619.2	204.7	88.0	^	^	^	^	^	^	^	^
La Salle	533.5	^	^	^	^	^	^	^	^	^	^
Lincoln	492.5	211.4	^	^	^	^	^	^	^	^	^
Livingston	780.5	284.8	^	^	^	^	^	^	^	^	^
Madison	588.7	174.1	^	^	^	^	^	^	^	^	^
Morehouse	605.4	239.4	82.1	80.0	^	^	^	^	^	^	^
Natchitoches	614.6	169.3	106.1	86.8	^	^	^	^	^	^	^
Orleans	525.2	170.2	83.2	51.3	26.5	22.9	16.5	17.6	17.9	11.8	13.9
Ouachita	564.4	213.6	76.0	51.0	24.6	^	17.3	19.6	15.6	12.6	18.5
Plaquemines	571.2	173.1	^	^	^	^	^	^	^	^	^
Pointe Coupee	662.8	222.7	78.2	85.6	^	^	^	^	^	^	^
Rapides	632.8	211.5	94.7	68.8	20.7	15.6	^	18.7	19.8	22.8	23.9
Red River	618.4	^	^	^	^	^	^	^	^	^	^
Richland	794.5	282.3	143.5	^	^	^	^	^	^	^	^
Sabine	449.4	198.6	^	^	^	^	^	^	^	^	^
St. Bernard	692.2	196.8	^	^	^	^	^	^	^	^	^
St. Charles	605.4	216.1	70.0	47.2	^	^	^	^	^	^	^
St. Helena	606.8	230.1	^	^	^	^	^	^	^	^	^
St. James	554.4	170.9	100.6	^	^	^	^	^	^	^	^
St. John the Baptist	555.2	223.2	53.3	63.0	31.7	^	^	^	^	^	^
St. Landry	711.6	203.4	98.0	81.4	23.3	25.4	32.6	26.1	26.5	^	21.1
St. Martin	662.9	205.1	75.1	100.2	^	^	^	^	^	^	^
St. Mary	559.7	167.8	67.8	65.7	41.2	^	^	^	^	^	^
St. Tammany	640.8	228.1	63.9	78.2	41.4	^	28.0	^	23.3	^	^
Tangipahoa	679.9	257.2	119.9	66.4	30.0	34.2	^	^	^	^	^
Tensas	587.3	210.3	^	^	^	^	^	^	^	^	^
Terrebonne	640.6	157.5	141.4	64.8	^	^	^	^	^	^	^
Union	615.5	250.8	^	^	^	^	^	^	^	^	^
Vermilion	810.6	235.3	121.1	^	^	^	^	^	^	^	^
Vernon	595.6	196.9	^	^	^	^	^	^	^	^	^
Washington	650.2	209.1	89.7	78.5	^	^	^	^	^	^	^
Webster	623.6	215.6	114.3	61.5	^	^	^	^	^	^	^

West Baton Rouge	715.3	259.6	102.7	^	^	^	^	^	^	^	^
West Carroll	525.2	^	^	^	^	^	^	^	^	^	^
West Feliciana	870.7	317.3	135.0	89.1	^	^	^	^	^	^	^
Winn	407.7	191.4	^	^	^	^	^	^	^	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Table E4. Incidence Rates¹ by Louisiana Parish² for the Ten Most Commonly Diagnosed Cancers, 2017-2021:
NH Black Females

	All Sites ³	Breast	Lung and Bronchus	Colon and Rectum	Corpus and Uterus, NOS	Pancreas	Kidney and Renal Pelvis	Thyroid	Myeloma	Non- Hodgkin Lymphoma	Cervix Uteri
Louisiana	423.1	137.3	44.4	43.6	24.6	15.6	15.5	13.5	12.9	12.8	10.9
Acadia	496.8	183.0	69.8	49.3	^	^	^	^	^	^	^
Allen	490.3	169.4	^	^	^	^	^	^	^	^	^
Ascension	411.3	143.6	45.3	35.8	^	^	^	^	^	^	^
Assumption	532.1	206.7	^	^	^	^	^	^	^	^	^
Avoyelles	474.8	182.4	44.7	^	^	^	^	^	^	^	^
Beauregard	488.0	^	^	^	^	^	^	^	^	^	^
Bienville	463.2	145.9	^	^	^	^	^	^	^	^	^
Bossier	426.6	129.0	57.6	42.1	38.0	^	24.9	^	^	^	^
Caddo	427.0	127.5	41.3	50.7	27.4	17.9	17.2	10.9	13.3	14.3	12.1
Calcasieu	418.7	119.8	54.7	48.5	17.6	21.1	14.2	^	^	16.5	11.9
Caldwell	513.3	^	^	^	^	^	^	^	^	^	^
Cameron	^	^	^	^	^	^	^	^	^	^	^
Catahoula	403.5	^	^	^	^	^	^	^	^	^	^
Claiborne	416.6	169.6	^	^	^	^	^	^	^	^	^
Concordia	341.3	125.4	^	^	^	^	^	^	^	^	^
De Soto	487.1	191.7	^	^	^	^	^	^	^	^	^
East Baton Rouge	416.4	138.0	37.3	38.6	25.4	14.4	14.8	17.0	16.0	17.2	10.0
East Carroll	570.4	^	121.2	^	^	^	^	^	^	^	^
East Feliciana	397.1	143.7	^	^	^	^	^	^	^	^	^
Evangeline	498.7	120.9	83.6	70.4	^	^	^	^	^	^	^
Franklin	394.0	^	^	^	^	^	^	^	^	^	^
Grant	383.5	^	^	^	^	^	^	^	^	^	^
Iberia	492.7	175.3	58.3	60.3	^	^	^	^	^	^	^
Iberville	447.3	145.9	43.6	46.0	^	^	^	^	^	^	^
Jackson	427.8	139.5	^	^	^	^	^	^	^	^	^
Jefferson	436.7	152.3	40.0	40.8	22.0	13.8	16.8	15.4	12.1	14.1	12.3
Jefferson Davis	430.0	145.6	^	^	^	^	^	^	^	^	^

Lafayette	447.9	154.5	47.6	45.4	28.8	17.3	14.0	15.3	10.9	^	^
Lafourche	491.5	154.1	53.9	^	^	^	^	^	^	^	^
La Salle	445.2	^	^	^	^	^	^	^	^	^	^
Lincoln	404.6	133.0	47.6	^	^	^	^	^	^	^	^
Livingston	433.2	120.9	^	^	^	^	^	^	^	^	^
Madison	318.9	^	^	^	^	^	^	^	^	^	^
Morehouse	454.0	108.2	^	72.3	40.7	^	^	^	^	^	^
Natchitoches	513.5	169.4	56.2	77.4	^	^	^	^	^	^	^
Orleans	378.8	122.4	45.0	37.2	18.8	14.5	14.1	10.6	10.7	12.7	9.3
Ouachita	403.2	127.1	33.4	46.2	32.8	18.1	14.9	^	10.9	12.8	12.2
Plaquemines	499.1	173.8	^	^	^	^	^	^	^	^	^
Pointe Coupee	382.6	107.3	^	^	^	^	^	^	^	^	^
Rapides	442.3	132.5	50.1	52.2	23.3	13.1	18.9	^	13.9	^	15.0
Red River	500.0	^	^	^	^	^	^	^	^	^	^
Richland	504.5	127.0	^	75.2	^	^	^	^	^	^	^
Sabine	473.3	163.2	^	^	^	^	^	^	^	^	^
St. Bernard	463.6	119.2	^	^	^	^	^	^	^	^	^
St. Charles	384.1	145.8	^	45.5	^	^	^	^	^	^	^
St. Helena	303.1	^	^	^	^	^	^	^	^	^	^
St. James	509.8	176.7	41.9	65.7	^	^	^	^	^	^	^
St. John the Baptist	378.7	129.5	35.1	38.4	25.3	^	^	^	^	^	^
St. Landry	484.2	170.7	58.0	39.7	30.4	21.5	^	^	^	^	^
St. Martin	433.7	155.4	48.5	49.4	^	^	^	^	^	^	^
St. Mary	431.6	148.6	44.6	51.8	^	^	^	^	^	^	^
St. Tammany	413.7	160.9	37.1	36.1	22.7	^	^	17.4	^	^	^
Tangipahoa	416.0	135.7	42.5	28.5	26.8	^	18.5	18.9	15.7	^	^
Tensas	415.9	^	^	^	^	^	^	^	^	^	^
Terrebonne	467.3	137.8	72.2	47.6	34.9	^	^	^	^	^	^
Union	531.7	163.4	^	^	^	^	^	^	^	^	^
Vermilion	499.4	142.6	^	^	^	^	^	^	^	^	^
Vernon	372.2	^	^	^	^	^	^	^	^	^	^
Washington	419.7	119.1	37.7	43.0	^	^	^	^	^	^	^
Webster	433.8	129.6	48.7	50.6	^	^	^	^	^	^	^
West Baton Rouge	467.2	166.8	^	55.4	^	^	^	^	^	^	^

West Carroll	387.9	^	^	^	^	^	^	^	^	^	^
West Feliciana	558.5	^	^	^	^	^	^	^	^	^	^
Winn	407.2	^	^	^	^	^	^	^	^	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases.

Table F1. Incidence Rates¹ by LTR Region² for the Ten Most Commonly Diagnosed Cancers, 2017-2021:
NH White Males

Primary Site				New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
Invasive cancers ³	U.S. ⁴	LA									
All Sites	509.0	554.8	↑	515.4 *	559.8	567.4	591.1 #	560.4	552.5	545.7	535.8 *
Prostate	113.7	124.6	↑	115.9 *	137.5 #	118.4 *	138.3 #	127.4	109.9 *	116.6 *	118.6
Lung and Bronchus	57.6	72.5	↑	63.3 *	65.0 *	75.7	77.2	76.9	80.5 #	74.6	78.8
Colon and Rectum	41.7	49.2	↑	43.2 *	43.3 *	50.8	56.8 #	51.5	60.2 #	47.4	49.2
Urinary Bladder	37.3	36.9		39.0	35.2	41.0 #	36.2	33.3	39.0	38.1	30.8 *
Melanoma of the Skin	43.1	34.6	↓	34.1	42.0 #	36.5	29.6 *	32.9	26.2 *	29.8 *	37.8
Kidney and Renal Pelvis	23.4	33.3	↑	28.0 *	33.5	34.5	39.0 #	33.5	30.3	33.3	31.7
Non-Hodgkin Lymphoma	24.1	24.6		23.7	24.8	27.0	26.2	25.4	23.3	23.0	21.3
Oral Cavity and Pharynx	20.1	23.1	↑	21.9	26.0 #	22.5	22.8	20.1	22.6	23.5	22.4
Leukemia	19.4	19.4		17.5	19.0	18.2	22.2	21.1	18.9	21.7	19.0
Pancreas	15.5	15.3		15.3	13.3	17.2	15.7	14.4	16.3	15.5	15.4

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table F2. Incidence Rates¹ by LTR Region² for the Ten Most Commonly Diagnosed Cancers, 2017-2021:
NH White Females

Primary Site			New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
Invasive cancers ³	U.S. ⁴	LA								
All Sites	445.7	444.1	420.5 *	439.4	455.0	457.3 #	429.7	435.5	461.3 #	456.4
Breast	138.7	130.2 ↓	139.9 #	129.5	141.9 #	137.9 #	114.2 *	104.4 *	126.8	117.5 *
Lung and Bronchus	49.5	54.9 ↑	46.9 *	55.2	55.8	57.7	56.2	58.1	55.1	57.9
Colon and Rectum	32.9	37.6 ↑	32.9 *	32.1 *	37.2	38.4	39.4	42.4	42.6 #	47.2 #
Thyroid	20.5	22.6 ↑	19.5	24.0	22.2	22.5	15.7 *	27.5 #	26.9 #	23.7
Melanoma of the Skin	28.9	20.6 ↓	21.4	23.8 #	19.7	14.2 *	18.0	19.9	20.9	28.8 #
Corpus and Uterus, NOS	27.4	20.6 ↓	19.2	19.1	18.4	22.6	21.3	24.6	23.6	20.7
Non-Hodgkin Lymphoma	16.3	17.5 ↑	17.2	16.1	19.6	18.3	18.0	17.3	18.4	14.2 *
Kidney and Renal Pelvis	11.4	16.9 ↑	13.1 *	15.9	17.6	19.7 #	20.2	15.8	15.5	19.6
Leukemia	11.8	12.2	9.7 *	11.5	12.2	12.7	15.1 #	11.6	15.0 #	11.5
Pancreas	11.8	12.1	10.6	11.9	11.5	13.8	12.3	12.2	12.5	13.1

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table F3. Incidence Rates¹ by LTR Region² for the Ten Most Commonly Diagnosed Cancers, 2017-2021:
NH Black Males

Primary Site				New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
Invasive cancers ³	U.S. ⁴	LA									
All Sites	530.3	599.5	↑	544.7 *	646.7 #	611.7	646.0 #	606.4	614.1	596.0	574.8
Prostate	190.6	197.8	↑	178.7 *	225.3 #	204.5	189.0	190.7	206.1	184.1	214.6
Lung and Bronchus	66.5	89.5	↑	82.9	91.8	84.0	99.5	88.4	94.9	98.3	80.7
Colon and Rectum	49.6	60.8	↑	53.3 *	61.1	65.8	69.5	60.3	64.4	64.7	59.3
Kidney and Renal Pelvis	25.3	29.8	↑	27.8	34.4	31.4	29.8	30.5	24.0	28.6	30.1
Liver and Intrahepatic Bile Duct	16.0	22.1	↑	22.4	30.1 #	17.5	24.2	22.8	13.6 *	22.9	6.5 *
Pancreas	17.8	20.2	↑	16.4 *	19.0	19.9	29.9 #	17.5	18.3	21.5	23.2
Urinary Bladder	19.4	19.0		18.7	21.2	16.2	19.1	18.1	17.9	21.5	14.4
Non-Hodgkin Lymphoma	17.1	16.8		18.8	17.2	16.9	17.2	16.4	18.8	15.3	12.0
Myeloma	17.2	16.3		13.4	17.9	16.2	16.7	15.8	18.1	19.0	15.5
Oral Cavity and Pharynx	13.4	15.9	↑	13.4	16.5	15.2	17.4	15.7	21.8	15.5	17.7

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table F4. Incidence Rates¹ by LTR Region² for the Ten Most Commonly Diagnosed Cancers, 2017-2021:
NH Black Females

Primary Site				New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
Invasive cancers ³	U.S. ⁴	LA									
All Sites	405.2	423.1	↑	397.7 *	418.0	432.3	464.7 #	429.7	425.5	437.6	420.1
Breast	131.3	137.3	↑	131.2	138.6	147.2	158.7 #	126.2	134.9	136.5	121.0 *
Lung and Bronchus	43.0	44.4		43.6	39.1 *	44.1	54.9 #	53.5	43.5	44.2	43.6
Colon and Rectum	37.8	43.6	↑	38.1 *	39.0	43.7	49.4	45.4	46.8	50.5 #	50.3
Corpus and Uterus, NOS	29.0	24.6	↓	19.8 *	23.8	26.3	23.9	23.1	23.7	29.9 #	33.3 #
Pancreas	15.1	15.6		14.1	14.6	13.3	17.2	21.3	14.4	17.3	18.5
Kidney and Renal Pelvis	13.2	15.5	↑	15.2	15.3	15.4	14.1	12.8	16.0	17.2	17.5
Thyroid	11.9	13.5	↑	12.3	15.9	16.8	15.2	^	14.1	11.3	11.6
Myeloma	13.1	12.9		11.1	16.4 #	14.1	11.0	^	11.5	13.8	12.9
Non-Hodgkin Lymphoma	11.9	12.8		12.9	15.1	10.9	12.1	16.2	8.6	12.5	9.8
Cervix Uteri	8.4	10.9	↑	10.5	10.7	8.8	10.0	10.7	15.6	11.5	12.4

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table G1. Incidence Rates¹ by LA OPH Region² for the Ten Most Commonly Diagnosed Cancers, 2017-2021:
NH White Males

Primary Site				New Orleans Region	Baton Rouge Region	Southwest Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region	Northlake Region
Invasive cancers ³	U.S. ⁴	LA										
All Sites	509.0	554.8	↑	516.5 *	560.0	562.4	591.9 #	560.4	552.5	545.7	535.8 *	567.7
Prostate	113.7	124.6	↑	116.8 *	144.7 #	114.5 *	140.3 #	127.4	109.9 *	116.6 *	118.6	123.1
Lung and Bronchus	57.6	72.5	↑	63.4 *	56.5 *	81.9 #	75.0	76.9	80.5 #	74.6	78.8	76.4
Colon and Rectum	41.7	49.2	↑	43.6 *	40.5 *	53.2	56.9 #	51.5	60.2 #	47.4	49.2	48.2
Urinary Bladder	37.3	36.9		39.1	35.9	41.5	36.0	33.3	39.0	38.1	30.8 *	37.2
Melanoma of the Skin	43.1	34.6	↓	33.9	45.0 #	22.8 *	30.2 *	32.9	26.2 *	29.8 *	37.8	43.9 #
Kidney and Renal Pelvis	23.4	33.3	↑	28.4 *	33.5	36.2	39.8 #	33.5	30.3	33.3	31.7	32.3
Non-Hodgkin Lymphoma	24.1	24.6		23.6	23.8	28.8 #	26.0	25.4	23.3	23.0	21.3	26.1
Oral Cavity and Pharynx	20.1	23.1	↑	21.8	26.3 #	23.1	23.0	20.1	22.6	23.5	22.4	23.5
Leukemia	19.4	19.4		17.6	19.0	19.3	22.3	21.1	18.9	21.7	19.0	17.9
Pancreas	15.5	15.3		14.9	13.5	16.1	15.3	14.4	16.3	15.5	15.4	16.5

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table G2. Incidence Rates¹ by LA OPH Region² for the Ten Most Commonly Diagnosed Cancers, 2017-2021:
NH White Females

Primary Site			New Orleans Region		Baton Rouge Region		Southeast Region		Acadiana Region		Southwest Region		Central Region		Northwest Region		Northeast Region		Northlake Region		
Invasive cancers ³	U.S. ⁴	LA																			
All Sites	445.7	444.1		421.2	*	432.0		438.9		460.8	#	429.7		435.5		461.3	#	456.4		459.7	#
Breast	138.7	130.2	↓	139.1	#	136.1		131.1		140.2	#	114.2	*	104.4	*	126.8		117.5	*	135.4	
Lung and Bronchus	49.5	54.9	↑	48.3	*	51.3		53.8		57.8		56.2		58.1		55.1		57.9		59.0	#
Colon and Rectum	32.9	37.6	↑	32.9	*	29.7	*	37.6		38.8		39.4		42.4		42.6	#	47.2	#	36.2	
Thyroid	20.5	22.6	↑	19.4	*	25.0		20.5		23.3		15.7	*	27.5	#	26.9	#	23.7		22.9	
Melanoma of the Skin	28.9	20.6	↓	21.3		26.0	#	14.8	*	14.6	*	18.0		19.9		20.9		28.8	#	22.1	
Corpus and Uterus, NOS	27.4	20.6	↓	19.1		17.7		20.5		22.5		21.3		24.6		23.6		20.7		18.8	
Non-Hodgkin Lymphoma	16.3	17.5	↑	17.3		15.5		20.6		17.8		18.0		17.3		18.4		14.2	*	18.3	
Kidney and Renal Pelvis	11.4	16.9	↑	13.2	*	14.1	*	18.6		19.6	#	20.2		15.8		15.5		19.6		17.8	
Leukemia	11.8	12.2		9.7	*	11.1		13.1		12.7		15.1	#	11.6		15.0	#	11.5		11.7	
Pancreas	11.8	12.1		10.5		11.4		11.1		14.2		12.3		12.2		12.5		13.1		12.2	

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table G3. Incidence Rates¹ by LA OPH Region² for the Ten Most Commonly Diagnosed Cancers, 2017-2021:
NH Black Males

Primary Site				New Orleans Region	Baton Rouge Region	Southwest Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region	Northlake Region
Invasive cancers ³	U.S. ⁴	LA										
All Sites	530.3	599.5	↑	545.2 *	641.0 #	589.0	658.6 #	606.4	614.1	596.0	574.8	662.8 #
Prostate	190.6	197.8	↑	178.8 *	221.7 #	189.3	191.8	190.7	206.1	184.1	214.6	238.0 #
Lung and Bronchus	66.5	89.5	↑	83.1	88.3	88.4	103.7 #	88.4	94.9	98.3	80.7	88.1
Colon and Rectum	49.6	60.8	↑	53.2 *	58.5	63.8	70.2	60.3	64.4	64.7	59.3	73.2
Kidney and Renal Pelvis	25.3	29.8	↑	27.7	33.6	32.5	28.8	30.5	24.0	28.6	30.1	35.4
Liver and Intrahepatic Bile Duct	16.0	22.1	↑	22.3	30.2 #	15.1 *	25.6	22.8	13.6 *	22.9	6.5 *	25.9
Pancreas	17.8	20.2	↑	16.4 *	20.2	15.6	31.4 #	17.5	18.3	21.5	23.2	21.4
Urinary Bladder	19.4	19.0		18.6	22.2	18.1	18.9	18.1	17.9	21.5	14.4	15.6
Non-Hodgkin Lymphoma	17.1	16.8		18.9	17.3	12.2	18.9	16.4	18.8	15.3	12.0	18.6
Myeloma	17.2	16.3		13.2	19.5	18.9	16.6	15.8	18.1	19.0	15.5	11.2
Oral Cavity and Pharynx	13.4	15.9	↑	13.4	16.8	15.2	18.3	15.7	21.8	15.5	17.7	14.3

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table G4. Incidence Rates¹ by LA OPH Region² for the Ten Most Commonly Diagnosed Cancers, 2017-2021:
NH Black Females

Primary Site				New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region	Northlake Region
Invasive cancers ³	U.S. ⁴	LA										
All Sites	405.2	423.1	↑	398.9 *	418.2	439.8	469.2 #	429.7	425.5	437.6	420.1	410.3
Breast	131.3	137.3	↑	131.7	139.3	147.4	160.4 #	126.2	134.9	136.5	121.0 *	138.4
Lung and Bronchus	43.0	44.4		44.0	39.6	45.0	56.3 #	53.5	43.5	44.2	43.6	36.8
Colon and Rectum	37.8	43.6	↑	38.1 *	39.7	48.9	49.2	45.4	46.8	50.5 #	50.3	34.7 *
Corpus and Uterus, NOS	29.0	24.6	↓	20.0 *	24.2	27.0	23.9	23.1	23.7	29.9 #	33.3 #	22.2
Pancreas	15.1	15.6		14.2	14.6	15.5	16.8	21.3	14.4	17.3	18.5	12.6
Kidney and Renal Pelvis	13.2	15.5	↑	15.4	14.4	16.8	13.8	12.8	16.0	17.2	17.5	16.0
Thyroid	11.9	13.5	↑	12.4	15.4	14.8	14.5	^	14.1	11.3	11.6	20.9 #
Myeloma	13.1	12.9		11.0	16.2 #	12.6	11.7	^	11.5	13.8	12.9	16.1
Non-Hodgkin Lymphoma	11.9	12.8		12.9	15.5	10.1	12.3	16.2	8.6	12.5	9.8	13.5
Cervix Uteri	8.4	10.9	↑	10.5	9.9	9.7	9.6	10.7	15.6	11.5	12.4	12.4

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

³Except for urinary bladder (in situ and invasive), only invasive cases are included.

⁴U.S. incidence rate estimates are from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, 17 regions.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Table H1. Number of Children and Adolescent Cancer Diagnoses,¹ 2017-2021 Combined, Louisiana

ICCC ² Primary Site	All Races			NH White			NH Black		
	Total	Boys	Girls	Total	Boys	Girls	Total	Boys	Girls
All ICCC Sites including Borderline & Benign Brain/CNS Tumors	1,218	645	573	733	391	342	357	180	177
I Leukemias, myeloproliferative & myelodysplastic diseases ³	263	163	100	148	86	62	79	53	26
II Lymphomas & reticuloendothelial neoplasms	165	111	54	103	75	28	49	26	23
III CNS & miscellaneous intracranial & intraspinal neoplasms ⁴	301	138	163	186	91	95	90	35	55
IV Neuroblastoma & other peripheral nervous cell tumors	42	18	24	28	11	17	11	^	6
V Retinoblastoma	12	6	6	7	^	^	^	^	^
VI Renal tumors	52	24	28	26	12	14	19	9	10
VII Hepatic tumors	16	9	7	12	7	^	^	^	^
VIII Malignant bone tumors	43	32	11	28	22	6	10	7	^
IX Soft tissue & other extraosseous sarcomas	80	46	34	37	23	14	38	20	18
X Germ cell tumors, trophoblastic tumors & neoplasms of gonads ⁵	57	30	27	32	20	12	17	^	13
XI Other malignant epithelial neoplasms & malignant melanomas ⁶	126	40	86	92	29	63	21	9	12
XII Other & unspecified malignant neoplasms	^	^	^	^	^	^	^	^	^
Not classified by SEER or in situ	59	27	32	33	12	21	18	9	9

¹Children and adolescent cancers include patients aged 0-19 years.

²ICCC: International Classification of Childhood Cancer. For more information: <https://seer.cancer.gov/iccc/iccc-iarc-2017.html>

³Group I includes myelodysplastic syndromes.

⁴Group III includes benign and borderline brain/CNS tumors.

⁵Group X includes benign and borderline intracranial and intraspinal germ cell tumors.

⁶Group XI includes in situ urinary bladder tumors.

^ Count is not displayed due to fewer than 6 cases during the five-year period.

Table H2. Percent Distribution of Children and Adolescent Cancers,¹ 2017-2021, Louisiana

ICCC ² Primary Site	All Races			NH White			NH Black		
	Total	Boys	Girls	Total	Boys	Girls	Total	Boys	Girls
All ICCC Sites including Borderline & Benign Brain/CNS Tumors	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
I Leukemias, myeloproliferative & myelodysplastic diseases ³	21.6	25.3	17.5	20.2	22.0	18.1	22.1	29.4	14.7
II Lymphomas & reticuloendothelial neoplasms	13.5	17.2	9.4	14.1	19.2	8.2	13.7	14.4	13.0
III CNS & miscellaneous intracranial & intraspinal neoplasms ⁴	24.7	21.4	28.4	25.4	23.3	27.8	25.2	19.4	31.1
IV Neuroblastoma & other peripheral nervous cell tumors	3.4	2.8	4.2	3.8	2.8	5.0	3.1	2.8	3.4
V Retinoblastoma	1.0	0.9	1.0	1.0	0.8	1.2	0.8	1.1	0.6
VI Renal tumors	4.3	3.7	4.9	3.5	3.1	4.1	5.3	5.0	5.6
VII Hepatic tumors	1.3	1.4	1.2	1.6	1.8	1.5	0.6	0.6	0.6
VIII Malignant bone tumors	3.5	5.0	1.9	3.8	5.6	1.8	2.8	3.9	1.7
IX Soft tissue & other extraosseous sarcomas	6.6	7.1	5.9	5.0	5.9	4.1	10.6	11.1	10.2
X Germ cell tumors, trophoblastic tumors & neoplasms of gonads ⁵	4.7	4.7	4.7	4.4	5.1	3.5	4.8	2.2	7.3
XI Other malignant epithelial neoplasms & malignant melanomas ⁶	10.3	6.2	15.0	12.6	7.4	18.4	5.9	5.0	6.8
XII Other & unspecified malignant neoplasms	0.2	0.2	0.2	0.1	0.0	0.3	0.0	0.0	0.0
Not classified by SEER or in situ	4.8	4.2	5.6	4.5	3.1	6.1	5.0	5.0	5.1

¹Children and adolescent cancers include patients aged 0-19 years.

²ICCC: International Classification of Childhood Cancer. For more information: <https://seer.cancer.gov/iccc/iccc-iarc-2017.html>

³Group I includes myelodysplastic syndromes.

⁴Group III includes benign and borderline brain/CNS tumors.

⁵Group X includes benign and borderline intracranial and intraspinal germ cell tumors.

⁶Group XI includes in situ urinary bladder tumors.

Table H3. Average Annual Cancer Incidence Rates¹ of Children and Adolescent Cancers,² 2017-2021, Louisiana

ICCC ³ Primary Site	All Races			NH White			NH Black		
	Total	Boys	Girls	Total	Boys	Girls	Total	Boys	Girls
All ICCC Sites excluding Borderline & Benign Brain/CNS Tumors	179.7	191.6	167.4	206.8	221.3	191.5	137.7	141.6	133.8
All ICCC Sites including Borderline & Benign Brain/CNS Tumors	199.2	207.0	191.1	229.9	239.5	219.9	153.0	152.5	153.6
I Leukemias, myeloproliferative & myelodysplastic diseases ³	43.0	52.3	33.3	46.7	52.9	40.2	34.0	45.2	22.6
II Lymphomas & reticuloendothelial neoplasms	26.9	35.6	17.9	32.0	45.7	17.6	20.9	21.9	19.8
III CNS & miscellaneous intracranial & intraspinal neoplasms ⁴	49.3	44.4	54.5	58.6	55.9	61.4	38.6	29.6	47.8
IV Neuroblastoma & other peripheral nervous cell tumors	6.9	5.8	8.0	9.0	^	11.1	^	^	^
V Retinoblastoma	^	^	^	^	^	^	^	^	^
VI Renal tumors	8.5	7.7	9.3	8.3	^	^	8.2	^	^
VII Hepatic tumors	2.6	^	^	^	^	^	^	^	^
VIII Malignant bone tumors	7.0	10.3	^	8.7	13.3	^	^	^	^
IX Soft tissue & other extraosseous sarcomas	13.1	14.7	11.4	11.7	14.1	^	16.3	16.9	15.6
X Germ cell tumors, trophoblastic tumors & neoplasms of gonads ⁵	9.3	9.6	9.0	10.0	12.1	^	7.3	^	^
XI Other malignant epithelial neoplasms & malignant melanomas ⁶	20.5	12.8	28.6	28.4	17.5	39.8	8.9	^	^
XII Other & unspecified malignant neoplasms	^	^	^	^	^	^	^	^	^
Not classified by SEER or in situ	9.7	8.7	10.7	10.2	^	13.3	7.7	^	^

¹Rates are per 1,000,000 and age-adjusted to the 2000 US Population (19 age groups - Census P25-1130) standard.

²Children and adolescent cancers include patients aged 0-19 years.

²ICCC: International Classification of Childhood Cancer. For more information: <https://seer.cancer.gov/iccc/iccc-iarc-2017.html>

³Group I includes myelodysplastic syndromes.

⁴Group III includes benign and borderline brain/CNS tumors.

⁵Group X includes benign and borderline intracranial and intraspinal germ cell tumors.

⁶Group XI includes in situ urinary bladder tumors.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Table I1. Age-specific Number of Cancer Cases¹, 2017-2021, Louisiana

Primary Site														
<i>Invasive Cancers²</i>	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+
All Sites	539	876	1,584	2,493	3,477	5,489	9,161	14,780	20,470	22,781	19,727	14,648	9,475	7,711
Oral Cavity and Pharynx	10	11	28	51	88	177	382	564	671	587	463	309	201	155
Lip	^	^	^	^	^	6	14	18	16	19	27	15	12	16
Tongue	^	^	10	12	28	57	111	174	215	207	142	109	55	41
Salivary Gland	^	^	8	10	8	13	11	27	43	44	48	44	38	25
Floor of Mouth	^	^	^	^	^	7	22	25	41	26	14	12	11	10
Gum and Other Mouth	^	^	^	7	16	25	45	67	79	70	76	44	50	41
Nasopharynx	^	^	6	7	10	10	18	21	23	22	12	10	^	^
Tonsil	^	^	^	13	14	35	104	154	146	113	77	34	11	^
Oropharynx	^	^	^	^	^	12	29	39	52	42	31	14	7	^
Hypopharynx	^	^	^	^	^	12	17	29	47	35	25	24	11	7
Other Oral Cavity and Pharynx	^	^	^	^	^	^	11	10	9	9	11	^	^	^
Digestive System	54	85	168	341	544	1,042	1,985	2,932	3,841	4,241	3,572	2,724	1,877	1,723
Esophagus	^	^	^	8	14	45	84	165	232	216	195	149	86	72
Stomach	^	^	21	46	32	74	123	213	280	317	263	219	147	174
Small Intestine	^	^	7	15	34	51	89	102	153	138	146	88	52	39
Colon and Rectum	42	66	109	214	355	646	1,214	1,353	1,612	1,914	1,604	1,209	897	830
Colon excluding Rectum	30	48	73	131	196	383	676	846	1,075	1,372	1,209	940	715	687
Cecum	^	^	12	15	30	66	107	150	178	290	245	210	179	181
Appendix	21	30	32	24	34	43	43	37	59	60	44	23	7	^
Ascending Colon	^	^	^	18	14	57	101	133	195	248	294	248	171	163
Hepatic Flexure	^	^	^	^	^	8	27	29	51	55	78	48	39	32
Transverse Colon	^	^	^	9	20	25	41	88	100	133	118	97	86	68
Splenic Flexure	^	^	^	^	6	7	28	29	36	49	27	39	22	19
Descending Colon	^	^	^	14	15	32	50	79	94	101	78	42	38	41
Sigmoid Colon	^	6	15	34	61	131	258	265	298	359	258	174	123	105
Large Intestine, NOS	^	^	^	8	11	14	21	36	64	77	67	59	50	73
Rectum and Rectosigmoid Junction	12	18	36	83	159	263	538	507	537	542	395	269	182	143
Rectosigmoid Junction	^	^	7	12	26	35	96	80	103	84	72	57	34	26
Rectum	12	17	29	71	133	228	442	427	434	458	323	212	148	117

Anus, Anal Canal and Anorectum	^	^	^	11	19	38	61	70	83	83	65	54	25	31
Liver and Intrahepatic Bile Duct	^	^	9	11	17	57	156	491	755	695	433	304	143	111
Liver	^	^	9	7	14	42	133	433	687	607	356	246	120	85
Intrahepatic Bile Duct	^	^	^	^	^	15	23	58	68	88	77	58	23	26
Gallbladder	^	^	^	6	^	11	16	29	42	55	77	47	33	37
Other Biliary	^	^	^	^	^	8	17	44	59	84	72	58	45	41
Pancreas	^	^	9	26	55	99	204	425	561	683	662	556	415	357
Retroperitoneum	^	^	^	^	^	^	6	9	17	7	9	8	^	^
Peritoneum, Omentum and Mesentery	^	^	^	^	^	^	8	9	14	21	12	12	8	9
Other Digestive Organs	^	^	^	^	^	^	7	22	33	28	34	20	21	19
Respiratory System	12	8	36	70	134	315	883	2,065	3,199	3,504	3,349	2,793	1,743	1,149
Nose, Nasal Cavity and Middle Ear	^	^	^	^	6	10	9	23	35	26	32	22	20	12
Larynx	^	^	^	11	15	46	115	237	287	270	184	132	65	39
Lung and Bronchus	6	8	24	54	113	258	756	1,800	2,871	3,207	3,128	2,633	1,656	1,095
Pleura	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Trachea, Mediastinum and Other	^	^	^	^	^	^	^	^	^	^	^	6	^	^
Bones and Joints	12	20	11	10	12	14	9	20	17	18	18	8	11	13
Soft Tissue including Heart	19	19	31	27	51	52	56	87	108	109	119	88	73	86
Skin excluding Basal and Squamous	40	92	153	189	227	291	380	486	638	725	714	559	431	422
Melanoma of the Skin	36	86	142	174	205	269	364	453	568	650	645	482	359	336
Other Non-Epithelial Skin	^	6	11	15	22	22	16	33	70	75	69	77	72	86
Breast	19	87	256	559	931	1,354	1,658	2,140	2,645	2,890	2,498	1,712	1,042	925
Female Genital System	19	65	193	273	342	397	553	764	985	974	737	459	319	247
Cervix Uteri	^	34	104	135	145	112	128	130	102	78	43	44	22	25
Corpus and Uterus, NOS	^	9	40	84	111	165	270	431	610	607	449	221	125	89
Corpus Uteri	^	9	40	81	109	162	261	418	593	583	433	213	120	80
Uterus, NOS	^	^	^	^	^	^	9	13	17	24	16	8	^	9
Ovary	10	20	27	38	56	80	87	128	180	172	142	114	92	72
Vagina	^	^	^	^	^	^	9	18	15	25	13	15	14	14
Vulva	^	^	13	13	24	31	39	35	49	54	58	39	42	37
Other Female Genital Organs	^	^	^	^	^	7	20	22	29	38	32	26	24	10
Male Genital System	65	91	97	100	135	372	1,216	2,532	4,039	4,868	3,543	1,986	932	505
Prostate	^	^	^	14	81	329	1,174	2,491	4,010	4,840	3,523	1,962	913	494
Testis	65	91	95	84	50	36	32	24	13	7	8	^	^	^

Penis	^	^	^	^	^	^	7	13	11	16	12	18	14	8
Other Male Genital Organs	^	^	^	^	^	^	^	^	^	^	^	6	^	^
Urinary System	10	22	74	164	264	465	707	1,192	1,709	1,880	1,815	1,472	991	859
Urinary Bladder	^	^	8	24	39	71	180	403	661	786	847	808	579	586
Kidney and Renal Pelvis	7	19	66	137	225	390	515	774	1,026	1,059	925	614	373	240
Ureter	^	^	^	^	^	^	^	8	15	15	27	28	19	15
Other Urinary Organs	^	^	^	^	^	^	7	7	7	20	16	22	20	18
Eye and Orbit	^	^	^	^	7	9	11	30	23	27	24	25	10	9
Brain and Other Nervous System	34	40	46	53	49	82	88	127	177	156	184	119	82	51
Brain	31	37	42	51	45	76	83	121	168	151	177	114	79	47
Cranial Nerves Other Nervous System	^	^	^	^	^	6	^	6	9	^	7	^	^	^
Endocrine System	87	126	220	296	314	331	326	384	418	354	278	162	76	37
Thyroid	82	125	214	290	304	321	311	363	383	316	250	142	66	33
Other Endocrine including Thymus	^	^	6	6	10	10	15	21	35	38	28	20	10	^
Lymphoma	100	139	160	160	169	254	333	519	638	761	794	707	491	386
Hodgkin Lymphoma	66	80	68	42	44	37	37	48	31	38	41	22	22	9
Hodgkin - Nodal	66	80	67	42	44	36	37	47	31	36	40	22	21	9
Hodgkin - Extranodal	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Non-Hodgkin Lymphoma	34	59	92	118	125	217	296	471	607	723	753	685	469	377
NHL - Nodal	23	34	57	66	74	142	217	318	402	485	537	474	323	254
NHL - Extranodal	11	25	35	52	51	75	79	153	205	238	216	211	146	123
Myeloma	^	^	8	19	37	89	155	213	337	411	357	315	204	174
Leukemia	39	34	47	82	80	108	201	317	406	499	483	465	407	311
Lymphocytic Leukemia	12	8	13	23	26	40	95	162	222	253	247	232	187	146
Acute Lymphocytic Leukemia	11	^	11	7	8	9	11	20	15	19	10	10	12	^
Chronic Lymphocytic Leukemia	^	^	^	10	12	25	77	131	201	219	225	212	163	137
Other Lymphocytic Leukemia	^	^	^	6	6	6	7	11	6	15	12	10	12	^
Myeloid and Monocytic Leukemia	25	25	34	58	50	63	97	150	171	230	212	214	204	139
Acute Myeloid Leukemia	15	14	15	30	23	36	62	86	111	158	138	155	132	92
Acute Monocytic Leukemia	^	^	^	^	^	^	^	^	^	^	^	^	6	6
Chronic Myeloid Leukemia	10	10	19	28	27	24	34	61	58	63	69	53	64	37
Other Myeloid/Monocytic Leukemia	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Other Leukemia	^	^	^	^	^	^	9	^	13	16	24	19	16	26
Other Acute Leukemia	^	^	^	^	^	^	^	^	^	^	7	^	^	10

Aleukemic, Subleukemic and NOS	^	^	^	^	^	^	7	^	11	14	17	14	11	16
Mesothelioma	^	^	^	^	7	^	8	11	21	50	64	58	29	31
Kaposi Sarcoma	^	11	22	14	8	11	7	^	^	^	7	^	^	8
Miscellaneous	11	23	31	78	78	121	203	392	595	723	708	683	551	620

In Situ Cancers (not included above)

Breast In Situ	^	7	20	74	191	302	385	466	583	632	502	299	133	71
----------------	---	---	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	----

[^]Statistic not displayed due to fewer than 6 cases.

¹Number of cases is the total for the 5-year time period.

²Except for urinary bladder (in situ and invasive), only invasive cases are included.

Table I2. Age-Specific Average Annual Cancer Incidence Rates,¹ 2017-2021, Louisiana

Primary Site														
<i>Invasive Cancers³</i>	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85+
All Sites	34.3	54.0	98.5	158.4	249.3	404.9	645.3	958.8	1,388.3	1,835.3	2,063.4	2,328.0	2,304.1	1,959.4
Oral Cavity and Pharynx	^	^	1.7	3.2	6.3	13.1	26.9	36.6	45.5	47.3	48.4	49.1	48.9	39.4
Lip	^	^	^	^	^	^	^	1.2	1.1	1.5	2.8	^	^	4.1
Tongue	^	^	^	^	2.0	4.2	7.8	11.3	14.6	16.7	14.9	17.3	13.4	10.4
Salivary Gland	^	^	^	^	^	^	^	1.8	2.9	3.5	5.0	7.0	9.2	6.4
Floor of Mouth	^	^	^	^	^	^	1.5	1.6	2.8	2.1	^	^	^	^
Gum and Other Mouth	^	^	^	^	1.1	1.8	3.2	4.3	5.4	5.6	7.9	7.0	12.2	10.4
Nasopharynx	^	^	^	^	^	^	1.3	1.4	1.6	1.8	^	^	^	^
Tonsil	^	^	^	^	^	2.6	7.3	10.0	9.9	9.1	8.1	5.4	^	^
Oropharynx	^	^	^	^	^	^	2.0	2.5	3.5	3.4	3.2	^	^	^
Hypopharynx	^	^	^	^	^	^	1.2	1.9	3.2	2.8	2.6	3.8	^	^
Other Oral Cavity and Pharynx	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Digestive System	3.4	5.2	10.4	21.7	39.0	76.9	139.8	190.2	260.5	341.7	373.6	432.9	456.5	437.8
Esophagus	^	^	^	^	^	3.3	5.9	10.7	15.7	17.4	20.4	23.7	20.9	18.3
Stomach	^	^	1.3	2.9	2.3	5.5	8.7	13.8	19.0	25.5	27.5	34.8	35.7	44.2
Small Intestine	^	^	^	^	2.4	3.8	6.3	6.6	10.4	11.1	15.3	14.0	12.6	9.9
Colon and Rectum	2.7	4.1	6.8	13.6	25.5	47.6	85.5	87.8	109.3	154.2	167.8	192.1	218.1	210.9
Colon excluding Rectum	1.9	3.0	4.5	8.3	14.1	28.2	47.6	54.9	72.9	110.5	126.5	149.4	173.9	174.6
Cecum	^	^	^	^	2.2	4.9	7.5	9.7	12.1	23.4	25.6	33.4	43.5	46.0
Appendix	1.3	1.8	2.0	1.5	2.4	3.2	3.0	2.4	4.0	4.8	4.6	3.7	^	^
Ascending Colon	^	^	^	1.1	^	4.2	7.1	8.6	13.2	20.0	30.8	39.4	41.6	41.4
Hepatic Flexure	^	^	^	^	^	^	1.9	1.9	3.5	4.4	8.2	7.6	9.5	8.1
Transverse Colon	^	^	^	^	1.4	1.8	2.9	5.7	6.8	10.7	12.3	15.4	20.9	17.3
Splenic Flexure	^	^	^	^	^	^	2.0	1.9	2.4	3.9	2.8	6.2	5.3	4.8
Descending Colon	^	^	^	^	^	2.4	3.5	5.1	6.4	8.1	8.2	6.7	9.2	10.4
Sigmoid Colon	^	^	^	2.2	4.4	9.7	18.2	17.2	20.2	28.9	27.0	27.7	29.9	26.7
Large Intestine, NOS	^	^	^	^	^	^	1.5	2.3	4.3	6.2	7.0	9.4	12.2	18.5
Rectum and Rectosigmoid Junction	^	1.1	2.2	5.3	11.4	19.4	37.9	32.9	36.4	43.7	41.3	42.8	44.3	36.3
Rectosigmoid Junction	^	^	^	^	1.9	2.6	6.8	5.2	7.0	6.8	7.5	9.1	8.3	6.6
Rectum	^	1.0	1.8	4.5	9.5	16.8	31.1	27.7	29.4	36.9	33.8	33.7	36.0	29.7

Anus, Anal Canal and Anorectum	^	^	^	^	1.4	2.8	4.3	4.5	5.6	6.7	6.8	8.6	6.1	7.9
Liver and Intrahepatic Bile Duct	^	^	^	^	1.2	4.2	11.0	31.9	51.2	56.0	45.3	48.3	34.8	28.2
Liver	^	^	^	^	^	3.1	9.4	28.1	46.6	48.9	37.2	39.1	29.2	21.6
Intrahepatic Bile Duct	^	^	^	^	^	^	1.6	3.8	4.6	7.1	8.1	9.2	5.6	6.6
Gallbladder	^	^	^	^	^	^	1.1	1.9	2.8	4.4	8.1	7.5	8.0	9.4
Other Biliary	^	^	^	^	^	^	1.2	2.9	4.0	6.8	7.5	9.2	10.9	10.4
Pancreas	^	^	^	1.7	3.9	7.3	14.4	27.6	38.0	55.0	69.2	88.4	100.9	90.7
Retroperitoneum	^	^	^	^	^	^	^	^	1.2	^	^	^	^	^
Peritoneum, Omentum and Mesentery	^	^	^	^	^	^	^	^	^	1.7	^	^	^	^
Other Digestive Organs	^	^	^	^	^	^	^	1.4	2.2	2.3	3.6	3.2	5.1	4.8
Respiratory System	^	^	2.2	4.4	9.6	23.2	62.2	134.0	217.0	282.3	350.3	443.9	423.9	292.0
Nose, Nasal Cavity and Middle Ear	^	^	^	^	^	^	^	1.5	2.4	2.1	3.3	3.5	4.9	^
Larynx	^	^	^	^	^	3.4	8.1	15.4	19.5	21.8	19.2	21.0	15.8	9.9
Lung and Bronchus	^	^	1.5	3.4	8.1	19.0	53.2	116.8	194.7	258.4	327.2	418.5	402.7	278.2
Pleura	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Trachea, Mediastinum and Other Respiratory Organs	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Bones and Joints	^	1.2	^	^	^	^	^	1.3	1.2	1.5	1.9	^	^	^
Soft Tissue including Heart	1.2	1.2	1.9	1.7	3.7	3.8	3.9	5.6	7.3	8.8	12.4	14.0	17.8	21.9
Skin excluding Basal and Squamous	2.5	5.7	9.5	12.0	16.3	21.5	26.8	31.5	43.3	58.4	74.7	88.8	104.8	107.2
Melanoma of the Skin	2.3	5.3	8.8	11.1	14.7	19.8	25.6	29.4	38.5	52.4	67.5	76.6	87.3	85.4
Other Non-Epithelial Skin	^	^	^	^	1.6	1.6	1.1	2.1	4.7	6.0	7.2	12.2	17.5	21.9
Breast	1.2	5.4	15.9	35.5	66.8	99.9	116.8	138.8	179.4	232.8	261.3	272.1	253.4	235.1
Female Genital System	1.2	4.0	12.0	17.3	24.5	29.3	39.0	49.6	66.8	78.5	77.1	72.9	77.6	62.8
Cervix Uteri	^	2.1	6.5	8.6	10.4	8.3	9.0	8.4	6.9	6.3	4.5	7.0	5.3	6.4
Corpus and Uterus, NOS	^	^	2.5	5.3	8.0	12.2	19.0	28.0	41.4	48.9	47.0	35.1	30.4	22.6
Corpus Uteri	^	^	2.5	5.1	7.8	11.9	18.4	27.1	40.2	47.0	45.3	33.9	29.2	20.3
Uterus, NOS	^	^	^	^	^	^	^	^	1.2	1.9	1.7	^	^	^
Ovary	^	1.2	1.7	2.4	4.0	5.9	6.1	8.3	12.2	13.9	14.9	18.1	22.4	18.3
Vagina	^	^	^	^	^	^	^	1.2	^	2.0	^	^	^	^
Vulva	^	^	^	^	1.7	2.3	2.7	2.3	3.3	4.4	6.1	6.2	10.2	9.4
Other Female Genital Organs	^	^	^	^	^	^	1.4	1.4	2.0	3.1	3.3	4.1	5.8	^
Male Genital System	4.1	5.6	6.0	6.4	9.7	27.4	85.6	164.3	273.9	392.2	370.6	315.6	226.6	128.3
Prostate	^	^	^	^	5.8	24.3	82.7	161.6	272.0	389.9	368.5	311.8	222.0	125.5

Testis	4.1	5.6	5.9	5.3	3.6	2.7	2.3	1.6	^	^	^	^	^	^
Penis	^	^	^	^	^	^	^	^	^	1.3	^	2.9	^	^
Other Male Genital Organs	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Urinary System	^	1.4	4.6	10.4	18.9	34.3	49.8	77.3	115.9	151.5	189.8	233.9	241.0	218.3
Urinary Bladder	^	^	^	1.5	2.8	5.2	12.7	26.1	44.8	63.3	88.6	128.4	140.8	148.9
Kidney and Renal Pelvis	^	1.2	4.1	8.7	16.1	28.8	36.3	50.2	69.6	85.3	96.8	97.6	90.7	61.0
Ureter	^	^	^	^	^	^	^	^	^	^	2.8	4.4	4.6	^
Other Urinary Organs	^	^	^	^	^	^	^	^	^	1.6	1.7	3.5	4.9	4.6
Eye and Orbit	^	^	^	^	^	^	^	1.9	1.6	2.2	2.5	4.0	^	^
Brain and Other Nervous System	2.2	2.5	2.9	3.4	3.5	6.0	6.2	8.2	12.0	12.6	19.2	18.9	19.9	13.0
Brain	2.0	2.3	2.6	3.2	3.2	5.6	5.8	7.8	11.4	12.2	18.5	18.1	19.2	11.9
Cranial Nerves Other Nervous System	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Endocrine System	5.5	7.8	13.7	18.8	22.5	24.4	23.0	24.9	28.3	28.5	29.1	25.7	18.5	9.4
Thyroid	5.2	7.7	13.3	18.4	21.8	23.7	21.9	23.5	26.0	25.5	26.1	22.6	16.0	8.4
Other Endocrine including Thymus	^	^	^	^	^	^	^	1.4	2.4	3.1	2.9	3.2	^	^
Lymphoma	6.4	8.6	9.9	10.2	12.1	18.7	23.5	33.7	43.3	61.3	83.0	112.4	119.4	98.1
Hodgkin Lymphoma	4.2	4.9	4.2	2.7	3.2	2.7	2.6	3.1	2.1	3.1	4.3	3.5	5.3	^
Hodgkin - Nodal	4.2	4.9	4.2	2.7	3.2	2.7	2.6	3.0	2.1	2.9	4.2	3.5	5.1	^
Hodgkin - Extranodal	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Non-Hodgkin Lymphoma	2.2	3.6	5.7	7.5	9.0	16.0	20.8	30.6	41.2	58.2	78.8	108.9	114.1	95.8
NHL - Nodal	1.5	2.1	3.5	4.2	5.3	10.5	15.3	20.6	27.3	39.1	56.2	75.3	78.5	64.5
NHL - Extranodal	^	1.5	2.2	3.3	3.7	5.5	5.6	9.9	13.9	19.2	22.6	33.5	35.5	31.3
Myeloma	^	^	^	1.2	2.7	6.6	10.9	13.8	22.9	33.1	37.3	50.1	49.6	44.2
Leukemia	2.5	2.1	2.9	5.2	5.7	8.0	14.2	20.6	27.5	40.2	50.5	73.9	99.0	79.0
Lymphocytic Leukemia	^	^	^	1.5	1.9	3.0	6.7	10.5	15.1	20.4	25.8	36.9	45.5	37.1
Acute Lymphocytic Leukemia	^	^	^	^	^	^	^	1.3	^	1.5	^	^	^	^
Chronic Lymphocytic Leukemia	^	^	^	^	^	1.8	5.4	8.5	13.6	17.6	23.5	33.7	39.6	34.8
Other Lymphocytic Leukemia	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Myeloid and Monocytic Leukemia	1.6	1.5	2.1	3.7	3.6	4.6	6.8	9.7	11.6	18.5	22.2	34.0	49.6	35.3
Acute Myeloid Leukemia	^	^	^	1.9	1.6	2.7	4.4	5.6	7.5	12.7	14.4	24.6	32.1	23.4
Acute Monocytic Leukemia	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Chronic Myeloid Leukemia	^	^	1.2	1.8	1.9	1.8	2.4	4.0	3.9	5.1	7.2	8.4	15.6	9.4
Other Myeloid/Monocytic Leukemia	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Other Leukemia	^	^	^	^	^	^	^	^	^	1.3	2.5	3.0	3.9	6.6

Other Acute Leukemia	^	^	^	^	^	^	^	^	^	^	^	^	^	^
Aleukemic, Subleukemic and NOS	^	^	^	^	^	^	^	^	^	^	1.8	^	^	4.1
Mesothelioma	^	^	^	^	^	^	^	^	1.4	4.0	6.7	9.2	7.1	7.9
Kaposi Sarcoma	^	^	1.4	^	^	^	^	^	^	^	^	^	^	^
Miscellaneous	^	1.4	1.9	5.0	5.6	8.9	14.3	25.4	40.4	58.2	74.1	108.5	134.0	157.5
<i>In Situ Cancers (not included above)</i>														
Breast In Situ	^	^	1.2	4.7	13.7	22.3	27.1	30.2	39.5	50.9	52.5	47.5	32.3	18.0

¹Rates are per 100,000 and age-adjusted to the 2000 US Population

²Except for urinary bladder (in situ and invasive), only invasive cases are included.

^Statistic not displayed due to fewer than 16 cases.

Mortality Tables

Table J1. Average Annual Number of Cancer Deaths by Site, Race, and Sex, 2017-2021, Louisiana

Primary Site	All Races			NH White			NH Black		
	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Malignant Cancers	9,364	5,058	4,306	6,249	3,391	2,858	2,855	1,528	1,326
Oral Cavity and Pharynx	182	137	45	126	94	32	53	40	13
Lip	^	^	^	^	^	^	^	^	^
Tongue	40	27	12	31	21	9	8	5	^
Salivary Gland	14	10	4	10	8	^	^	^	^
Floor of Mouth	^	^	^	^	^	^	^	^	^
Gum and Other Mouth	22	14	9	17	10	7	5	3	^
Nasopharynx	11	9	^	7	6	^	4	^	^
Tonsil	15	13	^	11	9	^	4	4	^
Oropharynx	21	17	4	12	10	^	9	7	^
Hypopharynx	8	6	^	5	4	^	^	^	^
Other Oral Cavity and Pharynx	49	40	9	32	25	6	16	13	^
Digestive System	2,606	1,537	1,069	1,651	978	673	867	509	358
Esophagus	212	172	40	157	131	26	51	38	14
Stomach	176	107	68	85	53	32	79	47	32
Small Intestine	21	12	9	13	8	5	8	4	4
Colon and Rectum	861	473	388	539	296	242	295	163	132
Colon excluding Rectum	683	369	314	423	229	194	238	128	110
Rectum and Rectosigmoid Junction	178	104	74	116	67	48	57	34	22
Anus, Anal Canal and Anorectum	16	7	9	12	5	7	4	^	^
Liver and Intrahepatic Bile Duct	524	366	158	317	215	102	183	135	48
Liver	443	326	118	263	190	74	159	122	38
Intrahepatic Bile Duct	81	40	41	53	25	28	24	13	11
Gallbladder	33	13	20	20	8	12	12	4	8
Other Biliary	30	16	14	22	12	10	7	4	^
Pancreas	689	352	337	459	240	220	213	105	108
Retroperitoneum	5	^	^	^	^	^	^	^	^
Peritoneum, Omentum and Mesentery	18	4	13	13	^	10	5	^	^
Other Digestive Organs	21	11	9	12	6	6	9	5	4
Respiratory System	2,513	1,462	1,051	1,744	978	766	719	453	266
Nose, Nasal Cavity and Middle Ear	11	5	6	7	3	4	3	^	^
Larynx	76	61	15	46	37	9	30	24	6
Lung and Bronchus	2,414	1,387	1,027	1,681	931	750	682	425	258
Pleura	6	5	^	5	4	^	^	^	^
Trachea, Mediastinum and Other Respiratory	6	4	^	4	^	^	^	^	^
Bones and Joints	38	20	19	27	14	13	10	5	5
Soft Tissue including Heart	64	34	30	40	21	19	22	11	11
Skin	142	101	41	126	90	36	14	9	5
Melanoma of the Skin	83	58	25	77	54	23	5	3	^

Non-Melanoma Skin	58	43	16	49	36	13	8	6	^
Breast	678	6	672	414	3	410	245	^	242
Female Genital System	442	--	442	265	--	265	163	--	163
Cervix Uteri	79	--	79	39	--	39	37	--	37
Corpus and Uterus, NOS	149	--	149	74	--	74	70	--	70
Corpus Uteri	90	--	90	45	--	45	42	--	42
Uterus, NOS	59	--	59	29	--	29	29	--	29
Ovary	181	--	181	127	--	127	48	--	48
Vagina	10	--	10	7	--	7	^	--	^
Vulva	16	--	16	12	--	12	3	--	3
Other Female Genital Organs	8	--	8	6	--	6	^	--	^
Male Genital System	455	455	--	263	263	--	180	180	--
Prostate	445	445	--	257	257	--	176	176	--
Testis	5	5	--	3	3	--	^	^	--
Penis	4	4	--	^	^	--	^	^	--
Other Male Genital Organs	^	^	--	^	^	--	^	^	--
Urinary System	482	324	159	362	249	113	109	66	43
Urinary Bladder	214	151	63	165	122	43	44	26	18
Kidney and Renal Pelvis	253	166	88	186	122	64	61	39	22
Ureter	3	^	^	^	^	^	^	^	^
Other Urinary Organs	12	6	6	9	4	4	^	^	^
Eye and Orbit	4	^	^	3	^	^	^	^	^
Brain and Other Nervous System	231	126	105	183	102	81	40	21	19
Endocrine System	41	17	24	26	12	14	13	4	8
Thyroid	26	9	17	18	7	11	7	^	5
Other Endocrine including Thymus	15	8	6	9	5	3	6	^	^
Lymphoma	304	172	132	230	128	101	63	36	27
Hodgkin Lymphoma	16	7	8	10	5	5	4	^	^
Non-Hodgkin Lymphoma	288	164	124	219	123	96	59	34	25
Myeloma	198	108	91	110	62	48	84	43	41
Leukemia	331	194	137	246	145	102	71	42	30
Lymphocytic Leukemia	81	49	32	60	36	24	19	12	7
Acute Lymphocytic Leukemia	19	12	8	13	8	5	5	3	^
Chronic Lymphocytic Leukemia	53	32	21	40	24	16	12	7	5
Other Lymphocytic Leukemia	10	6	4	8	5	^	^	^	^
Myeloid and Monocytic Leukemia	158	87	70	117	66	51	35	18	17
Acute Myeloid Leukemia	128	68	60	95	52	43	28	14	15
Acute Monocytic Leukemia	^	^	^	^	^	^	^	^	^
Chronic Myeloid Leukemia	15	9	6	13	8	5	^	^	^
Other Myeloid/Monocytic Leukemia	13	9	4	8	5	^	4	3	^
Other Leukemia	92	57	34	69	43	27	18	12	6
Other Acute Leukemia	16	9	7	11	6	5	3	^	^
Aleukemic, Subleukemic and NOS	76	48	28	58	37	22	14	10	5
Miscellaneous Malignant Cancer	651	363	288	433	249	184	202	105	96

^The NCI does not present counts for cells smaller than 10 for the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

-- Not Applicable

Table J2. Percent Distribution of Cancer Deaths by Site, Race, and Sex,
2017-2021, Louisiana

Primary Site	All Races			NH White			NH Black		
	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Malignant Cancers	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Oral Cavity and Pharynx	1.9	2.7	1.0	2.0	2.8	1.1	1.8	2.6	1.0
Lip	^	^	^	^	^	^	^	^	^
Tongue	0.4	0.5	0.3	0.5	0.6	0.3	0.3	0.3	^
Salivary Gland	0.1	0.2	0.1	0.2	0.2	^	^	^	^
Floor of Mouth	^	^	^	^	^	^	^	^	^
Gum and Other Mouth	0.2	0.3	0.2	0.3	0.3	0.2	0.2	0.2	^
Nasopharynx	0.1	0.2	^	0.1	0.2	^	0.1	^	^
Tonsil	0.2	0.2	^	0.2	0.3	^	0.1	0.2	^
Oropharynx	0.2	0.3	0.1	0.2	0.3	^	0.3	0.5	^
Hypopharynx	0.1	0.1	^	0.1	0.1	^	^	^	^
Other Oral Cavity and Pharynx	0.5	0.8	0.2	0.5	0.7	0.2	0.6	0.9	^
Digestive System	27.8	30.4	24.8	26.4	28.8	23.6	30.4	33.3	27.0
Esophagus	2.3	3.4	0.9	2.5	3.9	0.9	1.8	2.5	1.0
Stomach	1.9	2.1	1.6	1.4	1.6	1.1	2.8	3.1	2.4
Small Intestine	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3
Colon and Rectum	9.2	9.4	9.0	8.6	8.7	8.5	10.3	10.6	10.0
Colon excluding Rectum	7.3	7.3	7.3	6.8	6.8	6.8	8.3	8.4	8.3
Rectum and Rectosigmoid Junction	1.9	2.1	1.7	1.8	2.0	1.7	2.0	2.2	1.7
Anus, Anal Canal and Anorectum	0.2	0.1	0.2	0.2	0.1	0.3	0.1	^	^
Liver and Intrahepatic Bile Duct	5.6	7.2	3.7	5.1	6.3	3.6	6.4	8.8	3.6
Liver	4.7	6.4	2.7	4.2	5.6	2.6	5.6	8.0	2.9
Intrahepatic Bile Duct	0.9	0.8	0.9	0.9	0.7	1.0	0.8	0.9	0.8
Gallbladder	0.4	0.3	0.5	0.3	0.2	0.4	0.4	0.3	0.6
Other Biliary	0.3	0.3	0.3	0.4	0.3	0.4	0.2	0.3	^
Pancreas	7.4	7.0	7.8	7.3	7.1	7.7	7.5	6.9	8.1
Retroperitoneum	0.1	^	^	^	^	^	^	^	^
Peritoneum, Omentum and Mesentery	0.2	0.1	0.3	0.2	^	0.4	0.2	^	^
Other Digestive Organs	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.3
Respiratory System	26.8	28.9	24.4	27.9	28.8	26.8	25.2	29.7	20.0
Nose, Nasal Cavity and Middle Ear	0.1	0.1	0.1	0.1	0.1	0.1	0.1	^	^
Larynx	0.8	1.2	0.4	0.7	1.1	0.3	1.1	1.6	0.4
Lung and Bronchus	25.8	27.4	23.8	26.9	27.5	26.2	23.9	27.8	19.4
Pleura	0.1	0.1	^	0.1	0.1	^	^	^	^
Trachea, Mediastinum and Other Respiratory	0.1	0.1	^	0.1	^	^	^	^	^
Bones and Joints	0.4	0.4	0.4	0.4	0.4	0.5	0.3	0.3	0.4
Soft Tissue including Heart	0.7	0.7	0.7	0.6	0.6	0.7	0.8	0.7	0.8
Skin	1.5	2.0	1.0	2.0	2.7	1.3	0.5	0.6	0.4
Melanoma of the Skin	0.9	1.1	0.6	1.2	1.6	0.8	0.2	0.2	^
Non-Melanoma Skin	0.6	0.8	0.4	0.8	1.1	0.4	0.3	0.4	^
Breast	7.2	0.1	15.6	6.6	0.1	14.4	8.6	^	18.2

Female Genital System	4.7	--	10.3	4.2	--	9.3	5.7	--	12.3
Cervix Uteri	0.8	--	1.8	0.6	--	1.4	1.3	--	2.8
Corpus and Uterus, NOS	1.6	--	3.5	1.2	--	2.6	2.5	--	5.3
Corpus Uteri	1.0	--	2.1	0.7	--	1.6	1.5	--	3.2
Uterus, NOS	0.6	--	1.4	0.5	--	1.0	1.0	--	2.2
Ovary	1.9	--	4.2	2.0	--	4.4	1.7	--	3.6
Vagina	0.1	--	0.2	0.1	--	0.2	^	--	^
Vulva	0.2	--	0.4	0.2	--	0.4	0.1	--	0.2
Other Female Genital Organs	0.1	--	0.2	0.1	--	0.2	^	--	^
Male Genital System	4.9	9.0	--	4.2	7.7	--	6.3	11.8	--
Prostate	4.7	8.8	--	4.1	7.6	--	6.2	11.5	--
Testis	0.1	0.1	--	0.1	0.1	--	^	^	--
Penis	0.0	0.1	--	^	^	--	^	^	--
Other Male Genital Organs	^	^	--	^	^	--	^	^	--
Urinary System	5.2	6.4	3.7	5.8	7.4	3.9	3.8	4.3	3.2
Urinary Bladder	2.3	3.0	1.5	2.6	3.6	1.5	1.5	1.7	1.4
Kidney and Renal Pelvis	2.7	3.3	2.0	3.0	3.6	2.2	2.2	2.6	1.7
Ureter	0.0	^	^	^	^	^	^	^	^
Other Urinary Organs	0.1	0.1	0.1	0.1	0.1	0.2	^	^	^
Eye and Orbit	0.0	^	^	0.1	^	^	^	^	^
Brain and Other Nervous System	2.5	2.5	2.4	2.9	3.0	2.8	1.4	1.3	1.4
Endocrine System	0.4	0.3	0.6	0.4	0.4	0.5	0.4	0.3	0.6
Thyroid	0.3	0.2	0.4	0.3	0.2	0.4	0.2	^	0.4
Other Endocrine including Thymus	0.2	0.2	0.1	0.1	0.2	0.1	0.2	^	^
Lymphoma	3.2	3.4	3.1	3.7	3.8	3.5	2.2	2.4	2.1
Hodgkin Lymphoma	0.2	0.1	0.2	0.2	0.1	0.2	0.2	^	^
Non-Hodgkin Lymphoma	3.1	3.3	2.9	3.5	3.6	3.4	2.1	2.2	1.9
Myeloma	2.1	2.1	2.1	1.8	1.8	1.7	2.9	2.8	3.1
Leukemia	3.5	3.8	3.2	3.9	4.3	3.6	2.5	2.7	2.2
Lymphocytic Leukemia	0.9	1.0	0.7	1.0	1.1	0.8	0.7	0.8	0.5
Acute Lymphocytic Leukemia	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	^
Chronic Lymphocytic Leukemia	0.6	0.6	0.5	0.6	0.7	0.6	0.4	0.5	0.3
Other Lymphocytic Leukemia	0.1	0.1	0.1	0.1	0.1	^	^	^	^
Myeloid and Monocytic Leukemia	1.7	1.7	1.6	1.9	1.9	1.8	1.2	1.2	1.3
Acute Myeloid Leukemia	1.4	1.4	1.4	1.5	1.5	1.5	1.0	0.9	1.1
Acute Monocytic Leukemia	^	^	^	^	^	^	^	^	^
Chronic Myeloid Leukemia	0.2	0.2	0.1	0.2	0.2	0.2	^	^	^
Other Myeloid/Monocytic Leukemia	0.1	0.2	0.1	0.1	0.2	^	0.1	0.2	^
Other Leukemia	1.0	1.1	0.8	1.1	1.3	0.9	0.6	0.8	0.4
Other Acute Leukemia	0.2	0.2	0.2	0.2	0.2	0.2	0.1	^	^
Aleukemic, Subleukemic and NOS	0.8	0.9	0.6	0.9	1.1	0.8	0.5	0.6	0.3
Miscellaneous Malignant Cancer	7.0	7.2	6.7	6.9	7.3	6.4	7.1	6.9	7.3

^The NCI does not present counts for cells smaller than 10 for the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

-- Not Applicable

Table K. Average Annual Death Rate¹ by Site, Race, and Sex,
2017-2021, Louisiana

Primary Site	All Races			NH White			NH Black		
	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Malignant Cancers	168.6	206.2	141.3	163.8	198.4	138.2	194.9	250.2	158.3
Oral Cavity and Pharynx	3.2	5.2	1.5	3.3	5.3	1.6	3.3	5.8	1.5
Lip	^	^	^	^	^	^	^	^	^
Tongue	0.7	1.1	0.4	0.8	1.2	0.5	0.5	0.8	^
Salivary Gland	0.3	0.4	0.1	0.3	0.5	^	^	^	^
Floor of Mouth	^	^	^	^	^	^	^	^	^
Gum and Other Mouth	0.4	0.5	0.3	0.5	0.6	0.3	0.3	0.4	^
Nasopharynx	0.2	0.3	^	0.2	0.3	^	0.3	^	^
Tonsil	0.3	0.5	^	0.3	0.5	^	0.2	0.5	^
Oropharynx	0.4	0.6	0.1	0.3	0.5	^	0.5	1.0	^
Hypopharynx	0.1	0.2	^	0.1	0.2	^	^	^	^
Other Oral Cavity and Pharynx	0.8	1.5	0.3	0.8	1.4	0.3	1.0	2.0	^
Digestive System	46.3	60.2	34.9	42.8	55.6	32.1	58.1	78.1	43.1
Esophagus	3.7	6.6	1.3	4.0	7.3	1.2	3.3	5.6	1.6
Stomach	3.2	4.4	2.3	2.3	3.2	1.5	5.6	7.5	4.1
Small Intestine	0.4	0.5	0.3	0.3	0.5	0.2	0.6	0.7	0.5
Colon and Rectum	15.7	19.3	12.9	14.3	17.5	11.8	20.3	26.1	16.1
Colon excluding Rectum	12.5	15.1	10.4	11.2	13.6	9.4	16.5	20.8	13.5
Rectum and Rectosigmoid Junction	3.2	4.2	2.5	3.1	3.9	2.4	3.8	5.3	2.7
Anus, Anal Canal and Anorectum	0.3	0.3	0.3	0.3	0.3	0.3	0.3	^	^
Liver and Intrahepatic Bile Duct	8.8	13.3	5.0	7.9	11.5	4.8	11.1	18.3	5.5
Liver	7.4	11.7	3.7	6.5	10.1	3.4	9.5	16.3	4.3
Intrahepatic Bile Duct	1.4	1.6	1.3	1.4	1.4	1.4	1.6	2.0	1.3
Gallbladder	0.6	0.5	0.6	0.5	0.4	0.6	0.8	0.7	0.9
Other Biliary	0.5	0.7	0.5	0.6	0.7	0.5	0.5	0.7	^
Pancreas	12.3	14.0	10.9	11.9	13.6	10.4	14.6	16.8	12.9
Retroperitoneum	0.1	^	^	^	^	^	^	^	^
Peritoneum, Omentum and Mesentery	0.3	0.2	0.4	0.3	^	0.5	0.3	^	^
Other Digestive Organs	0.4	0.5	0.3	0.3	0.4	0.3	0.6	0.8	0.4
Respiratory System	44.2	57.9	33.6	44.5	55.4	36.2	48.2	72.5	31.0
Nose, Nasal Cavity and Middle Ear	0.2	0.2	0.2	0.2	0.2	0.2	0.2	^	^
Larynx	1.3	2.4	0.5	1.2	2.0	0.4	2.0	3.8	0.7
Lung and Bronchus	42.4	54.9	32.9	42.9	52.8	35.4	45.8	67.9	30.1
Pleura	0.1	0.2	^	0.1	0.2	^	^	^	^
Trachea, Mediastinum and Other Respiratory	0.1	0.2	^	0.1	^	^	^	^	^
Bones and Joints	0.7	0.8	0.6	0.8	0.9	0.7	0.6	0.8	0.6
Soft Tissue including Heart	1.2	1.4	1.1	1.2	1.3	1.0	1.4	1.6	1.3
Skin	2.7	4.4	1.4	3.5	5.6	1.8	0.9	1.4	0.6
Melanoma of the Skin	1.6	2.5	0.9	2.1	3.3	1.2	0.4	0.6	^
Non-Melanoma Skin	1.1	1.9	0.5	1.3	2.3	0.6	0.5	0.8	^
Breast	12.5	0.2	22.6	11.2	0.2	20.4	16.8	^	28.7

Female Genital System	8.1	--	14.8	7.1	--	13.3	10.9	--	19.0
Cervix Uteri	1.6	--	3.0	1.3	--	2.5	2.6	--	4.6
Corpus and Uterus, NOS	2.6	--	4.7	1.9	--	3.5	4.5	--	7.9
Corpus Uteri	1.6	--	2.9	1.2	--	2.1	2.7	--	4.7
Uterus, NOS	1.0	--	1.8	0.7	--	1.3	1.8	--	3.2
Ovary	3.3	--	6.0	3.4	--	6.2	3.3	--	5.6
Vagina	0.2	--	0.3	0.2	--	0.3	^	--	^
Vulva	0.3	--	0.5	0.3	--	0.6	0.2	--	0.4
Other Female Genital Organs	0.1	--	0.3	0.1	--	0.3	^	--	^
Male Genital System	8.4	20.7	--	6.9	16.8	--	13.5	35.7	--
Prostate	8.2	20.3	--	6.7	16.4	--	13.2	35.0	--
Testis	0.1	0.2	--	0.1	0.2	--	^	^	--
Penis	0.1	0.2	--	^	^	--	^	^	--
Other Male Genital Organs	^	^	--	^	^	--	^	^	--
Urinary System	8.9	13.9	5.1	9.5	15.1	5.3	7.7	11.3	5.1
Urinary Bladder	4.0	6.8	2.0	4.4	7.7	2.0	3.2	4.5	2.2
Kidney and Renal Pelvis	4.6	6.8	2.8	4.9	7.1	3.1	4.2	6.5	2.6
Ureter	0.1	^	^	^	^	^	^	^	^
Other Urinary Organs	0.2	0.2	0.2	0.2	0.3	0.2	^	^	^
Eye and Orbit	0.1	^	^	0.1	^	^	^	^	^
Brain and Other Nervous System	4.3	5.0	3.6	5.0	6.0	4.2	2.7	3.1	2.3
Endocrine System	0.8	0.7	0.8	0.7	0.7	0.7	0.9	0.7	1.1
Thyroid	0.5	0.4	0.6	0.5	0.4	0.5	0.5	^	0.7
Other Endocrine including Thymus	0.3	0.4	0.2	0.2	0.3	0.2	0.4	^	^
Lymphoma	5.7	7.5	4.3	6.1	7.9	4.7	4.5	6.1	3.4
Hodgkin Lymphoma	0.3	0.3	0.3	0.3	0.3	0.3	0.3	^	^
Non-Hodgkin Lymphoma	5.4	7.2	4.0	5.8	7.6	4.4	4.2	5.8	3.1
Myeloma	3.6	4.6	2.9	2.9	3.8	2.3	6.1	7.7	5.1
Leukemia	6.3	8.6	4.6	6.7	9.1	5.0	5.2	7.3	3.8
Lymphocytic Leukemia	1.6	2.3	1.1	1.6	2.4	1.1	1.4	2.1	0.9
Acute Lymphocytic Leukemia	0.4	0.5	0.3	0.4	0.5	0.3	0.4	0.5	^
Chronic Lymphocytic Leukemia	1.0	1.5	0.7	1.1	1.5	0.7	1.0	1.5	0.6
Other Lymphocytic Leukemia	0.2	0.3	0.1	0.2	0.4	^	^	^	^
Myeloid and Monocytic Leukemia	3.0	3.7	2.4	3.2	4.0	2.6	2.5	2.9	2.1
Acute Myeloid Leukemia	2.4	2.9	2.0	2.6	3.1	2.1	2.0	2.2	1.9
Acute Monocytic Leukemia	^	^	^	^	^	^	^	^	^
Chronic Myeloid Leukemia	0.3	0.4	0.2	0.4	0.5	0.3	^	^	^
Other Myeloid/Monocytic Leukemia	0.3	0.4	0.2	0.2	0.3	^	0.3	0.4	^
Other Leukemia	1.8	2.6	1.1	1.9	2.7	1.3	1.3	2.2	0.7
Other Acute Leukemia	0.3	0.4	0.2	0.3	0.4	0.2	0.3	^	^
Aleukemic, Subleukemic and NOS	1.5	2.2	0.9	1.6	2.4	1.1	1.1	1.8	0.6
Miscellaneous Malignant Cancer	11.8	14.8	9.5	11.3	14.6	8.9	13.9	17.5	11.7
In situ, benign or unknown behavior neoplasm	4.1	5.3	3.3	4.1	5.3	3.3	4.3	5.8	3.4

¹Rates are per 100,000 and age-adjusted to the 2000 Population (19 age groups – Census P25-1130) standard.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

--Not Applicable

Table L1. Average Annual Death Rates¹ for Selected Cancers by Race and Sex, 2017-2021:
U.S., Louisiana, and 7-Parish Industrial Corridor² (Please review: [Cautions in Interpretation](#))

Primary Site	NH White Males				NH White Females				NH Black Males				NH Black Females			
	US	Louisiana	Ind. Corr.		US	Louisiana	Ind. Corr.		US	Louisiana	Ind. Corr.		US	Louisiana	Ind. Corr.	
All Malignant Cancers	182.0	198.4	↑	171.0 *	132.7	138.2	↑	124.0 *	212.7	250.2	↑	239.0	147.5	158.3	↑	144.2 *
Oral Cavity and Pharynx	4.2	5.3	↑	4.4	1.5	1.6		1.5	4.3	5.8	↑	5.9	1.2	1.5		^
Esophagus	7.6	7.3		7.7	1.5	1.2	↓	^	4.6	5.6	↑	5.9	1.5	1.6		^
Stomach	2.9	3.2		2.8	1.5	1.5		^	6.9	7.5		7.5	3.4	4.1	↑	3.4
Small Intestine	0.5	0.5		^	0.3	0.2		^	0.9	0.7		^	0.6	0.5		^
Colon and Rectum	15.4	17.5	↑	14.3 *	11.0	11.8	↑	9.3 *	21.9	26.1	↑	22.6	13.9	16.1	↑	14.1
Liver and Intrahepatic Bile Duct	8.5	11.5	↑	10.3	3.7	4.8	↑	4.0	12.6	18.3	↑	19.2	4.7	5.5	↑	6.3
Pancreas	13.3	13.6		11.2 *	9.8	10.4		9.2	15.4	16.8		16.4	12.4	12.9		11.4
Larynx	1.6	2.0	↑	^	0.4	0.4		^	2.8	3.8	↑	3.6	0.5	0.7		^
Lung and Bronchus	43.2	52.8	↑	41.9 *	32.1	35.4	↑	31.8 *	48.9	67.9	↑	62.7	26.9	30.1	↑	24.0 *
Breast	0.3	0.2		^	19.7	20.4		18.4	0.5	^		^	27.2	28.7		30.4
Cervix Uteri	--	--		--	2.1	2.5	↑	1.7	--	--		--	3.3	4.6	↑	4.3
Corpus and Uterus, NOS	--	--		--	4.7	3.5	↓	2.3 *	--	--		--	9.3	7.9	↓	6.9
Ovary	--	--		--	6.5	6.2		6.8	--	--		--	5.7	5.6		5.1
Prostate	18.2	16.4	↓	15.1	--	--		--	37.5	35.0		31.9	--	--		--
Urinary Bladder	8.0	7.7		6.0	2.2	2.0		1.3	5.3	4.5		5.7	2.2	2.2		^
Kidney and Renal Pelvis	5.3	7.1	↑	6.8	2.2	3.1	↑	2.5	5.0	6.5	↑	6.8	2.1	2.6	↑	2.7
Brain and Other Nervous System	6.2	6.0		5.4	4.1	4.2		4.7	3.3	3.1		3.1	2.3	2.3		^
Hodgkin Lymphoma	0.3	0.3		^	0.2	0.3		^	0.3	^		^	0.2	^		^
Non-Hodgkin Lymphoma	7.1	7.6		6.4	4.0	4.4		3.9	5.1	5.8		5.9	2.9	3.1		2.8
Myeloma	3.7	3.8		3.2	2.2	2.3		2.0	7.4	7.7		8.3	5.0	5.1		6.1
Leukemia	8.6	9.1		7.5	4.7	5.0		5.4	6.6	7.3		5.5	4.2	3.8		4.1

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Ascension, East Baton Rouge, Iberville, St. Charles, St. James, St. John the Baptist, and West Baton Rouge Parishes comprise the Industrial Corridor.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

*The Industrial Corridor rate is significantly lower (P <0.05) than the Louisiana rate.

#The Industrial Corridor rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate. -- Not applicable

Table L2. Average Annual Death Rates¹ for Selected Cancers by Race and Sex, 2017-2021:
U.S., Louisiana, and 11-Parish Industrial Corridor² (Please review: [Cautions in Interpretation](#))

Primary Site	NH White Males				NH White Females				NH Black Males				NH Black Females			
	US	Louisiana	Ind. Corr.		US	Louisiana	Ind. Corr.		US	Louisiana	Ind. Corr.		US	Louisiana	Ind. Corr.	
All Malignant Cancers	182.0	198.4	↑	177.4 *	132.7	138.2	↑	127.1 *	212.7	250.2	↑	231.2 *	147.5	158.3	↑	147.3 *
Oral Cavity and Pharynx	4.2	5.3	↑	5.3	1.5	1.6		1.4	4.3	5.8	↑	4.4	1.2	1.5		1.3
Esophagus	7.6	7.3		6.9	1.5	1.2	↓	0.9	4.6	5.6	↑	4.8	1.5	1.6		1.3
Stomach	2.9	3.2		2.6	1.5	1.5		0.7 *	6.9	7.5		6.7	3.4	4.1	↑	3.5
Small Intestine	0.5	0.5		^	0.3	0.2		^	0.9	0.7		^	0.6	0.5		^
Colon and Rectum	15.4	17.5	↑	14.0 *	11.0	11.8	↑	9.6 *	21.9	26.1	↑	22.0 *	13.9	16.1	↑	14.3
Liver and Intrahepatic Bile Duct	8.5	11.5	↑	10.7	3.7	4.8	↑	4.2	12.6	18.3	↑	17.7	4.7	5.5	↑	5.2
Pancreas	13.3	13.6		11.9 *	9.8	10.4		9.2	15.4	16.8		14.3	12.4	12.9		11.3
Larynx	1.6	2.0	↑	1.8	0.4	0.4		^	2.8	3.8	↑	3.6	0.5	0.7		^
Lung and Bronchus	43.2	52.8	↑	44.3 *	32.1	35.4	↑	31.0 *	48.9	67.9	↑	62.1 *	26.9	30.1	↑	27.2
Breast	0.3	0.2		^	19.7	20.4		20.5	0.5	^		^	27.2	28.7		28.3
Cervix Uteri	--	--		--	2.1	2.5	↑	1.9	--	--		--	3.3	4.6	↑	4.4
Corpus and Uterus, NOS	--	--		--	4.7	3.5	↓	3.0	--	--		--	9.3	7.9	↓	7.2
Ovary	--	--		--	6.5	6.2		6.6	--	--		--	5.7	5.6		5.7
Prostate	18.2	16.4	↓	15.9	--	--		--	37.5	35.0		33.9	--	--		--
Urinary Bladder	8.0	7.7		6.8	2.2	2.0		2.0	5.3	4.5		5.1	2.2	2.2		2.1
Kidney and Renal Pelvis	5.3	7.1	↑	6.7	2.2	3.1	↑	2.2 *	5.0	6.5	↑	6.3	2.1	2.6	↑	2.7
Brain and Other Nervous System	6.2	6.0		5.5	4.1	4.2		3.9	3.3	3.1		3.0	2.3	2.3		2.1
Hodgkin Lymphoma	0.3	0.3		^	0.2	0.3		^	0.3	^		^	0.2	^		^
Non-Hodgkin Lymphoma	7.1	7.6		6.9	4.0	4.4		3.9	5.1	5.8		6.6	2.9	3.1		2.5
Myeloma	3.7	3.8		3.2	2.2	2.3		2.1	7.4	7.7		8.2	5.0	5.1		4.7
Leukemia	8.6	9.1		7.6 *	4.7	5.0		4.8	6.6	7.3		6.2	4.2	3.8		3.3

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Ascension, East Baton Rouge, Iberville, Jefferson, Orleans, Plaquemines, St. Bernard, St. Charles, St. James, St. John the Baptist, and West Baton Rouge Parishes comprise the Industrial Corridor.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

*The Industrial Corridor rate is significantly lower (P <0.05) than the Louisiana rate.

#The Industrial Corridor rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate. -- Not applicable

Table M1. Death Rates¹ by Louisiana Parish² for the Ten Most Common Cancer Deaths, 2017-2021:
NH White Males

	All Malignant Cancers	Lung and Bronchus	Colon and Rectum	Prostate	Pancreas	Liver and Intrahepatic Bile Duct	Leukemia	Urinary Bladder	Non- Hodgkin Lymphoma	Esophagus	Kidney and Renal Pelvis
Louisiana	198.4	52.8	17.5	16.4	13.6	11.5	9.1	7.7	7.6	7.3	7.1
Acadia Parish	250.8	72.6	27.4	18.0	14.2	14.2	^	^	^	^	^
Allen Parish	278.7	90.1	^	^	^	^	^	^	^	^	^
Ascension Parish	163.2	44.8	12.6	11.8	12.6	11.5	^	^	^	^	^
Assumption Parish	183.9	51.0	^	^	^	^	^	^	^	^	^
Avoyelles Parish	238.7	78.9	28.2	22.1	20.7	^	^	^	^	^	^
Beauregard Parish	228.0	71.0	21.7	^	^	^	^	^	^	^	^
Bienville Parish	238.5	^	^	^	^	^	^	^	^	^	^
Bossier Parish	192.3	49.5	14.4	13.0	14.8	10.1	10.9	12.6	6.4	6.0	9.5
Caddo Parish	189.1	45.6	16.1	17.5	13.2	11.4	9.4	8.5	7.4	7.4	5.5
Calcasieu Parish	192.7	56.4	12.8	12.4	14.2	14.3	11.0	5.5	6.4	6.8	7.0
Caldwell Parish	204.7	80.3	^	^	^	^	^	^	^	^	^
Cameron Parish	121.2	^	^	^	^	^	^	^	^	^	^
Catahoula Parish	263.5	^	^	^	^	^	^	^	^	^	^
Claiborne Parish	194.8	56.4	^	^	^	^	^	^	^	^	^
Concordia Parish	221.6	61.7	^	^	^	^	^	^	^	^	^
De Soto Parish	183.4	44.7	^	^	^	^	^	^	^	^	^
East Baton Rouge Parish	162.1	36.8	13.2	15.8	11.1	9.3	8.3	7.2	6.5	7.2	5.8
East Carroll Parish	231.6	^	^	^	^	^	^	^	^	^	^
East Feliciana Parish	194.5	54.0	^	^	^	^	^	^	^	^	^
Evangeline Parish	204.9	61.7	25.5	^	^	^	^	^	^	^	^
Franklin Parish	235.0	91.4	^	^	^	^	^	^	^	^	^
Grant Parish	235.0	61.1	32.9	^	^	^	^	^	^	^	^
Iberia Parish	223.4	56.8	20.6	19.0	16.5	13.9	^	^	^	^	^
Iberville Parish	256.6	86.2	^	^	^	^	^	^	^	^	^
Jackson Parish	245.7	72.7	^	43.8	^	^	^	^	^	^	^
Jefferson Parish	188.3	49.7	12.2	15.4	12.5	11.8	8.5	8.8	7.8	6.6	7.4
Jefferson Davis Parish	243.3	77.7	24.3	27.8	^	^	^	^	^	^	^

Lafayette Parish	179.2	44.4	16.6	15.2	14.9	10.3	9.1	8.6	7.3	5.8	6.2
Lafourche Parish	213.8	58.0	25.5	14.2	11.8	13.6	10.7	8.8	10.2	10.6	7.7
La Salle Parish	220.7	62.9	^	^	^	^	^	^	^	^	^
Lincoln Parish	183.4	41.6	^	^	^	^	^	^	^	^	^
Livingston Parish	190.3	55.7	18.5	13.9	10.0	14.6	8.0	5.4	7.2	4.7	7.1
Madison Parish	204.6	^	^	^	^	^	^	^	^	^	^
Morehouse Parish	212.5	54.4	^	^	^	^	^	^	^	^	^
Natchitoches Parish	224.4	55.5	24.3	^	^	^	^	^	^	^	^
Orleans Parish	153.5	30.9	16.0	20.1	12.2	7.4	5.1	^	4.9	6.1	^
Ouachita Parish	217.8	51.4	21.0	18.8	16.1	6.7	10.9	10.3	10.1	6.6	8.2
Plaquemines Parish	214.1	50.0	^	^	^	^	^	^	^	^	^
Pointe Coupee Parish	199.4	49.4	^	^	^	^	^	^	^	^	^
Rapides Parish	196.2	48.6	24.4	14.1	14.7	11.8	9.1	^	9.0	8.2	6.4
Red River Parish	282.0	^	^	^	^	^	^	^	^	^	^
Richland Parish	207.9	83.3	^	^	^	^	^	^	^	^	^
Sabine Parish	275.8	84.6	^	^	^	^	^	^	^	^	^
St. Bernard Parish	235.4	74.2	^	^	^	19.6	^	^	^	^	^
St. Charles Parish	198.1	38.5	21.5	20.4	^	^	^	^	^	^	^
St. Helena Parish	223.6	^	^	^	^	^	^	^	^	^	^
St. James Parish	146.9	44.4	^	^	^	^	^	^	^	^	^
St. John the Baptist Parish	203.3	48.8	^	^	^	^	^	^	^	^	^
St. Landry Parish	221.1	61.0	20.0	14.0	13.7	^	^	^	^	^	^
St. Martin Parish	208.0	64.8	24.9	^	17.9	^	^	^	^	^	^
St. Mary Parish	224.4	68.6	22.7	^	15.0	^	^	^	^	^	^
St. Tammany Parish	185.1	43.8	13.1	18.7	13.7	10.6	7.8	9.3	6.1	6.3	5.7
Tangipahoa Parish	227.0	61.8	21.5	27.3	17.1	12.0	12.2	7.7	8.1	6.6	6.4
Tensas Parish	201.2	^	^	^	^	^	^	^	^	^	^
Terrebonne Parish	228.9	71.5	20.2	13.4	15.5	11.6	9.2	^	10.5	8.3	8.3
Union Parish	201.3	52.5	^	^	^	^	^	^	^	^	^
Vermilion Parish	208.5	50.2	19.5	19.1	11.4	11.4	^	^	^	^	^
Vernon Parish	240.4	82.8	27.1	20.4	^	^	^	^	^	^	^
Washington Parish	228.2	57.1	16.0	^	19.1	27.0	^	^	^	^	^
Webster Parish	254.4	71.3	28.0	^	19.2	^	^	^	^	^	^
West Baton Rouge Parish	161.9	43.0	^	^	^	^	^	^	^	^	^

West Carroll Parish	242.6	83.9	^	^	^	^	^	^	^	^	^
West Feliciana Parish	157.5	^	^	^	^	^	^	^	^	^	^
Winn Parish	252.2	85.9	^	^	^	^	^	^	^	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table M2. Death Rates¹ by Louisiana Parish² for the Ten Most Common Cancer Deaths, 2017-2021:
NH White Females

	All Malignant Cancers	Lung and Bronchus	Breast	Colon and Rectum	Pancreas	Ovary	Leukemia	Liver and Intrahepatic Bile Duct	Non- Hodgkin Lymphoma	Brain and Other Nervous System	Corpus and Uterus, NOS
Louisiana	138.2	35.4	20.4	11.8	10.4	6.2	5.0	4.8	4.4	4.2	3.5
Acadia	157.8	44.6	20.5	18.5	13.0	^	^	^	^	^	^
Allen	164.1	45.2	^	^	^	^	^	^	^	^	^
Ascension	124.6	33.7	22.0	6.7	10.3	^	^	^	^	^	^
Assumption	130.9	41.7	^	^	^	^	^	^	^	^	^
Avoyelles	152.1	44.4	16.8	18.1	^	^	^	^	^	^	^
Beauregard	182.1	57.0	22.0	18.8	15.5	^	^	^	^	^	^
Bienville	140.4	^	^	^	^	^	^	^	^	^	^
Bossier	142.0	40.6	21.1	9.4	9.8	7.4	^	5.2	^	^	^
Caddo	148.1	37.3	20.0	15.1	11.8	7.0	5.5	5.7	4.0	4.7	3.2
Calcasieu	147.7	37.3	20.8	13.4	12.9	5.7	7.0	5.4	3.8	4.5	3.6
Caldwell	118.5	^	^	^	^	^	^	^	^	^	^
Cameron	145.7	^	^	^	^	^	^	^	^	^	^
Catahoula	124.7	^	^	^	^	^	^	^	^	^	^
Claiborne	145.2	^	^	^	^	^	^	^	^	^	^
Concordia	163.6	^	^	^	^	^	^	^	^	^	^
De Soto	138.2	32.3	^	^	^	^	^	^	^	^	^
East Baton Rouge	118.9	28.1	17.4	8.5	9.0	8.8	5.7	3.8	3.8	5.1	2.6
East Carroll	^	^	^	^	^	^	^	^	^	^	^
East Feliciana	131.6	46.9	^	^	^	^	^	^	^	^	^
Evangeline	140.8	45.0	^	^	^	^	^	^	^	^	^
Franklin	153.5	31.6	^	^	^	^	^	^	^	^	^
Grant	148.2	54.3	^	^	^	^	^	^	^	^	^
Iberia	136.7	40.4	17.4	10.7	11.2	^	^	^	^	^	^
Iberville	141.4	37.6	^	^	^	^	^	^	^	^	^
Jackson	127.9	37.9	^	^	^	^	^	^	^	^	^
Jefferson	132.3	29.7	22.8	10.0	10.6	6.3	4.6	4.5	4.4	3.1	3.4
Jefferson Davis	159.8	39.4	20.5	^	^	^	^	^	^	^	^

Lafayette	137.5	32.3	21.9	11.4	11.3	7.1	3.8	4.0	4.6	2.9	3.1
Lafourche	139.7	36.6	20.5	16.6	^	^	^	^	6.5	^	^
La Salle	154.6	48.8	^	^	^	^	^	^	^	^	^
Lincoln	134.5	33.9	21.1	^	^	^	^	^	^	^	^
Livingston	136.6	38.9	16.9	9.3	10.5	5.5	5.8	5.8	4.9	^	3.9
Madison	176.3	^	^	^	^	^	^	^	^	^	^
Morehouse	142.0	55.3	^	^	^	^	^	^	^	^	^
Natchitoches	165.7	33.2	24.5	^	^	^	^	^	^	^	^
Orleans	114.2	25.7	20.0	8.5	5.7	6.1	^	^	^	4.0	4.4
Ouachita	148.8	39.3	24.1	11.9	10.6	6.3	6.1	4.6	^	4.5	^
Plaquemines	142.6	38.0	^	^	^	^	^	^	^	^	^
Pointe Coupee	117.3	^	^	^	^	^	^	^	^	^	^
Rapides	131.2	36.2	20.6	13.0	11.1	^	^	6.4	5.7	^	^
Red River	129.2	^	^	^	^	^	^	^	^	^	^
Richland	109.9	32.6	^	^	^	^	^	^	^	^	^
Sabine	152.5	57.0	^	^	^	^	^	^	^	^	^
St. Bernard	162.7	50.3	24.7	^	^	^	^	^	^	^	^
St. Charles	155.0	42.6	20.3	^	^	^	^	^	^	^	^
St. Helena	150.6	^	^	^	^	^	^	^	^	^	^
St. James	103.9	^	^	^	^	^	^	^	^	^	^
St. John the Baptist	157.6	35.2	27.7	^	^	^	^	^	^	^	^
St. Landry	165.5	39.3	24.1	19.8	12.5	^	^	^	^	^	^
St. Martin	134.4	35.3	21.3	16.7	^	^	^	^	^	^	^
St. Mary	131.1	38.7	15.8	^	^	^	^	^	^	^	^
St. Tammany	126.9	32.1	19.1	10.5	9.3	5.4	4.9	3.5	4.8	4.2	3.2
Tangipahoa	142.7	33.1	22.2	10.7	7.3	9.9	^	6.2	6.0	^	^
Tensas	210.7	^	^	^	^	^	^	^	^	^	^
Terrebonne	149.5	33.9	21.4	10.0	12.3	^	6.5	^	8.8	^	^
Union	184.6	39.8	^	^	^	^	^	^	^	^	^
Vermilion	143.5	36.8	21.7	18.9	11.2	^	^	^	^	^	^
Vernon	181.6	43.5	29.8	^	15.7	^	^	^	^	^	^
Washington	146.1	39.2	30.4	^	14.8	^	^	^	^	^	^
Webster	152.1	30.7	24.2	^	17.3	^	^	^	^	^	^
West Baton Rouge	115.6	45.0	^	^	^	^	^	^	^	^	^

West Carroll	114.6	^	^	^	^	^	^	^	^	^	^	^
West Feliciana	116.2	^	^	^	^	^	^	^	^	^	^	^
Winn	158.4	^	^	^	^	^	^	^	^	^	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table M3. Death Rates¹ by Louisiana Parish² for the Ten Most Common Cancer Deaths, 2017-2021:
NH Black Males

	All Malignant Cancers	Lung and Bronchus	Prostate	Colon and Rectum	Liver and Intrahepatic Bile Duct	Pancreas	Myeloma	Stomach	Leukemia	Kidney and Renal Pelvis	Oral Cavity and Pharynx
Louisiana	250.2	67.9	35.0	26.1	18.3	16.8	7.7	7.5	7.3	6.5	5.8
Acadia	335.3	98.7	^	^	^	^	^	^	^	^	^
Allen	288.4	^	^	^	^	^	^	^	^	^	^
Ascension	228.0	65.9	^	^	^	^	^	^	^	^	^
Assumption	316.5	113.9	^	^	^	^	^	^	^	^	^
Avoyelles	378.0	116.0	^	^	^	^	^	^	^	^	^
Beauregard	250.0	^	^	^	^	^	^	^	^	^	^
Bienville	250.0	^	^	^	^	^	^	^	^	^	^
Bossier	198.2	48.6	^	^	^	^	^	^	^	^	^
Caddo	255.8	68.9	37.5	31.9	24.5	19.2	7.6	7.3	8.8	5.8	6.2
Calcasieu	245.2	77.7	27.2	30.2	25.0	16.4	^	^	^	^	^
Caldwell	^	^	^	^	^	^	^	^	^	^	^
Cameron	^	^	^	^	^	^	^	^	^	^	^
Catahoula	661.3	^	^	^	^	^	^	^	^	^	^
Claiborne	272.4	93.3	^	^	^	^	^	^	^	^	^
Concordia	290.7	^	^	^	^	^	^	^	^	^	^
De Soto	298.6	60.6	^	^	^	^	^	^	^	^	^
East Baton Rouge	228.7	60.8	25.5	23.1	22.3	17.5	8.5	7.2	4.5	6.5	4.9
East Carroll	411.6	^	^	^	^	^	^	^	^	^	^
East Feliciana	248.8	^	^	^	^	^	^	^	^	^	^
Evangeline	305.5	97.7	^	^	^	^	^	^	^	^	^
Franklin	287.5	^	^	^	^	^	^	^	^	^	^
Grant	^	^	^	^	^	^	^	^	^	^	^
Iberia	296.6	70.3	^	^	^	39.3	^	^	^	^	^
Iberville	342.5	105.6	^	^	^	^	^	^	^	^	^
Jackson	336.7	^	^	^	^	^	^	^	^	^	^
Jefferson	248.2	76.3	37.8	20.3	14.7	13.5	11.5	^	8.6	^	^

Jefferson Davis	324.0	^	^	^	^	^	^	^	^	^	^
Lafayette	254.9	75.3	18.6	26.6	23.1	22.4	^	^	^	^	^
Lafourche	307.6	98.8	^	^	^	^	^	^	^	^	^
La Salle	^	^	^	^	^	^	^	^	^	^	^
Lincoln	192.4	^	^	^	^	^	^	^	^	^	^
Livingston	311.2	^	^	^	^	^	^	^	^	^	^
Madison	296.1	^	^	^	^	^	^	^	^	^	^
Morehouse	294.5	100.6	^	^	^	^	^	^	^	^	^
Natchitoches	273.6	92.2	^	^	^	^	^	^	^	^	^
Orleans	214.5	54.9	34.3	22.7	17.3	12.0	7.1	6.0	5.9	5.5	2.5
Ouachita	253.4	67.3	55.8	21.4	^	15.7	^	^	^	^	^
Plaquemines	291.6	^	^	^	^	^	^	^	^	^	^
Pointe Coupee	271.6	^	^	^	^	^	^	^	^	^	^
Rapides	270.6	80.2	44.6	34.1	20.4	^	^	^	^	^	^
Red River	304.8	^	^	^	^	^	^	^	^	^	^
Richland	326.2	^	^	^	^	^	^	^	^	^	^
Sabine	189.0	^	^	^	^	^	^	^	^	^	^
St. Bernard	263.5	^	^	^	^	^	^	^	^	^	^
St. Charles	269.9	54.6	^	^	^	^	^	^	^	^	^
St. Helena	217.1	^	^	^	^	^	^	^	^	^	^
St. James	252.9	78.3	^	^	^	^	^	^	^	^	^
St. John the Baptist	221.8	42.9	50.7	^	^	^	^	^	^	^	^
St. Landry	325.8	73.9	31.3	41.2	28.8	28.2	^	^	^	^	^
St. Martin	270.8	53.2	^	58.9	^	^	^	^	^	^	^
St. Mary	240.8	53.7	^	^	^	^	^	^	^	^	^
St. Tammany	212.9	38.0	39.2	^	^	^	^	^	^	^	^
Tangipahoa	304.4	108.4	45.3	^	27.5	^	^	^	^	^	^
Tensas	^	^	^	^	^	^	^	^	^	^	^
Terrebonne	277.9	81.3	^	^	^	^	^	^	^	^	^
Union	330.3	^	^	^	^	^	^	^	^	^	^
Vermilion	315.0	^	^	^	^	^	^	^	^	^	^
Vernon	234.2	^	^	^	^	^	^	^	^	^	^
Washington	321.6	91.9	^	^	^	^	^	^	^	^	^
Webster	258.2	96.0	^	^	^	^	^	^	^	^	^

West Baton Rouge	269.2	^	^	^	^	^	^	^	^	^	^
West Carroll	^	^	^	^	^	^	^	^	^	^	^
West Feliciana	232.6	^	^	^	^	^	^	^	^	^	^
Winn	199.1	^	^	^	^	^	^	^	^	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table M4. Death Rates¹ by Louisiana Parish² for the Ten Most Common Cancer Deaths, 2017-2021:
NH Black Females

	All Malignant Cancers	Lung and Bronchus	Breast	Colon and Rectum	Pancreas	Corpus and Uterus, NOS	Ovary	Liver and Intrahepatic Bile Duct	Myeloma	Corpus Uteri	Cervix Uteri
Louisiana	158.3	30.1	28.7	16.1	12.9	7.9	5.6	5.5	5.1	4.7	4.6
Acadia	208.3	^	^	^	^	^	^	^	^	^	^
Allen	177.0	^	^	^	^	^	^	^	^	^	^
Ascension	141.9	^	44.5	^	^	^	^	^	^	^	^
Assumption	222.0	^	^	^	^	^	^	^	^	^	^
Avoyelles	174.3	^	^	^	^	^	^	^	^	^	^
Beauregard	167.9	^	^	^	^	^	^	^	^	^	^
Bienville	148.5	^	^	^	^	^	^	^	^	^	^
Bossier	139.7	28.9	^	^	^	^	^	^	^	^	^
Caddo	166.0	28.3	27.3	20.3	16.0	11.0	4.7	4.5	5.3	7.1	4.8
Calcasieu	163.9	29.7	26.4	16.6	15.7	^	^	^	^	^	^
Caldwell	^	^	^	^	^	^	^	^	^	^	^
Cameron	^	^	^	^	^	^	^	^	^	^	^
Catahoula	^	^	^	^	^	^	^	^	^	^	^
Claiborne	143.8	^	^	^	^	^	^	^	^	^	^
Concordia	146.6	^	^	^	^	^	^	^	^	^	^
De Soto	185.5	^	^	^	^	^	^	^	^	^	^
East Baton Rouge	141.9	23.6	26.6	15.1	12.3	7.2	4.6	7.0	6.5	^	4.5
East Carroll	343.0	^	^	^	^	^	^	^	^	^	^
East Feliciana	106.9	^	^	^	^	^	^	^	^	^	^
Evangeline	200.5	74.5	^	^	^	^	^	^	^	^	^
Franklin	136.4	^	^	^	^	^	^	^	^	^	^
Grant	^	^	^	^	^	^	^	^	^	^	^
Iberia	170.7	29.8	37.6	^	^	^	^	^	^	^	^
Iberville	169.8	^	52.5	^	^	^	^	^	^	^	^
Jackson	203.3	^	^	^	^	^	^	^	^	^	^
Jefferson	166.4	31.8	25.7	14.8	13.3	7.9	^	^	^	^	5.7
Jefferson Davis	162.1	^	^	^	^	^	^	^	^	^	^

Lafayette	161.5	28.7	33.3	11.4	14.4	^	^	^	^	^	^
Lafourche	209.2	54.1	^	^	^	^	^	^	^	^	^
La Salle	^	^	^	^	^	^	^	^	^	^	^
Lincoln	176.2	36.7	35.6	^	^	^	^	^	^	^	^
Livingston	127.4	^	^	^	^	^	^	^	^	^	^
Madison	209.0	^	^	^	^	^	^	^	^	^	^
Morehouse	206.4	^	^	^	^	^	^	^	^	^	^
Natchitoches	156.2	38.4	^	^	^	^	^	^	^	^	^
Orleans	142.3	28.2	26.9	13.3	10.8	7.7	6.5	4.4	3.5	5.3	4.1
Ouachita	153.2	30.6	27.2	13.9	16.7	^	^	^	^	^	^
Plaquemines	176.3	^	^	^	^	^	^	^	^	^	^
Pointe Coupee	169.8	^	^	^	^	^	^	^	^	^	^
Rapides	166.9	34.4	34.6	22.3	16.4	^	^	^	^	^	^
Red River	^	^	^	^	^	^	^	^	^	^	^
Richland	203.1	^	^	^	^	^	^	^	^	^	^
Sabine	197.8	^	^	^	^	^	^	^	^	^	^
St. Bernard	258.5	^	^	^	^	^	^	^	^	^	^
St. Charles	137.0	^	^	^	^	^	^	^	^	^	^
St. Helena	73.9	^	^	^	^	^	^	^	^	^	^
St. James	189.4	^	^	^	^	^	^	^	^	^	^
St. John the Baptist	152.4	^	^	^	^	^	^	^	^	^	^
St. Landry	186.4	37.9	26.0	21.0	^	^	^	^	^	^	^
St. Martin	157.1	35.2	^	^	^	^	^	^	^	^	^
St. Mary	173.1	34.8	^	^	^	^	^	^	^	^	^
St. Tammany	140.7	24.2	23.2	^	^	^	^	^	^	^	^
Tangipahoa	162.5	34.9	24.8	^	^	^	^	^	^	^	^
Tensas	219.6	^	^	^	^	^	^	^	^	^	^
Terrebonne	177.4	39.2	38.2	^	^	^	^	^	^	^	^
Union	181.8	^	^	^	^	^	^	^	^	^	^
Vermilion	155.5	^	^	^	^	^	^	^	^	^	^
Vernon	195.4	^	^	^	^	^	^	^	^	^	^
Washington	196.2	35.9	^	^	^	^	^	^	^	^	^
Webster	199.9	34.4	^	^	^	^	^	^	^	^	^
West Baton Rouge	122.0	^	^	^	^	^	^	^	^	^	^

West Carroll	^	^	^	^	^	^	^	^	^	^	^
West Feliciana	157.0	^	^	^	^	^	^	^	^	^	^
Winn	161.8	^	^	^	^	^	^	^	^	^	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²Cases are assigned to the parish of residence, not the parish where the diagnosis or treatment took place.

^Statistic not displayed due to fewer than 16 cases during the five-year period.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table N1. Death Rates¹ by LTR Region² for the Ten Most Common Cancer Deaths, 2017-2021:
NH White Males

Primary Site	U.S.	LA		New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
All Malignant Cancers	182.0	198.4	↑	181.7 *	182.9 *	200.4	205.7	207.4	219.8 #	205.6	213.9 #
Lung and Bronchus	43.2	52.8	↑	46.1 *	47.8 *	51.2	55.5	63.0 #	62.4 #	52.7	59.3 #
Colon and Rectum	15.4	17.5	↑	13.6 *	15.5	17.2	20.4 #	15.6	27.3 #	17.9	18.3
Prostate	18.2	16.4	↓	16.3	16.7	16.5	14.9	13.7	17.5	16.2	20.0 #
Pancreas	13.3	13.6		12.6	11.8	13.6	14.8	15.3	15.4	14.1	14.6
Liver and Intrahepatic Bile Duct	8.5	11.5	↑	11.2	12.1	11.9	11.5	14.5 #	10.7	11.4	7.4 *
Leukemia	8.6	9.1		7.3	8.4	8.9	9.4	10.6	9.2	11.1	9.5
Urinary Bladder	8.0	7.7		7.4	6.8	8.1	7.2	7.5	8.0	9.0	7.8
Non-Hodgkin Lymphoma	7.1	7.6		7.3	6.9	7.4	8.5	7.8	8.2	7.4	7.9
Esophagus	7.6	7.3		6.1	6.8	8.5	7.1	8.0	7.8	8.1	6.2
Kidney and Renal Pelvis	5.3	7.1	↑	6.4	6.7	7.2	7.7	7.7	6.1	7.6	7.8

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table N2. Death Rates¹ by LTR Region² for the Ten Most Common Cancer Deaths, 2017-2021:
NH White Females

Primary Site	U.S.	LA		New Orleans Region		Baton Rouge Region		Southeast Region		Acadiana Region		Southwest Region		Central Region		Northwest Region		Northeast Region
All Malignant Cancers	132.7	138.2	↑	129.4 *		127.7 *		135.9		142.4		154.7 #		147.3		146.5 #		144.4
Lung and Bronchus	32.1	35.4	↑	30.0 *		33.6		34.3		37.0		40.9 #		39.7		37.5		38.5
Breast	19.7	20.4		22.2		18.4		20.7		20.5		21.3		20.6		20.8		19.6
Colon and Rectum	11.0	11.8	↑	9.7 *		9.1 *		12.0		14.5 #		13.9		14.1		12.6		12.2
Pancreas	9.8	10.4		9.2		8.7 *		9.5		11.2		14.1 #		11.4		11.1		11.8
Ovary	6.5	6.2		6.3		7.4		4.9		6.6		5.6		4.8		6.9		5.5
Leukemia	4.7	5.0		4.1		5.3		5.3		4.4		6.1		4.3		5.4		4.8
Liver and Intrahepatic Bile Duct	3.7	4.8	↑	4.4		5.1		4.0		5.0		5.8		5.5		5.4		4.0
Non-Hodgkin Lymphoma	4.0	4.4		4.0		4.2		5.8 #		3.8		3.9		6.5 #		4.2		3.2
Brain and Other Nervous System	4.1	4.2		3.3		4.1		4.3		4.0		4.2		3.1		5.1		5.3
Corpus and Uterus, NOS	4.7	3.5	↓	3.6		3.1		3.1		3.5		4.6		3.3		3.3		4.5

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table N3. Death Rates¹ by LTR Region² for the Ten Most Common Cancer Deaths, 2017-2021:
NH Black Males

Primary Site	U.S.	LA		New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
All Malignant Cancers	212.7	250.2	↑	224.5 *	247.9	256.4	282.2 #	254.2	281.6 #	251.8	263.0
Lung and Bronchus	48.9	67.9	↑	61.1	69.7	64.1	70.9	75.4	81.3	71.2	68.2
Prostate	37.5	35.0		34.9	31.5	40.2	25.5 *	27.5	41.4	34.4	55.0 #
Colon and Rectum	21.9	26.1	↑	22.0	22.9	23.6	30.9	30.9	37.5 #	30.7	26.6
Pancreas	15.4	16.8		12.9 *	15.7	16.2	25.6 #	15.4	13.4	17.5	21.5
Liver and Intrahepatic Bile Duct	12.6	18.3	↑	16.7	21.0	15.8	23.7 #	23.0	14.2	20.7	7.5 *
Myeloma	7.4	7.7		8.1	8.3	7.5	9.0	^	^	7.3	^
Stomach	6.9	7.5		5.9	6.6	9.9	9.5	^	8.8	7.8	7.4
Leukemia	6.6	7.3		6.5	6.4	9.6	11.0	^	^	7.1	^
Urinary Bladder	5.3	4.5		4.8	5.6	^	^	^	^	^	^
Non-Hodgkin Lymphoma	5.1	5.8		7.0	6.3	^	5.9	^	^	3.9	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table N4. Death Rates¹ by LTR Region² for the Ten Most Common Cancer Deaths, 2017-2021:
NH Black Females

Primary Site	U.S.	LA		New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
All Malignant Cancers	147.5	158.3	↑	149.4 *	144.0 *	166.5	172.9 #	165.1	167.7	163.6	178.0 #
Breast	27.2	28.7		26.6	30.2	29.3	28.2	27.3	35.1	26.9	31.9
Lung and Bronchus	26.9	30.1	↑	29.3	24.3 *	33.6	36.6 #	33.0	33.5	28.8	33.9
Colon and Rectum	13.9	16.1	↑	14.4	14.1	19.0	16.7	16.8	18.9	19.1	16.5
Pancreas	12.4	12.9		11.4	12.5	9.0 *	14.3	15.3	13.9	15.0	15.7
Corpus and Uterus, NOS	9.4	7.9	↓	7.4	7.3	8.1	7.9	^	^	10.7 #	10.2
Ovary	5.7	5.6		6.0	5.0	6.6	6.7	^	^	4.6	6.5
Corpus Uteri	5.1	4.7		4.9	3.2	5.5	5.1	^	^	7.1 #	6.1
Myeloma	5.0	5.1		3.5	5.6	6.7	5.7	^	^	5.1	5.8
Liver and Intrahepatic Bile Duct	4.7	5.5	↑	4.3	6.2	6.5	8.0	^	6.9	4.5	5.3
Uterus, NOS	4.3	3.2	↓	2.5	4.1	^	^	^	^	3.7	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[LTR Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table O1. Death Rates¹ by LA OPH Region² for the Ten Most Common Cancer Deaths, 2017-2021:
NH White Males

Primary Site	U.S.	LA		New Orleans Region		Baton Rouge Region		Southeast Region		Acadiana Region		Southwest Region		Central Region		Northwest Region		Northeast Region		Northlake Region
All Malignant Cancers	182.0	198.4	↑	182.7 *		169.6 *		210.8 #		204.4		207.4		219.8 #		205.6		213.9 #		197.8
Lung and Bronchus	43.2	52.8	↑	46.2 *		42.6 *		58.9 #		54.5		63.0 #		62.4 #		52.7		59.3 #		50.4
Colon and Rectum	15.4	17.5	↑	13.7 *		13.4 *		20.9 #		20.2		15.6		27.3 #		17.9		18.3		16.2
Prostate	18.2	16.4	↓	16.5		15.7		12.8 *		15.6		13.7		17.5		16.2		20.0 #		18.8
Pancreas	13.3	13.6		12.4		11.3		13.1		14.8		15.3		15.4		14.1		14.6		13.8
Liver and Intrahepatic Bile Duct	8.5	11.5	↑	11.0		11.2		11.8		11.3		14.5 #		10.7		11.4		7.4 *		13.1
Leukemia	8.6	9.1		7.8		7.6		9.2		9.2		10.6		9.2		11.1		9.5		8.8
Urinary Bladder	8.0	7.7		7.5		6.7		7.3		7.1		7.5		8.0		9.0		7.8		8.2
Non-Hodgkin Lymphoma	7.1	7.6		7.2		6.3		9.2		8.4		7.8		8.2		7.4		7.9		7.0
Esophagus	7.6	7.3		6.3		7.1		10.0 #		7.0		8.0		7.8		8.1		6.2		6.3
Kidney and Renal Pelvis	5.3	7.1	↑	6.5		6.6		8.1		7.9		7.7		6.1		7.6		7.8		6.4

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table O2. Death Rates¹ by LA OPH Region² for the Ten Most Common Cancer Deaths, 2017-2021:
NH White Females

Primary Site	U.S.	LA		New Orleans Region		Baton Rouge Region		Southeast Region		Acadiana Region		Southwest Region		Central Region		Northwest Region		Northeast Region		Northlake Region
All Malignant Cancers	132.7	138.2	↑	129.8	*	120.8	*	141.1		143.4		154.7	#	147.3		146.5	#	144.4		133.5
Lung and Bronchus	32.1	35.4	↑	30.2	*	31.1	*	36.3		36.9		40.9	#	39.7		37.5		38.5		34.9
Breast	19.7	20.4		22.3		18.0		19.7		20.9		21.3		20.6		20.8		19.6		19.9
Colon and Rectum	11.0	11.8	↑	9.8	*	8.3	*	13.4		14.6	#	13.9		14.1		12.6		12.2		10.4
Pancreas	9.8	10.4		9.1		9.0		8.6		11.5		14.1	#	11.4		11.1		11.8		9.4
Ovary	6.5	6.2		6.5		7.4		5.0		6.4		5.6		4.8		6.9		5.5		6.1
Leukemia	4.7	5.0		4.2		5.2		5.3		4.4		6.1		4.3		5.4		4.8		5.2
Liver and Intrahepatic Bile Duct	3.7	4.8	↑	4.3		4.6		4.7		5.0		5.8		5.5		5.4		4.0		4.7
Non-Hodgkin Lymphoma	4.0	4.4		4.0		3.7		6.6	#	3.6		3.9		6.5	#	4.2		3.2		5.0
Brain and Other Nervous System	4.1	4.2		3.2		4.6		4.0		4.3		4.2		3.1		5.1		5.3		3.8
Corpus and Uterus, NOS	4.7	3.5	↓	3.6		2.4		3.2		3.6		4.6		3.3		3.3		4.5		3.5

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table O3. Death Rates¹ by LA OPH Region² for the Ten Most Common Cancer Deaths, 2017-2021:
NH Black Males

Primary Site	U.S.	LA		New Orleans Region		Baton Rouge Region	Southeast Region	Acadiana Region		Southwest Region	Central Region		Northwest Region	Northeast Region	Northlake Region
All Malignant Cancers	212.7	250.2	↑	225.7 *		239.1	256.7	288.0 #		254.2	281.6 #		251.8	263.0	268.9
Lung and Bronchus	48.9	67.9	↑	61.7		62.9	67.5	73.1		75.4	81.3		71.2	68.2	77.3
Prostate	37.5	35.0		35.1		29.0	34.4	25.0 *		27.5	41.4		34.4	55.0 #	45.6
Colon and Rectum	21.9	26.1	↑	21.9 *		23.2	26.1	31.8		30.9	37.5 #		30.7	26.6	19.8
Liver and Intrahepatic Bile Duct	12.6	18.3	↑	16.7		21.3	14.1	24.9 #		23.0	14.2		20.7	7.5 *	19.9
Pancreas	15.4	16.8		12.9 *		16.9	13.7	26.4 #		15.4	13.4		17.5	21.5	16.9
Myeloma	7.4	7.7		8.0		8.9	^	9.0		^	^		7.3	^	^
Stomach	6.9	7.5		6.1		6.6	10.8	9.8		^	8.8		7.8	7.4	^
Leukemia	6.6	7.3		6.8		5.2	6.5	12.3 #		^	^		7.1	^	11.5
Kidney and Renal Pelvis	5.0	6.5	↑	6.0		6.9	^	7.8		^	^		6.9	7.0	^
Oral Cavity and Pharynx	4.3	5.8	↑	3.3 *		5.3	10.9 #	8.4		^	10.3		5.4	6.3	^

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Table O4. Death Rates¹ by LA OPH Region² for the Ten Most Common Cancer Deaths, 2017-2021:
NH Black Females

Primary Site	U.S.	LA		New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region	Northlake Region
All Malignant Cancers	147.5	158.3	↑	149.7 *	142.0 *	172.1	172.7 #	165.1	167.7	163.6	178.0 #	152.5
Lung and Bronchus	26.9	30.1	↑	29.5	23.3 *	34.5	36.7 #	33.0	33.5	28.8	33.9	29.1
Breast	27.2	28.7		26.7	31.2	30.2	28.7	27.3	35.1	26.9	31.9	24.5
Colon and Rectum	13.9	16.1	↑	14.3	14.0	18.8	16.8	16.8	18.9	19.1	16.5	16.5
Pancreas	12.4	12.9		11.2	11.9	12.2	13.8	15.3	13.9	15.0	15.7	11.4
Corpus and Uterus, NOS	9.4	7.9	↓	7.4	7.0	8.6	7.3	^	^	10.7 #	10.2	8.9
Ovary	5.7	5.6		6.0	5.0	7.0	7.3	^	^	4.6	6.5	^
Liver and Intrahepatic Bile Duct	4.7	5.5	↑	4.4	6.0	6.3	8.6 #	^	6.9	4.5	5.3	6.0
Myeloma	5.0	5.1		3.7	6.2	^	6.0	^	^	5.1	5.8	^
Corpus Uteri	5.1	4.7		4.8	2.9 *	6.2	5.0	^	^	7.1 #	6.1	^
Cervix Uteri	3.3	4.6	↑	4.4	4.2	^	3.9	^	^	4.8	^	6.4

¹Rates are per 100,000 and age-adjusted to the 2000 US Population (19 age groups – Census P25-1130) standard.

²[Louisiana Office of Public Health Regions](#)

^Statistic not displayed due to fewer than 16 cases during the five-year period.

*The regional rate is significantly lower (P <0.05) than the Louisiana rate.

#The regional rate is significantly higher (P <0.05) than the Louisiana rate.

↑ or ↓ The Louisiana rate is significantly higher or lower (P <0.05) than the U.S. rate.

Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Survival and Prevalence Tables

Table P. 5-Year Relative Survival, 2010-2020, Louisiana

Primary Site ¹	All Races			NH White					NH Black		
	Total	Male	Female	Total	Male	Female			Total	Male	Female
All Sites	65.7%	65.5%	65.9%	67.4%	66.9%	↑	67.9%	↑	61.4%	62.1%	60.7%
Oral Cavity and Pharynx	62.6%	62.5%	62.8%	67.6%	68.2%	↑	66.0%	↑	45.0%	42.8%	50.8%
Lip	87.5%	87.9%	81.5%	87.7%	88.4%		80.3%		83.4%	80.4%	100.0%
Tongue	65.5%	65.5%	65.6%	70.4%	70.6%	↑	70.0%	↑	39.6%	37.9%	44.3%
Salivary Gland	72.5%	66.7%	81.5%	69.1%	64.4%		78.8%		79.7%	73.6%	84.2%
Floor of Mouth	47.2%	44.4%	52.8%	51.8%	48.0%	↑	58.0%	↑	35.3%	36.9%	24.6%
Gum and Other Mouth	56.1%	56.6%	55.4%	59.3%	60.4%		57.9%		48.7%	48.8%	47.9%
Nasopharynx	60.4%	58.5%	66.8%	60.3%	58.3%		65.7%		50.9%	51.0%	50.0%
Tonsil	72.0%	73.3%	65.1%	76.3%	77.4%	↑	69.6%	↑	52.6%	54.5%	42.4%
Oropharynx	46.3%	48.1%	40.9%	53.6%	57.2%	↑	44.4%		26.3%	23.7%	32.7%
Hypopharynx	31.3%	29.8%	38.1%	38.3%	36.9%	↑	43.6%		20.0%	18.3%	25.8%
Other Oral Cavity and Pharynx	44.8%	44.3%	46.2%	55.4%	57.5%	↑	46.8%		21.1%	13.4%	40.1%
Digestive System	44.0%	41.1%	47.7%	45.7%	43.0%	↑	49.3%	↑	40.9%	37.4%	45.3%
Esophagus	20.0%	17.8%	28.2%	21.7%	19.1%	↑	33.3%	↑	15.6%	13.9%	19.9%
Stomach	32.3%	29.3%	37.2%	34.6%	32.2%	↑	38.9%		29.8%	26.0%	35.4%
Small Intestine	72.0%	72.6%	71.1%	74.6%	72.7%		76.5%	↑	67.0%	70.2%	63.6%
Colon and Rectum	64.3%	63.4%	65.2%	66.2%	65.6%	↑	66.9%	↑	60.5%	58.8%	62.2%
Colon excluding Rectum	63.9%	63.8%	64.0%	66.2%	66.0%	↑	66.4%	↑	59.5%	59.2%	59.7%
Cecum	63.1%	64.1%	62.2%	65.9%	66.3%		65.6%	↑	58.1%	60.2%	56.5%
Appendix	79.4%	80.9%	78.0%	84.0%	87.9%	↑	81.1%	↑	63.2%	61.3%	64.9%
Ascending Colon	66.2%	63.2%	68.8%	67.8%	64.8%		70.6%		64.3%	62.1%	65.9%
Hepatic Flexure	63.8%	65.6%	61.7%	65.0%	66.1%		62.6%		62.5%	65.6%	58.2%
Transverse Colon	62.4%	60.2%	64.2%	63.7%	64.0%	↑	63.3%		59.0%	51.5%	65.4%
Splenic Flexure	63.9%	64.2%	62.9%	63.9%	62.7%		65.1%		64.0%	65.2%	61.4%
Descending Colon	64.1%	64.8%	63.0%	66.3%	68.0%		63.5%		60.1%	58.4%	61.1%
Sigmoid Colon	67.3%	67.8%	66.5%	69.6%	69.6%	↑	69.5%	↑	62.1%	63.0%	61.2%
Large Intestine, NOS	27.2%	29.0%	25.0%	26.3%	28.8%		23.2%		28.1%	28.0%	27.4%
Rectum and Rectosigmoid Junction	65.2%	62.9%	68.5%	66.2%	64.8%	↑	68.3%		63.1%	58.3%	69.4%
Rectosigmoid Junction	59.2%	57.5%	61.7%	61.9%	61.6%	↑	62.5%		52.8%	48.1%	58.9%
Rectum	66.8%	64.3%	70.3%	67.4%	65.7%	↑	69.9%		65.4%	60.5%	71.6%
Anus, Anal Canal and Anorectum	69.6%	63.6%	73.6%	72.6%	65.5%		76.5%		61.0%	57.6%	64.0%
Liver and Intrahepatic Bile Duct	16.9%	16.2%	19.0%	18.0%	17.3%	↑	20.2%		13.8%	13.4%	15.5%
Liver	18.0%	17.0%	21.6%	19.5%	18.3%	↑	24.0%		14.4%	13.9%	17.0%
Intrahepatic Bile Duct	6.2%	4.2%	8.0%	6.3%	5.1%	↑	7.0%		4.8%	4.1%	5.1%
Gallbladder	18.2%	14.2%	19.9%	17.9%	13.8%		19.6%		17.7%	17.7%	18.0%
Other Biliary	17.2%	15.3%	18.8%	17.7%	14.2%		21.3%		15.8%	16.0%	15.0%
Pancreas	8.8%	8.4%	9.2%	9.2%	8.9%	↑	9.5%		7.8%	6.7%	8.8%
Retroperitoneum	52.6%	45.5%	57.7%	52.1%	44.6%		59.4%		52.7%	37.5%	57.2%
Peritoneum, Omentum and Mesentery	26.8%	8.3%	28.7%	27.0%	11.9%		28.6%		22.2%	0.0%	25.1%
Other Digestive Organs	12.8%	11.5%	13.8%	9.7%	11.3%		7.6%		19.9%	12.5%	24.7%

Respiratory System	23.4%	22.1%	25.2%	23.9%	22.3%		25.9%		21.9%	21.2%	23.1%
Nose, Nasal Cavity and Middle Ear	62.2%	63.3%	60.5%	65.7%	67.0%		63.9%		47.9%	48.7%	44.8%
Larynx	57.7%	58.0%	56.3%	59.5%	59.5%	↑	59.0%		53.5%	54.0%	51.3%
Lung and Bronchus	20.0%	17.3%	23.5%	20.7%	17.7%		24.2%		18.3%	16.3%	21.2%
Pleura	20.2%	21.0%	20.2%	23.1%	23.3%		24.4%		0.0%	0.0%	0.0%
Trachea, Mediastinum and Other Respiratory	43.1%	46.0%	37.4%	45.5%	54.9%		33.3%		40.7%	40.3%	41.8%
Bones and Joints	64.3%	59.1%	69.6%	65.9%	57.0%		73.0%		58.7%	57.8%	59.9%
Soft Tissue including Heart	63.4%	64.4%	61.9%	66.6%	66.9%		66.0%	↑	56.4%	59.2%	53.5%
Skin excluding Basal and Squamous	92.5%	91.1%	94.4%	92.8%	91.5%	↑	94.8%		78.9%	71.0%	84.9%
Melanoma of the Skin	92.9%	91.7%	94.7%	93.4%	92.1%	↑	95.4%	↑	64.5%	55.8%	70.6%
Other Non-Epithelial Skin	88.1%	85.6%	90.9%	86.3%	84.9%		87.9%	↓	91.3%	83.0%	95.3%
Breast	88.3%	78.1%	88.4%	90.9%	80.6%		91.0%	↑	82.9%	73.1%	83.0%
Female Genital System	65.1%	--	65.1%	69.5%	--		69.5%	↑	55.8%	--	55.8%
Cervix Uteri	64.1%	--	64.1%	67.3%	--		67.3%	↑	57.8%	--	57.8%
Corpus and Uterus, NOS	74.9%	--	74.9%	82.2%	--		82.2%	↑	60.7%	--	60.7%
Corpus Uteri	76.8%	--	76.8%	83.5%	--		83.5%	↑	63.4%	--	63.4%
Uterus, NOS	20.3%	--	20.3%	23.8%	--		23.8%		14.0%	--	14.0%
Ovary	45.2%	--	45.2%	47.5%	--		47.5%	↑	38.7%	--	38.7%
Vagina	46.4%	--	46.4%	46.8%	--		46.8%		48.1%	--	48.1%
Vulva	72.3%	--	72.3%	73.5%	--		73.5%		67.6%	--	67.6%
Other Female Genital Organs	45.8%	--	45.8%	49.4%	--		49.4%		35.9%	--	35.9%
Male Genital System	99.5%	99.5%	--	99.8%	99.8%	↑	--		97.9%	97.9%	--
Prostate	99.8%	99.8%	--	99.9%	99.9%	↑	--		98.2%	98.2%	--
Testis	96.9%	96.9%	--	97.7%	97.7%	↑	--		89.9%	89.9%	--
Penis	66.3%	66.3%	--	69.9%	69.9%		--		56.3%	56.3%	--
Other Male Genital Organs	84.0%	84.0%	--	98.2%	98.2%	↑	--		54.9%	54.9%	--
Urinary System	76.3%	77.0%	74.9%	77.6%	78.1%	↑	76.4%	↑	71.8%	72.3%	71.1%
Urinary Bladder	77.9%	79.8%	71.9%	79.9%	80.9%	↑	76.4%	↑	67.3%	73.0%	55.6%
Kidney and Renal Pelvis	76.2%	75.2%	77.7%	76.7%	76.1%	↑	77.7%		75.0%	72.5%	78.3%
Ureter	45.8%	46.6%	44.3%	46.6%	47.3%		45.2%		34.5%	35.7%	35.4%
Other Urinary Organs	46.1%	54.6%	33.2%	49.0%	56.1%		33.6%		39.3%	49.3%	27.9%
Eye and Orbit	79.4%	80.3%	78.2%	78.7%	81.1%		75.7%		84.7%	74.9%	94.1%
Brain and Other Nervous System	32.8%	31.5%	34.4%	31.1%	29.9%		32.7%		35.0%	33.2%	37.1%
Brain	29.7%	29.0%	30.6%	28.4%	27.8%		29.1%		31.7%	30.9%	32.6%
Cranial Nerves Other Nervous System	78.8%	73.9%	83.8%	79.7%	72.5%		86.8%		73.0%	66.4%	76.6%
Endocrine System	97.4%	94.5%	98.2%	98.0%	95.6%	↑	98.7%	↑	95.0%	89.5%	96.2%
Thyroid	98.7%	97.1%	99.1%	99.0%	97.7%		99.4%	↑	97.7%	95.6%	97.9%
Other Endocrine including Thymus	66.3%	68.2%	63.9%	62.5%	64.0%		61.0%		69.2%	71.1%	66.9%
Lymphoma	72.6%	71.2%	74.3%	74.4%	73.5%	↑	75.3%	↑	67.2%	64.1%	70.7%
Hodgkin Lymphoma	85.2%	84.7%	85.7%	85.3%	85.7%		84.5%		85.4%	82.3%	88.9%
Hodgkin - Nodal	85.8%	85.5%	85.9%	85.9%	86.6%		84.8%		85.7%	82.9%	88.9%
Hodgkin - Extranodal	48.9%	44.0%	60.2%	43.7%	30.8%		60.2%		61.4%	61.4%	^
Non-Hodgkin Lymphoma	70.6%	69.0%	72.5%	72.8%	71.8%	↑	74.0%	↑	63.3%	59.9%	67.1%
NHL - Nodal	68.1%	66.0%	70.7%	70.6%	68.8%	↑	72.6%	↑	58.9%	56.4%	61.4%
NHL - Extranodal	75.5%	75.0%	75.7%	77.2%	77.6%	↑	76.5%		70.8%	66.3%	74.9%
Myeloma	55.7%	54.8%	56.8%	55.6%	56.0%		55.0%		55.3%	52.2%	58.2%

Leukemia	64.6%	63.8%	65.6%	66.3%	64.9%	↑	68.0%	↑	58.7%	59.7%	57.6%
Lymphocytic Leukemia	84.0%	82.3%	86.4%	85.6%	83.7%	↑	88.3%	↑	76.7%	76.6%	76.9%
Acute Lymphocytic Leukemia	69.5%	67.6%	71.6%	71.1%	70.5%		71.6%		62.9%	59.7%	67.2%
Chronic Lymphocytic Leukemia	88.1%	86.1%	90.9%	89.0%	86.6%		92.5%	↑	82.0%	82.7%	81.1%
Other Lymphocytic Leukemia	81.1%	79.0%	83.9%	83.8%	80.9%		89.4%		66.0%	67.3%	59.7%
Myeloid and Monocytic Leukemia	41.5%	39.4%	43.9%	40.6%	38.0%		43.7%		43.2%	41.4%	45.0%
Acute Myeloid Leukemia	25.8%	23.7%	28.1%	24.0%	20.9%		27.7%		29.3%	29.2%	29.4%
Acute Monocytic Leukemia	21.9%	26.7%	14.6%	21.2%	28.7%		12.0%		22.9%	16.8%	25.7%
Chronic Myeloid Leukemia	67.7%	65.2%	70.7%	67.1%	64.6%		70.0%		68.4%	64.2%	72.8%
Other Myeloid/Monocytic Leukemia	32.4%	23.6%	45.1%	30.6%	29.4%		36.1%		22.7%	0.0%	67.8%
Other Leukemia	55.8%	58.9%	52.0%	54.7%	56.6%		51.8%		57.0%	59.5%	52.8%
Other Acute Leukemia	28.9%	22.1%	37.0%	27.0%	19.4%		35.7%		26.5%	^	40.6%
Aleukemic, Subleukemic and NOS	67.1%	73.8%	58.0%	66.2%	71.7%		58.9%		69.2%	80.1%	55.8%
Mesothelioma	9.3%	6.2%	16.6%	9.8%	7.3%		15.5%		7.0%	0.0%	20.9%
Kaposi Sarcoma	70.2%	70.7%	60.4%	87.8%	87.6%	↑	83.0%		55.5%	57.3%	^
Miscellaneous	39.2%	37.6%	40.9%	41.2%	40.6%	↑	42.0%	↑	33.5%	28.9%	37.7%

¹Except for urinary bladder (in situ and invasive), only invasive cases are included.

^The statistic could not be calculated.

↑ or ↓ Within Louisiana, white sex-specific relative survival is significantly (p < 0.05) higher or lower than black sex-specific relative survival.

--Not applicable.

Table Q. Louisiana Prevalence Counts by Region, Invasive Cancers Only, January 1, 2021^{1,2}

Site/Region	Louisiana	New Orleans Region	Baton Rouge Region	Southeast Region	Acadiana Region	Southwest Region	Central Region	Northwest Region	Northeast Region
All Sites	197,564	37,120	41,326	29,343	27,460	12,553	12,298	23,678	14,247
Oral Cavity and Pharynx	5,200	893	1,085	805	726	341	355	618	383
Esophagus	729	118	158	104	95	55	52	100	46
Stomach	1,575	355	322	219	221	84	114	177	84
Colon and Rectum	19,528	3,487	3,825	2,633	2,984	1,278	1,381	2,404	1,542
Liver and Intrahepatic Bile Duct	1,483	439	293	234	169	83	46	154	65
Pancreas	1,245	261	241	218	171	61	70	148	77
Larynx	1,997	369	402	294	301	128	116	253	132
Lung and Bronchus	9,128	1,801	1,754	1,331	1,375	586	587	1,025	677
Melanoma of the Skin	9,831	1,501	2,398	1,657	1,098	678	601	1,055	850
Breast ³	40,963	8,392	8,389	6,147	5,780	2,394	2,160	4,831	2,919
Cervix Uteri	2,444	484	455	302	352	177	161	338	176
Corpus and Uterus, NOS	6,208	1,181	1,184	844	870	398	406	849	476
Ovary	1,781	355	393	298	221	111	108	191	103
Prostate	46,538	8,544	10,679	6,218	6,382	2,920	2,786	5,740	3,267
Testis	1,818	341	385	269	254	138	128	190	115
Urinary Bladder ⁴	8,090	1,486	1,608	1,404	1,085	531	550	940	492
Kidney and Renal Pelvis	10,588	1,882	2,202	1,669	1,579	693	667	1,165	740
Brain and Other Nervous System	1,488	275	311	242	207	92	103	163	95
Thyroid	9,214	1,556	1,707	1,448	1,396	601	660	1,119	728
Hodgkin Lymphoma	1,933	369	372	310	264	127	139	227	125
Non-Hodgkin Lymphoma	8,632	1,694	1,706	1,392	1,174	610	530	981	545
Myeloma	2,558	530	578	371	282	135	131	346	186
Leukemia	5,379	847	1,055	858	760	395	364	688	412
Acute Lymphocytic Leukemia	783	135	174	123	109	56	45	86	55
Mesothelioma	115	28	26	23	13	11	^	^	7
Kaposi Sarcoma	217	95	48	15	20	8	^	18	9

¹ January 1, 2021, 21-Year Limited Duration Prevalence counts are based on 2021 cancer prevalence proportions from SEER 17 registries. Populations were estimated by averaging 2020 and 2021 populations.

²Inclusion methods: For all sites, we count first invasive tumor for each person diagnosed during the previous 21 years (2000-2020). For each specific cancer site, we count first invasive tumor for each site diagnosed during the previous 21 years (2000-2020).

³ Breast tumor includes both sexes. ⁴ Urinary bladder category includes urinary bladder tumor in situ. ^Statistic not displayed due to fewer than 6 prevalent cases.

Table R. Louisiana Prevalence Counts by Age Group, Invasive Cancers
Only, January 1, 2021^{1,2}

Site/Ages	All ages	0-19	20-39	40-49	50-59	60-69	70-79	80-89
All Sites	197,564	3,411	15,353	24,368	51,734	65,082	36,025	9,683
Oral Cavity and Pharynx	5,200	47	292	736	1,678	1,595	723	221
Esophagus	729	^	11	60	180	273	164	42
Stomach	1,575	^	78	167	389	513	338	92
Colon and Rectum	19,528	52	874	2,231	5,675	6,099	3,573	1,170
Liver and Intrahepatic Bile Duct	1,483	44	25	62	415	633	254	53
Pancreas	1,245	6	62	102	274	425	293	85
Larynx	1,997	^	45	226	617	714	320	80
Lung and Bronchus	9,128	9	128	441	1,908	3,442	2,597	766
Melanoma of the Skin	9,831	110	1,446	1,553	2,288	2,383	1,598	595
Breast ³	40,963	^	2,515	7,415	11,292	11,934	6,663	2,019
Cervix Uteri	2,444	^	907	685	480	263	79	29
Corpus and Uterus, NOS	6,208	^	403	834	1,870	2,082	849	167
Ovary	1,781	52	258	291	455	422	224	78
Prostate	46,538	^	40	1,662	12,151	21,377	9,921	1,386
Testis	1,818	95	1,163	362	157	34	^	^
Urinary Bladder ⁴	8,090	8	168	505	1,644	2,735	2,266	820
Kidney and Renal Pelvis	10,588	178	588	1,466	2,839	3,348	1,848	420
Brain and Other Nervous System	1,488	541	398	203	163	119	61	11
Thyroid	9,214	167	2,392	2,020	2,190	1,649	681	121
Hodgkin Lymphoma	1,933	275	942	280	225	133	58	20
Non-Hodgkin Lymphoma	8,632	247	876	979	1,942	2,439	1,703	528
Myeloma	2,558	^	63	241	576	885	594	201
Leukemia	5,379	790	474	519	1,010	1,304	918	368
Acute Lymphocytic Leukemia	783	614	71	25	39	23	9	^
Mesothelioma	115	^	13	13	20	28	27	11
Kaposi Sarcoma	217	^	98	46	29	17	16	12

¹ January 1, 2021, 21-Year Limited Duration Prevalence. Populations were estimated by averaging 2020 and 2021 populations.

² Inclusion methods: For all sites, we count first invasive tumor for each person diagnosed during the previous 21 years (2000-2020). For each specific cancer site, we count first invasive tumor for each site diagnosed during the previous 21 years (2000-2020).

³ Breast tumor includes both sexes.

⁴ Urinary bladder category includes urinary bladder tumor in situ.

^Statistic not displayed due to fewer than 6 prevalent cases.

Other Tables

Table S. Percent of Cases^{1,2} with Microscopic Confirmation by Primary Site, All Races and Both Sexes Combined, 2017-2021, Louisiana

	Microscopically Confirmed	All Cases	Percent Microscopically Confirmed
All Sites	126,158	134,253	94.0%
Oral Cavity and Pharynx	3,649	3,708	98.4%
Esophagus	1,230	1,267	97.1%
Stomach	1,874	1,920	97.6%
Small Intestine	906	919	98.6%
Colon and Rectum	11,784	12,096	97.4%
Colon excluding Rectum	8,150	8,410	96.9%
Rectum and Rectosigmoid Junction	3,634	3,686	98.6%
Liver	1,480	2,763	53.6%
Pancreas	3,511	4,064	86.4%
Larynx	1,390	1,407	98.8%
Lung and Bronchus	15,787	17,610	89.6%
Melanoma of the Skin	4,779	4,791	99.7%
Breast	18,548	18,717	99.1%
Corpus and Uterus, NOS	3,168	3,216	98.5%
Ovary	1,157	1,232	93.9%
Prostate	19,493	19,832	98.3%
Urinary Bladder	4,930	5,001	98.6%
Kidney and Renal Pelvis	5,837	6,424	90.9%
Brain and Other Nervous System	1,283	1,470	87.3%
Thyroid	3,231	3,246	99.5%
Hodgkin Lymphoma	651	657	99.1%
Non-Hodgkin Lymphoma	4,967	5,095	97.5%
Myeloma	1,925	2,321	82.9%
Leukemia	3,447	3,733	92.3%
Mesothelioma	277	290	95.5%
Kaposi Sarcoma	110	115	95.7%

¹Case counts represent the total combined number of cases for the 5-year period.

²Except for urinary bladder (in situ and invasive), only invasive cases are included.

References

- [1] A. Fritz, C. Percy, A. Jack, K. Shanmugaratnam, L. Sobin, D. M. Parkin and S. Whelan, Eds., International Classification of Diseases for Oncology, 3rd ed., Geneva: World Health Organization, 2000.
- [2] American Cancer Society, "Cancer Facts & Figures 2024," Atlanta, 2024.
- [3] Campaign for Tobacco-Free Kids, "State Cigarette Excise Tax Rates & Rankings," 14 June 2024. [Online]. Available: <https://www.tobaccofreekids.org/assets/factsheets/0097.pdf>. [Accessed 14 August 2024].
- [4] Centers for Disease Control and Prevention, "Obesity and Cancer" 7 November 2023. [Online]. Available: <https://www.cdc.gov/cancer/risk-factors/obesity.html>. [Accessed 14 August 2024].
- [5] Centers for Disease Control and Prevention, "Prevalence of Obesity Based on Self-Reported Weight and Height Among U.S. Adults by State and Territory, BRFSS, 2022," 21 September 2023. [Online]. Available: <https://www.cdc.gov/obesity/php/data-research/adult-obesity-prevalence-maps.html>. [Accessed 14 August 2024].
- [6] Centers for Disease Control and Prevention, "Cancers Linked With HPV Each Year" 14 November 2023. [Online]. Available: <https://www.cdc.gov/cancer/hpv/cases.html>. [Accessed 14 August 2024].
- [7] Centers for Disease Control and Prevention, "HPV Vaccination," 9 July 2024. [Online]. Available: <https://www.cdc.gov/hpv/vaccines/index.html>. [Accessed 14 August 2024].

Appendices

Appendix A. Abbreviations and Symbols

HIDD	Hospital in-patient discharge data
HIV	Human Immunodeficiency Virus
ICD-O-2	<i>International Classification of Diseases for Oncology</i> , 2 nd edition
ICD-O-3	<i>International Classification of Diseases for Oncology</i> , 3 rd edition
LTR	Louisiana Tumor Registry
NCI	National Cancer Institute
NAACCR	North American Association of Central Cancer Registries
NPCR	National Program of Cancer Registries
OPH	Louisiana Office of Public Health
SEER	Surveillance, Epidemiology and End Results Program of the National Cancer Institute
STD	Sexually Transmitted Disease
--	Not applicable
^	Rate is not calculated for a case count lower than sixteen during the five-year period.

Appendix B. Regions of Louisiana

Because the Louisiana Tumor Registry was created as an agency of the Louisiana Office of Public Health (OPH), it follows the Department of Health and Hospitals' regional divisions that were in effect when the LTR was created in LTR analyses and publications. Using OPH boundaries enables state officials to take advantage of the existing public health structure in case alarming cancer incidence patterns emerged.

Later, the OPH revised its health regions to respond to changing population patterns (especially the growth of the area north of Lake Pontchartrain, now Region 9) and to eliminate the geographic isolation of Plaquemines Parish for public health operations. Regions 5-8 did not change.

The Tumor Registry, however, has retained the traditional OPH regional boundaries, in order to monitor historical incidence trends.

Maps of the regions are available at:

OPH: <http://www.dhh.louisiana.gov/assets/images/maps/regionmap.jpg>

LTR: <http://sph.lsuhscc.edu/louisiana-tumor-registry/about-the-registry/host-institutions/>

Regions of the Louisiana Tumor Registry

Regional Registry	Beginning Date of the Registry	Average Annual Population, 2017-2021 ¹	Parishes Covered
Region 1 – New Orleans	1974	867,265	Jefferson, Orleans, St. Bernard
Region 2 – Baton Rouge	1983	1,000,624	Ascension, Assumption, East Baton Rouge, East Feliciana, Iberville, Livingston, Pointe Coupée, St. Helena, Tangipahoa, West Baton Rouge, West Feliciana
Region 3 – Southeast Louisiana	1983	655,647	Lafourche, Plaquemines, St. Charles, St. James, St. John, St. Tammany, Terrebonne, Washington
Region 4 – Acadiana	1983	645,300	Acadia, Evangeline, Iberia, Lafayette, St. Landry, St. Martin, St. Mary, Vermilion
Region 5 – Southwest Louisiana	1983	310,213	Allen, Beauregard, Calcasieu, Cameron, Jefferson Davis
Region 6 – Central Louisiana	1988	298,423	Avoyelles, Catahoula, Concordia, Grant, La Salle, Rapides, Vernon, Winn
Region 7 – Northwest Louisiana	1988	527,786	Bienville, Bossier, Caddo, Claiborne, De Soto, Natchitoches, Red River, Sabine, Webster
Region 8 – Northeast Louisiana	1988	353,015	Caldwell, East Carroll, Franklin, Jackson, Lincoln, Madison, Morehouse, Ouachita, Richland, Tensas, Union, West Carroll
Entire State	1988	4,658,273	

¹Source: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Plus Data, 17 Registries, Nov 2023 Sub (2000-2021) - Linked To County Attributes - Total U.S., 1969-2022 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2024, based on the November 2023 submission.

Regions of the Office of Public Health

Region	Parishes Covered
Region 1 – New Orleans	Jefferson, Orleans, Plaquemines, St. Bernard
Region 2 – Baton Rouge	Ascension, East Baton Rouge, East Feliciana, Iberville, Pointe Coupée, West Baton Rouge, West Feliciana
Region 3 – Southeast	Assumption, Lafourche, St. Charles, St. James, St. John the Baptist, St. Mary, Terrebonne
Region 4 – Acadiana	Acadia, Evangeline, Iberia, Lafayette, St. Landry, St. Martin, Vermilion
Region 5 – Southwest	Allen, Beauregard, Calcasieu, Cameron, Jefferson Davis
Region 6 – Central	Avoyelles, Catahoula, Concordia, Grant, La Salle, Rapides, Vernon, Winn
Region 7 – Northwest	Bienville, Bossier, Caddo, Claiborne, De Soto, Natchitoches, Red River, Sabine, Webster
Region 8 – Northeast	Caldwell, East Carroll, Franklin, Jackson, Lincoln, Madison, Morehouse, Ouachita, Richland, Tensas, Union, West Carroll
Region 9 - Northlake	Livingston, St. Helena, St. Tammany, Tangipahoa, Washington

Appendix C. Host Institutions of the LTR Regional Registries

The Louisiana Tumor Registry sincerely thanks the following healthcare institutions for their generosity in providing a home, along with internet and other support services, to the LTR regional offices for many years:

Regions 1 & 3: LSU Board of Supervisors and LSU Health Sciences Center-New Orleans (since 1995)

Region 2: Mary Bird Perkins Cancer Center (since 1983)

Region 4: Acadiana Medical Research Foundation (since 1983)

Region 5: Mary Bird Perkins Cancer Center (since 2013)

Region 6: Acadiana Medical Research Foundation (since 2023)

Regions 7 & 8: University of Louisiana at Monroe (since 1988)

Previous host institutions included

University of Louisiana at Monroe (Region 6, 1988-2023)

Christus St. Patrick Hospital (Region 5, 1983-2013)

Louisiana Office of Public Health (Regions 1 & 3, 1983-1995)

Appendix D. Cancer-Related Organizations

American Cancer Society: <http://www.cancer.org/>

Behavioral Risk Factor Surveillance System: <http://www.cdc.gov/brfss/>

Centers for Disease Control and Prevention: <http://www.cdc.gov/>

Louisiana Breast and Cervical Health Program: <http://lbchp.org/>

Louisiana Cancer Prevention and Control Programs: <http://louisianacancer.org/>

Louisiana Cancer Registrars' Association: <http://www.lcra-usa.org/>

Louisiana Department of Health: <http://dhh.louisiana.gov/>

National Cancer Institute: <https://www.cancer.gov/>

National Cancer Registrars Association: <https://www.ncra-usa.org/>

National Program of Cancer Registries, CDC: <https://www.cdc.gov/cancer/npcr/index.htm>

North American Association of Central Cancer Registries: <http://www.naaccr.org/>

SEER Program (NCI): <http://seer.cancer.gov/>

State Cancer Profiles: <http://statecancerprofiles.cancer.gov/>

Tobacco-Free Louisiana: <http://tobaccofreeliving.org/>

Appendix E. Data Use

LTR data are included in the following publications that accept only high-quality data:

- American Cancer Society Cancer Statistics Center:
<https://cancerstatisticscenter.cancer.org/#!/>
- NAACCR's annual publication, *Cancer in North America* (CINA):
<https://www.naaccr.org/cancer-in-north-america-cina-volumes/>
- NAACCR CiNA Explorer:
<https://apps.naaccr.org/explorer>
- *Cancer Incidence in Five Continents*, published by the World Health Organization's International Association for Research on Cancer:
<https://ci5.iarc.fr/Default.aspx>
- *United States Cancer Statistics*, published by the CDC and the NCI:
- United States Cancer Statistics: Data Visualizations:
<https://gis.cdc.gov/Cancer/USCS/#/AtAGlance/>
- SEER Cancer Explorer Network, published by the SEER Program:
<https://seer.cancer.gov/statistics-network/>
- State Cancer Profiles, published by the CDC:
<http://statecancerprofiles.cancer.gov/>
- SEER Public Use Data File:
<http://seer.cancer.gov/data/>
- Louisiana Health Report Card:
https://ldh.la.gov/assets/oph/Center-PHI/2022_Health_Report_Card.pdf
- LDH Health Data Explorer:
<https://healthdata.ldh.la.gov/>